Name:Dr. Jeff Geschwind

Address: 40 Harbor Road, Westport, CT 06880

Current Positions: Director of Oncology, USA Clinics Group and Oncology Centers, New York, New York
Medical Director, Oncology, Image-guided Therapy and Imaging Core Lab, NAMSA, New York, New York
Medical Advisor, Medical Affairs, HistoSonics, Ann Arbor, Michigan
Medical Advisor, BetaGlue Therapeutics, Milan, Italy
Consultant, Philips Healthcare, Best, The Netherlands
Consultant and Founder, Cage Pharma

Education:
Sc.B University of Paris, Lakanal College (Biology and Physics) 1982
University of Paris School of Medicine (Medical School Curriculum) 1982 – 1984
University of Pennsylvania (Post-Baccalaureate Pre-Health Program) 1984 – 1987
M.D. Boston University School of Medicine 1987 – 1991
Johns Hopkins University School of Medicine (Master’s Program in Biological Chemistry and Molecular Biology, Coursework, no degree) 2002
Yale University School of Management, Emerging Leaders Program 2016-2017

Career/Academic Appointments:

1991 – 1992 Transitional Internship, Medicine and Surgery, Framingham Union Hospital (affiliated with Boston and Harvard Universities) Framingham, Massachusetts
1992 – 1996 Diagnostic Radiology Residency-Scholar’s Program, University of California – San Francisco, San Francisco, California
1996 – 1998 Clinical Fellow in Cardiovascular and Interventional Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland
1997 – 1998 Clinical Instructor, Cardiovascular and Interventional Radiology, Johns Hopkins University of Medicine, Baltimore, Maryland
1998 – 2002 Assistant Professor of Radiology and Surgery, Cardiovascular and Interventional Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland
2001 – 2002 Assistant Professor of Oncology, Johns Hopkins University school of Medicine
Baltimore, Maryland
2002-2006 Associate Professor of Radiology, Surgery and Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland
2007-2015 Professor of Radiology, Surgery and Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland
2015-2017 Professor of Radiology and Oncology (tenured), Yale University School of Medicine, New Haven, Connecticut
2017–present Consultant, PreScience Labs, Baltimore, Maryland
2019-present Medical Director, Oncology and Image-guided Therapy, Syntactx/NAMSA, New York
City, New York
2019-present Director of Oncology, USA Clinics and Oncology Centers, Northbrook, Illinois
2020-present Director Radiology, Medical and Scientific Affairs, Imaging Endpoints, Scottsdale,
Arizona
2020-present Consultant and Medical Director, Histosonics, Minneapolis, Minnesota
Administrative Positions:
2015-2017 Chairman, Department of Radiology and Biomedical Imaging, Yale University School of Medicine; Chief, Department of Radiology, Yale New Haven Hospital, New Haven, Connecticut
2014-2015 Vice Chairman, Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
2007-2014 Director, Interventional Radiology Center, Johns Hopkins Hospital
Baltimore, Maryland
2002-2014 Director, Cardiovascular Diagnostic Laboratory, Chief, Division of Interventional Radiology Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
2001-2002 Interim Director, Cardiovascular Diagnostic Laboratory, Section Chief, Interventional Radiology, Johns Hopkins Hospital, Baltimore, Maryland
2000-2014 Chief, Interventional Radiology Research, Cardiovascular and Interventional Radiology, Johns Hopkins Hospital, Baltimore, Maryland

Board Certification:

Diplomate of the American Board of Radiology, 1998 (Recertification September 2023)

Medical Licensures:
Connecticut Medical License Number 54802
New York Medical License Number 307165-01

Industry Experience as a Key Opinion Leader, Advisor, Consultant and Founder:

Liver Cancer Key Opinion Leader:

• Bayer Healthcare 2009-2017
• Guerbet Group, France 2010-2017
• Merck and Co. 2016-2017
• Bristol-Myers Squibb 2016-2017
• BTG 2005-2017
• Johnson & Johnson (Ethicon) 2015-2017
• Boston Scientific 2004-2017
• Histosonics 2019-present

Interventional Oncology Key Opinion Leader:

• Philips Healthcare 2003-present
• Terumo 2011-2017
  Boston Scientific 2004-2017

Radiology:

• Member of the Radiology Medical Advisory Network, Philips Healthcare (2012-2016). Served as a consultant and advisor on radiology- and health care-related issues.

General Consultant:

• Bayer Healthcare 2009-2017
• Philips Healthcare 2003-2017
• BTG 2005-2017
• Merck and Co. 2016-2017
• Bristol-Myers Squibb 2016-2017
• Guerbet Group 2010-2017
• Boston Scientific 2004-2017
• Histosonics 2019-present

Founder of Oncology Company (PreScience Labs in 2009 now Cage Pharma):

• Founder and CEO of PreScience Labs, LLC, a bio-pharmaceutical company focused on the development of new drugs targeting the metabolism of tumors, that has previously raised $4.2 million from angel investors and closed its first institutional funding round, a $2 million Series AA round led by Camden Partners Exelixis Fund.
• Consultant, PreScience Labs/Cage Pharma

Drug Development Experience:

• Principal Investigator on over 45 clinical trials, mostly investigator-initiated, requiring regulatory oversight from the FDA.
• Held numerous physician-sponsored IDEs and INDs.
• Have advised a number of companies including Guerbet, BTG and Boston Scientific on issues related to FDA approval process of drug-device combination, drugs and devices.
• Have helped design pivotal clinical trials for FDA regulatory approval.

Professional Society Memberships:

• Radiology Society of North America
• American Society of Oncology
• American Association for the Study of the Liver
• American Association for Cancer Research
• Society f Interventional Radiology
• Cardiovascular and Interventional Society of Europe
• Society of Interventional Oncology
• International Liver
• Cancer Association

Professional Honors & Recognition
2024 Sigma Xi, Full Member
2019 Albert Nelson Marquis Lifetime Achievement Award Who’s Who
2017 Inaugural President, Society of Interventional Oncology
2017 Chinese University of Hong Kong Member of the Visiting Committee to Evaluate the Department of Imaging and Interventional Radiology
2016-2021 Castle Connolly Top Doctors New Haven, Connecticut
2015 University of Texas Houston School of Medicine Visiting Professor
2015-2021 Castle Connolly Top Doctors in Cancer
2014 Castle Connolly Baltimore Magazine Top Doctors: Vascular and Interventional Radiology
2014 Brown University Medical School Visiting Professor
2013 John Doppman Memorial Lecture for Imaging Sciences, National Institutes of Health, Bethesda, Maryland
2013 Appointed Principal Investigator NCI/ECOG1208 Multicenter trial
2013 Elected Fellow of the Cardiovascular and Interventional Radiology Society of Europe (CIRSE)
2013 Wilhelm Conrad Roentgen Honorary Lecture, European Congress of Radiology, Interventional Oncology: The Era of Molecular Targeted Therapy, Vienna, Austria
2012 Council of Distinguished Investigators, Academy of Radiology Research
2011-2018 Top Doctor, US News and World Report
2011 Distinguished Alumnus Award, Boston University School of Medicine, Boston, Massachusetts
2011 Distinguished/featured abstracts (X4), Society of Interventional Radiology Annual Meeting, Chicago, Illinois
2011 Society of Interventional Radiology Foundation, Resident/Fellow Research Award (mentee Manon Buijs), Chicago, Illinois
2010-2018 Top Doctor and Top Doctor in Cancer, Castle Connelly Medical
2010 Outstanding Faculty Award, Society of Interventional Radiology 35th Annual Scientific Meeting, March 2010, Tampa, Florida
2009 Journal of Vascular and Interventional Radiology, Distinguished Reviewer Award
2008 Journal of Vascular and Interventional Radiology, Distinguished Reviewer Award
2007 Society of Interventional Radiology Scientific Meeting Distinguished Poster Award
2007 Chairman, World Conference on Interventional Oncology 2nd Annual Meeting, Washington DC
2007 Journal of Vascular and Interventional Radiology, Distinguished Reviewer Award
2007 Merit Award, American Society of Clinical Oncology Gastrointestinal Cancer Symposium
2006 Appointed Founding Member of the International Liver Cancer Association
2006 Appointed to the Society of Interventional Radiology Research Foundation Board
2006 Recognized as one of the “Top Ten Radiologists in the USA” by Medical Imaging Magazine
2005 Merit Award, American Society of Clinical Oncology Gastrointestinal Cancer Symposium
2004 Cum Laude Award for Outstanding Scientific Paper on Cross Sectional Imaging, Society of Computed Body Tomography and Magnetic Resonance
2004 Elected Fellow of the Society of Interventional Radiology (FSIR)
2004 Elected to Alpha Omega Alpha Honor Society (Distinguished Alumnus)
Boston University School of Medicine
2004 Kodak-AUR Advanced Program Radiology Management Course, Association of University Radiologists
2003 Leadership Development Program, Johns Hopkins University School of Medicine
2003 Certificate of Merit, American Roentgen Ray Society
2002 Visiting Professor, Chinese University of Hong Kong
2002 Kodak-AUR Introduction to Management Program,
Association of University Radiologists
2002 Distinguished Faculty Award- Top 10%, Society of Cardiovascular and Interventional Radiology 2002: Lecture faculty.
2001 American Roentgen Ray Society Scholar
2001 The Dr. Ernie J. Ring Academic Development Program, Society of Cardiovascular and Interventional Radiology
The Dr. Gary J. Becker Young Investigator Award,Society of Cardiovascular and Interventional Radiology
2000 Olga Gatewood Fellowship, Department of Radiology, The Johns Hopkins Hospital
Annual Research Award, The Johns Hopkins Hospital Department of Radiology
1998 Chief Fellow, Cardiovascular and Interventional Radiology, Department of Radiology,
Johns Hopkins Hospital
1995 Alexander Margulis Society Excellence in Research Award,
University of California San Francisco
Annual Memorial Award, Association of University Radiologists
1989, 90 Selected as medical student representative to the Boston University School of Medicine Board of Visitors
1989 Selected to present research paper at the National Student Research Forum,
Galveston, Texas

Active Grants while at Yale

Agency: Guerbet Healthcare
Title: “Lipiodol as an imaging biomarker of drug delivery (tumor uptake) and tumor viability”
PI: J.F. Geschwind, M.D
Percent effort: 3%
Total costs for project period: $821,500
Project period: 10/01/2016 – 09/30/2019

Agency: NIH/NCI
I.D. # RO1 CA206180
Title: “Quantitative Multimodal Image Guidance for Improved Liver Cancer Treatment”
Co-PI: J.F. Geschwind, M.D
Percent effort: 4%
Project period: 8/01/2016 – 6/30/2020
Total costs for project period: $3,174,564

Agency: Guerbet
Title: “Randomized Phase 2 Trial of Chemoembolization and Sorafenib: Comparison Between Continuous and Sequential Treatment Regimens”
PI: J.F. Geschwind, M.D
Percent effort: 2%
Project period: 05/27/2016-05/11/2020
Total costs for project period: $1,183,665

Agency: Biocompatibles/BTG
Title: “Irinotecan Drug-Eluting Bead (DEBIRI) Therapy for Patients with Liver Metastases from Colorectal Cancer”
PI: J.F. Geschwind, M.D
Percent effort: 2%
Total costs for project period: $50,000
Project period: 03/16/2016-01/12/2017

Agency: Biocompatibles/BTG
Title: “Doxorubicin-eluting LC Bead M1 for patients with hepatocellular carcinoma”
PI: J.F. Geschwind, M.D
Percent effort: 2%
Total costs for project period: $50,000
Project period: 03/16/2016-12/08/2016

Agency: Guerbet PK Clinical Trial
Title: “Pharmacokinetics of doxorubicin in cTACE of primary and secondary liver cancer”
PI: J.F. Geschwind, M.D
Percent effort: 2%
Project period: 01/01/2016 –12/31/2018
Total costs for project period: $248,771

Agency: Philips Healthcare
Title: “Exhibit B-10 Specific Research Plan for Image-Guided Interventional Oncology: Plan, See, Reach Treat & Asses Project”
PI: J.F. Geschwind, M.D
Percent effort: 3%
Project period: 01/01/2016 –12/31/2018
Total costs for project period: $1,050,000

Agency: Boston Scientific Corporation
Title: “Paclitaxel-Eluting-Beads Transarterial Chemoembolization using Oncospheres in a Rabbit VX2 Liver Cancer Model”
PI: J.F. Geschwind, M.D
Percent effort: 5%
Total costs for project period: $400,000
Project period: 9/1/2015 – 12/31/2016

Agency: NIH/NCI
I.D. # RO1 CA160771-01
Title: “See, Reach, Treat Tumor: Optimized Chemoembolization Drug delivery”
Co-P.I: J.F. Geschwind, M.D.
Percent effort: 2%
Project period: 9/20/11 – 4/01/2017
Total costs for project period: $557,730

Agency: Philips Healthcare
Title: “Exhibit C-7 AJAX Project”
Co-P.I: J.F. Geschwind, M.D
Percent effort: 3%
Total costs for project period: $962,189
Project period: 1/1/2009 – 12/31/2016

Past Grants

Agency: Max Kade Foundation
Title: “Post-Doc Research Exchange Grant”
P.I.: J.F. Geschwind, M.D
Role: Mentor
Percent effort: no salary support
Total costs for project period: $64,200
Project period: 4/1/2014 – 03/31/2015

Agency: Biocompatibles/BTG
Title: “Preclinical Radiopaque Bead Evaluation”
PI: J.F. Geschwind, M.D
Percent effort: no salary support
Total costs for project period: $278,133
Project period: 8/15/2013 – 9/1/2014

Agency: C.R. Bard
Title: “Interventional Radiology Clinical Fellowship”
PI: J.F. Geschwind, M.D
Percent effort: no salary support
Role: Mentor
Total costs for project period: $81,539
Project period: 7/1/2013 – 6/30/2015

Agency: Boston Scientific
Title: “Boston Scientific Interventional Cardiology and Peripheral Interventions Fellowship”
PI: J.F. Geschwind, M.D
Percent effort: no salary support
Role: Mentor
Total costs for project period: $20,000
Project period: 7/10/2013 – 7/10/2014

Agency: Nordion/BTG
IIS Project #: TSI-12-04
Title: “Validation of Dose Estimation Methods and Measurement of Normal Liver Dose in Y-90 TheraSphere Therapy with Quantitative Nuclear Imaging (JHU Protocol #: J1289)”
PI: J.F. Geschwind, M.D
Percent effort: 8%
Total costs for project period: $568,310
Project period: 7/1/2013 – 6/30/2014

Agency:  Department of Defense (DOD) Congressionally Directed Medical Research
I.D.# W81XWH-11-1-0343
Title: “Targeting Tumor Metabolism Can Improve Antitumor Immune Response to Breast Cancer”
Role: Mentor
Percent effort: no salary support
Total costs for project period: $121,250
Project period: 9/1/2012 – 9/30/2013

Agency:  SIR Foundation
Title: “Image-guided Detection and Molecular Therapy for AFP-positive Human Hepatocellular Carcinoma”
PI: J.F. Geschwind, M.D.
Role: Mentor
Percent effort: no salary support
Total costs for project period: $25,000
Project period: 06/01/2012 – 06/01/2013

Agency: Nordion/BTG
Title: “EPOCH Phase III Clinical Trial of Radioembolization with Yttrium 90 in Second Line after Failed FOLFIRI or FOLFOX in Patients with Colorectal Liver Metastases”
PI: J.F. Geschwind, M.D
Percent effort: 5%
Total costs for project period: $666,290
Project period: 04/12/2012 – 03/31/2015

Agency: Guerbet Healthcare
Title: “Lipiodol: Imaging biomarkers to assess tumor response to chemoembolotherapy”
PI: J.F. Geschwind, M.D
Percent effort: 12%
Total costs for project period: $327,300
Project period: 2/1/2012– 01/31/2015

Agency: NIH
Title: “Johns Hopkins Clinical Research Scholars Junior Faculty KL2 Award”
Mentor: J.F. Geschwind, M.D.
Percent effort: No salary support
Total costs for project period: $75,000
Project period: 1/1/11 – 6/30/2012

Agency: Biocompatibles
Title: “Research Fund”
PI: J.F. Geschwind, M.D.
Percent effort: No salary support
Total costs for project period: $125,000
Project period: —

Agency: Nordion
Title: “Intra-arterial Y-90 TheraSpheres for Metastatic Liver Cancer #TSI-09-12”
PI: J.F. Geschwind, M.D.
Percent effort: 15%
Total costs for project period: $ 428,722.30
Project period: 07/01/2010 – 05/31/2012

Agency: Biocompatibles
Title: “Trial Sorafenib combined with LC bead-TACE”
PI: J.F. Geschwind, M.D.
Percent effort: 2%
Total costs for project period: $90,000
Project period: 03/29/2010 – 12/31/2012

Agency: RSNA
Title: “Radiological Society of North America (RSNA) Deputy Editor Duties”
PI: J.F. Geschwind, M.D.
Percent effort: 10%
Total costs for project period: $30,000/year
Project period: 3/1/2009 – 6/1/2012

Agency: Bayer Healthcare
Title: “Global investigation of therapeutic decision in hepatocellular carcinoma and its treatment (GIDEON)”
PI: J.F. Geschwind, M.D.
Percent effort: No salary support
Total costs for project period: $68,000.00
Project period: 3/1/2009 – 2/28/2014

Agency: Philips Medical Systems
Title: “Real-time Image Processing for radiation exposure reduction during Interventional Radiological procedures”
PI: J.F. Geschwind, M.D
Percent effort: No salary support
Total costs for project period: $20,200
Project period: 03/01/2009 – 02/28/2010

Agency: Bayer Healthcare
Title: “Phase II trial of Doxorubicin-eluting microspheres chemoembolization with sorafenib in patients with hepatocellular carcinoma.
PI: J.F. Geschwind, M.D.
Percent effort: 30%
Total costs for project period: $750,000
Project period: 1/1/09-12/31/11

Agency: Philips Medical Systems
Title: “In vivo regional blood flow measurements of the liver using digital radiography”
PI: J.F. Geschwind, M.D
Percent effort: 10%
Total Cost for project period:
Project period: 1/1/09-12/31/11

Agency: Genentech
Title: “Anti-Tumor Angiogenesis Study in rabbit VX2 tumor model”
PI: J.F. Geschwind, M.D
Percent effort: 10%
Total costs for project period: $280,217                                   
Project period: 11/20/08-12/15/10

Agency: Biocompatibles
Title: “Treatment of patients with hepatic neuroendocrine metastases using drug-eluting bead embolization”
PI: J.F. Geschwind, M.D
Percent effort: No salary support
Total costs for project period: $60,000
Project period: 5/23/08 – 5/22/11                         

Agency: The Abdulrahman A. Abdulmalik Research Fund
Title: “Therapy for liver cancer by targeting energy metabolism”
PI: J.F. Geschwind, M.D
Percent effort: No salary support
Total costs for project period: $1,000,000
Project period: 5/01/08 – 4/30/12

Agency: Charles Wallace Pratt Research Fund
Title: “Therapy for liver cancer by targeting energy metabolism”
PI: J.F. Geschwind, M.D
Percent effort: No salary support
Total costs for project period: $400,000
Project period: 5/01/08 – 4/30/12

Agency: Biosphere Medical
Title: “Evaluation of Iron Oxide Embosphere Particle Distribution by MR Imaging in an Animal Model of Liver Cancer”
PI: J.F. Geschwind, M.D
Total costs for project period: $ 75,189
Project period: 9/1/06 – 8/31/08

Agency: Boston Scientific Corporation
Title: Evaluation of New Drug Delivery Systems in an Animal Model of Liver Cancer
PI: J.F. Geschwind, M.D
Total costs for project period: $ 450,707
Project period: 9/1/06 – 8/31/08

Agency: Genentech and Biosphere Medical
Title: “Phase II Trial of Bevacizumab Combined with Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma”
PI: J.F. Geschwind, M.D
Percent effort: No salary support
Total costs for project period $ 430,000
Project period: 5/1/06 – 4/30/08

Agency: Biocompatibles Limited
Title: “Treatment of patients with hepatocellular carcinoma using doxorubicin-eluting beads”
PI: J.F. Geschwind, M.D
Total costs for project period: $ 273,000
Project period: 9/15/05 – 6/30/09

Agency: Philips Medical Systems
Title: “Use of 3-D rotational angiography in oncologic interventions”
PI: J.F. Geschwind, M.D
No salary support
Total costs for project period: $ 182,000
Project period: 7/1/05 – 6/30/08

Agency: NIH/NCI
I.D. # RO1 CA100883-01
Title: “Therapy for liver cancer by targeting energy metabolism”
P.I. J.F. Geschwind
Percent effort: 25%
Total costs for project period: $1,214,569
Project period: 4/01/05 – 3/31/08

Agency: Boston Scientific Corporation
Title: “A non-GLP pharmacokinetic profile of taxol and doxorubicin-loaded Contour SE microspheres in a rabbit model of liver cancer”
P.I. J.F. Geschwind
Total costs for project period: $127,702
Project period: 2004

Agency: NIH NCI
I.D. # P50 – CA103175
Title: “In-Vivo Cellular Molecular Imaging Center”
P.I.: Z. Bhujwalla
Role: Co-Investigator
Percent effort: 2%
Total costs for project period: $1,234,892
Project period: 8/10/03 – 7/31/08

Agency: Biocompatibles/PC technology
Title: “Sustained release of doxorubicin through a new drug-eluting bead following transcatheter arterial chemoembolization in a rabbit model of liver cancer”
P.I. J.F. Geschwind
Percent effort: 5%
Total costs for project period: $118,448
Project Period: 2003

Agency: Cardiovascular and Interventional Radiology Research and Education Fund
Title: “Cardiovascular and Interventional Radiology Research and Education Fund Research Grant Serial assessment of early tumor response to transarterial chemoembolization using line scan diffusion MR imaging”
Role: Co-Investigator
Percent effort: Direct costs only
Total costs for project period: $25,000
Project period: 2003

Agency: Institutional Research Grant (Johns Hopkins University)
Title: “Novel therapy for liver cancer: Direct intraarterial injection of a potent inhibitor of energy production”
P.I. J.F. Geschwind, M.D.
Percent effort: Direct costs only
Total costs for project period: $20,000
Project period: 2003

Agency: National Cancer Institute Pilot Program (Johns Hopkins)
Title: “Novel local delivery of angiogenesis inhibitors by intra-arterial injection in a rabbit liver tumor model”
Role: Co-investigator
Percent effort: Direct costs only (no salary support)
Total costs for project period: $40,000
Project period: 2002

Agency: Rex Medical
Title “Chemical ablation of liver tissues with a new injection device: Assessment of necrosis in normal pigs”
P.I. J.F. Geschwind, M.D.
Percent effort: 5%
Total costs for project period: $37,649
Project period: 2002

Agency: FeRx, Incorporated
Title: “Dose ranging study of the effects of Magnetically Targeted 90Y-MTCs on VX2 rabbit liver tumors”
P.I. J.F. Geschwind, M.D.
Percent effort: 10%
Total costs for project period: $64,788
Project period: 2002

Agency: MDS Nordion, Incorporated
Title: “Use of TheraSpheres for treatment of unresectable hepatocellular carcinoma: A preliminary study”
P.I. J.F. Geschwind, M.D.
Percent effort: 5%
Total costs for project period: $75,000
Project period: 2001

Agency: Biosphere Medical
Title: “Effects of the type of embolization particles on carboplatinum concentration in liver tumors following transcatheter arterial chemoembolization in a rabbit model of liver cancer (VX2)”
P.I. J.F. Geschwind, M.D.
Percent effort: 15%
Total costs for project period: $62,900
Project period: 2001

Agency: American Roentgen Ray Society Scholarship Program
Title: “Molecular targeting in liver cancer”
PI: J.F. Geschwind, M.D.
Percent effort: 50%
Total costs for project period: $120,000
Project period: 2001

Agency: Cardiovascular and Interventional Radiology Research and Education Fund Research Grant. Ernest Ring Award.
Title: “Inhibition of type II hexokinase and glucose metabolism by intraarterial injection of 2-deoxyglucose in a rabbit model of liver cancer”
PI: J.F. Geschwind, M.D.
Percent effort: 25%
Total costs for project period: $50,000
Project period: 2001

Agency: Radiology Society of North America Seed Grant
Title: “Preoperative chemoembolization in the treatment of patients with liver cancer: assessment of tumor response with diffusion MRI and correlation with histopathology.”
PI: J.F. Geschwind, M.D.
Percent effort: Direct costs only
Total costs for project period: $25,000
Project period: 2000

Agency: Rita Inc.
Title: “Evaluation of radiofrequency ablation (RFA) for malignant lung tumors”
Principal Investigator: Dr. S. Yang (Cardiothoracic Surgery)
Role: Co-Principal Investigator
Percent effort: Direct costs only
Total costs for project period: $60,000
Project period: 2000

Agency: Johns Hopkins University School of Medicine
Title: “Gatewood Fellowship, Glycolytic rate and Type II hexokinase expression: Assessment in a rabbit model of liver tumor”
PI: J.F. Geschwind, M.D..
Percent effort: Direct costs only
Total costs for project period: $10,000
Project period: 2000

Agency: Matrix Pharmaceuticals
Title: “Effects of percutaneous cisplatin/epinephrine gel (IntraDose) injected into liver tumors in a rabbit model: Evaluation of tumor necrosis using diffusion MRI”
PI: J.F. Geschwind, M.D.
Percent effort: 10%
Total costs for project period: $73,056
Project period: 1999-2001

Agency: American College of Radiology Imaging Network (ACRIN)
Title: “Phase III multi-center clinical trial: chemoembolization versus systemic chemotherapy for the treatment of colorectal liver metastases”
Site Principal Investigator: J.F. Geschwind, M.D.
Percent effort: 10%
Total costs for project period: $2,200,000
Project period: No patient enrollment

Agency: Matrix Pharmaceuticals
Title: “Percutaneous cisplatin/epinephrine injectable gel (IntraDose) therapy for hepatocellular carcinoma: A phase II clinical trial”
PI: P. Thuluvath, M.D. (Hepatology)
Role: Co-Investigator
Percent effort: 5%
Total costs for project period: $290,000
Project period: 1999-2001

Agency: American Cancer Society
Title: “Effects of chemoembolization on liver tumors: Implication for therapy”
P.I. J.F. Geschwind, M.D.
Percent effort: Directs costs only
Total costs for project period: $20,000
Project period: 1997-98

Agency: Bristol-Meyers-Squibb Oncology Research
Title: “Chemoembolization on liver tumors: assessment of tumor response”
P.I. J.F. Geschwind, M.D.
Percent effort: Direct costs only
Total costs for project period: $3,000
Project period: 1997-98

Agency: N.I.H. Training Grant in Cardiovascular Imaging
Title: “Assessment of myocardial cell viability in perfused myocardial infarction”
P.I.: Charles Higgins, MD
Role: Recipient
Percent effort: 100%
Total costs for project period: $45,000
Project period: July1993-June 1994

Invited Speaking Engagements, Presentations, Symposia & Workshops
International/National

2024 Society of Abdominal Imaging Annual Meeting, Histotripsy for the Treatment of Liver Cancer: Initial clinical results, October 8, 2024, Washington DC
2024 Global Embolization Symposium and Technologies (GEST), GEST Liver Cancer Management, Staging Systems for HCC, May 17, 2024, New York City, New York
2024 European Conference on Interventional Oncology 15th Annual Meeting, Clinical Focus Plenary
Session, AI for Designing Clinical Studies and Writing Papers, April 29, 2024, Palma de Majorca, Spain
2024 Spectrum Conference, Plenary Session on Hepatocellular Carcinoma, Impact of Conventional TACE on the Management of HCC, January 12, 2024, Miami, Florida
2023 Advanced Interventional Management Symposium, 31st Annual Meeting, Updates on Liver Cancer Therapy (HCC and Liver Metastases), Histotripsy for Liver Cancer: Results of the Theresa Clinical Trial. November 13th, 2023, New York City, New York
2023 Advanced Interventional Management Symposium, 31st Annual Meeting, Updates on Liver Cancer Therapy (HCC and Liver Metastases), Hepatocellular Carcinoma Staging: Where are we? November 13th, 2023, New York City, New York
2023 Global Embolization Symposium and Technologies (GEST), GEST Liver Cancer Management, Staging Systems for HCC, May 18, 2023, New York City, New York
2023 European Conference on Interventional Oncology 14th Annual Meeting, Clinical Focus Plenary Session, Clinical Research and the Need for Contract Research Organizations (CROs), April 17, 2023, Stockholm, Sweden
2023 Spectrum Conference, Plenary Session on Hepatocellular Carcinoma, Update on Hepatocellular Carcinoma Staging and Classification, January 14, 2023, Miami, Florida
2022 Advanced Interventional Management Symposium, 30th Annual Meeting, Controversies and Clinical Management in Liver Cancer, Updates in Hepatocellular Carcinoma Staging. November 14th, 2022, New York City, New York
2022 Advanced Interventional Management Symposium, 30th Annual Meeting, Controversies and Clinical Research in Liver Cancer Therapy, Clinical Research in Oncology: Importance of CROs and Cancer Imaging. November 14th, 2022, New York City, New York
2022 European Conference on Interventional Oncology 13th Annual Meeting, Clinical Focus Plenary Session, Clinical Research and the Need for Contract Research Organizations (CROs), April 25, 2022, Vienna, Austria
2022 Global Embolization Symposium and Technologies (GEST), GEST Innovation – Research, Sustaining Eureka: How to Transform a Moment of Insight into Innovation? May 19, 2022, New York City, New York
2022 Spectrum Conference, Plenary Session on Hepatocellular Carcinoma, Hepatocellular Carcinoma Staging and Classification: Where are we Now? January 14, 2022, Miami, Florida
2021 Global Embolization Symposium and Technologies (GEST), Liver Cancer Focus Day, Is there a Role for Loco-regional Therapy in Advanced HCC? May 15, 2021, Virtual Conference
2021 European Conference on Interventional Oncology 12th Annual Meeting held virtually, Plenary Session on Artificial Intelligence in Interventional Oncology, Artificial intelligence (AI) in Interventional Oncology: Response Prediction and Virtual Tumor Board Assistant, April 10, 2021, Virtual Conference
2020 French Society of Radiology (Journees Francophones de Radiologie Diagnostique et Interventionelle) Annual Meeting, Plenary Session on Interventional Oncology, Embolotherapy for liver cancer: Changes at the molecular level and New concepts in embolotherapy for liver cancer, October 2-5, 2020, Paris, France
2020 Global Embolization Symposium and Technologies (GEST), Virtual Meeting, Session on Hepatocellular Carcinoma, Most Influential Publications on HCC in the Past Year, September 1-4, 2020
2020 Global Embolization Symposium and Technologies (GEST), Virtual Meeting, Session on Hepatocellular Carcinoma, Panel Discussion, September 1-4, 2020
2020 Pan Arab Interventional Radiology Society Annual Meeting, Plenary Session Case Discussion, Management of Patients with Hepatocellular Carcinoma, February 27, 2020, Dubai, United Arab Emirates
2020 Pan Arab Interventional Radiology Society Annual Meeting, Plenary Session Artificial Intelligence and Image-guidance in IR, Role of Artificial Intelligence in Oncology, February 28, 2020, Dubai, United Arab Emirates
2020 Pan Arab Interventional Radiology Society Annual Meeting, Plenary Session PAIRS Meets GEST, How Immunotherapy will Change the Landscape in the Management of Hepatocellular Carcinoma, February 27, 2020, Dubai, United Arab Emirates
2020 Pan Arab Interventional Radiology Society Annual Meeting, Plenary Session Intravascular Oncology, Intraprocedural Imaging and Navigation Tools in Intraarterial Therapy for Liver Cancer, February 27, 2020, Dubai, United Arab Emirates
2019 Advanced Interventional Management Symposium, 27th Annual Meeting, TACE, Y90, Ablation or Radiation: What, When, and Why? November 18th, 2019, New York City, New York
2019 Symposium on Clinical Interventional Oncology, Artificial Intelligence and what it Means for Interventional Oncology, October 11-13, 2019, Miami, Florida
2019 European Conference on Embolotherapy (ET), Particles, Description of Use and Concept, June 28, 2019, Valencia, Spain
2019 European Conference on Interventional Oncology 10th Annual Meeting, Hepatocellular Carcinoma – Practice in 2019, Determinants of Survival after TACE in Patients with HCC, April 8th, 2019, Amsterdam, The Netherlands
2019 Society of Interventional Radiology, 44th Annual Meeting, Moonshot Technologies for Next-Gen IR, Inhibiting Glycolysis to Advance Tumor Embolization, March 25th, 2019, Austin, TX
2018 Advanced Interventional Management Symposium, 26th Annual Meeting, Management of Hepatocellular Carcinoma, November 12th, 2018, New York City, New York
2017 Advanced Interventional Management Symposium, 25th Annual Meeting, Imaging after Locoregional Therapy for Hepatocellular Carcinoma, November 13th, 2017, New York City, New York
2017 International Society of Gastrointestinal Oncology 14th Annual Meeting, Hepatocellular Carcinoma: Case Discussions and Tumor Board, October 26th, 2017, Arlington, Virginia
2017 International Society of Gastrointestinal Oncology 14th Annual Meeting, Loco-regional Management of Advanced Intrahepatic Cholangiocarcinoma, October 26th, 2017, Arlington, Virginia
2017 Digestive Disease Interventions Annual Meeting, Imaging Guidance for Hepatobiliary Interventions: Assessment of Tumor Response, October 20th, 2017, New York City, New York
2017 World Conference on Interventional Oncology (WCIO) Annual Meeting, Biomarkers in Liver Cancer, Intraprocedural Imaging Biomarkers to See, Reach and Treat Liver Cancer, June 9th, 2017, Boston, Massachusetts
2017 Pan Arab Interventional Radiology Society Annual Meeting, Plenary Session Interventional Oncology, Role of Combination Therapies in Hepatocellular Carcinoma, March 18th, 2017, Dubai, United Arab Emirates
2017 Pan Arab Interventional Radiology Society Annual Meeting, Plenary Session Interventional Oncology, Drug Eluting Bead TACE vs. Conventional TACE for Hepatocellular Carcinoma, March 18th, 2017, Dubai, United Arab Emirates
2017 Society of Interventional Radiology, 43rd Annual Meeting, Regional Therapy for Liver Cancer: Practical Approach for Expanding Options, March 8th 2017, Washington DC
2017 Society of Interventional Radiology, 43rd Annual Meeting, Advanced Concepts in Chemoembolization, March 8th 2017, Washington DC
2017 Society of Interventional Radiology, 43rd Annual Meeting, Imaging Biomarkers in the Management of HCC: Diagnosis, Staging and Imaging Assessment, How do I do it: Novel Imaging Strategies for Intra-procedural Tumor Response Assessment, March 8th 2017, Washington DC
2017 Society of Interventional Radiology, 43rd Annual Meeting, WCIO meets SIR, Molecular Oncology, Tumor Metabolism, March 6th 2017, Washington DC
2017 Chinese University of Hong Kong, Visiting Committee Member Department of Imaging and Interventional Radiology, January 23-25, 2017, Hong Kong, China
2016 Yale School of Medicine Department of Internal Medicine Section of Digestive Diseases, Yale Liver Update, Liver Cancer: Loco-regional Therapy (TACE, Y90, Ablation), December 2nd, 2016, New Haven, Connecticut
2016 Radiology Society of North America, 102nd Scientific Assembly and Annual Meeting, Interventional Oncology Series, Key Note Lecture, Transcatheter Interventional Oncology: 30 Years of Progress, Challenges and Opportunities , November 30th, 2016, Chicago, Illinois
2016 Radiology Society of North America, 102nd Scientific Assembly and Annual Meeting, Interventional Oncology Series, Hepatocellular Carcinoma, Transarterial Chemoembolization in 2016: Techniques, Results and Practice Patterns, November 28th, 2016, Chicago, Illinois
2016 British Society of Interventional Radiology Annual Meeting, Oncologic Interventions, Yttrium 90 Radioembolization: 1st, 2nd or 3rd Line Treatment for Colorectal Liver Metastases, November 16th, 2016, Manchester, United Kingdom
2016 British Society of Interventional Radiology Annual Meeting, Oncologic Interventions, Treatment of Intermediate and Advanced Hepatocellular Carcinoma, November 15th, 2016, Manchester, United Kingdom
2016 British Society of Interventional Radiology Annual Meeting, Key Note Lecture, Recent Advances and Trials in Interventional Oncology, November 15th, 2016, Manchester, United Kingdom
2016 Advanced Interventional Management Symposium, 24th Annual Meeting, TACE Remains the Standard for Hepatocellular Carcinoma Measuring less than 5cm, November 14th, 2016, New York City, New York
2016 Tumor Registrars Association of Connecticut (TRAC), Annual Education Meeting, Interventional Radiology for Liver Cancer, November 9th, 2016, New Haven, Connecticut
2016 International Society of Gastrointestinal Oncology 13th Annual Meeting, Loco-regional Management of Colorectal Liver Metastases, October 27th, 2016, Arlington, Virginia
2016 International Society of Gastrointestinal Oncology 13th Annual Meeting, Debate: Is There a Role for Combined Chemoembolization and Sorafenib in Hepatocellular Carcinoma? Pro, October 27th, 2016, Arlington, Virginia
2016 French Society of Radiology (Journees Francophones de Radiologie Diagnostique et Interventionelle) Annual Meeting, Plenary Session on Interventional Oncology, Novel Therapies in Interventional Oncology, October 17th, 2016, Paris, France
2016 French Society of Radiology (Journees Francophones de Radiologie Diagnostique et Interventionelle) Annual Meeting, Plenary Session on Interventional Oncology, Rationale for Intraarterial Therapies of Liver Cancer: Drugs and Embolization, October 17th, 2016, Paris, France
2016 Hackensack University Medical Center Inaugural Hepatobiliary Symposium, Non-Surgical Management of Liver Cancer, October 7th 2016, Hackensack, New Jersey
2016 Italian Society of Medical Radiology (SIRM), 47th Annual Meeting, Special Session on Interventional Oncology, See, Visualize, Treat and Assess tumor Response after Therapy for Liver Cancer, September 16th 2016, Naples, Italy
2016 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Special Symposium on Drug-eluting Microspheres for Hepatocellular Carcinoma, See the Difference-Intra-procedural Benefits of Radio-opaque Beads Visualized during Image-guided Therapy, September 11th, 2016, Barcelona, Spain
2016 Interventional Radiology 101, Annual Course in Interventional Radiology, Intraarterial Therapies for Primary and Secondary Liver Cancer, August 20th 2016, Boston, Massachusetts
2016 The 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE), Symposium on Casting a New Light on Loco-regional Targeted Therapy in HCC, Conventional TACE: Mechanisms of Action, July 9th, 2016, Hong Kong, China
2016 The 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE), Debate Session, HCC with Intrahepatic Portal Vein Invasion should be Treated with Loco-regional Therapy, July 9th, 2016, Hong Kong, China
2016 The 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE), Imaging for Liver Cancer, The Key for Accurate Assessment of HCC after TACE, July 9th, 2016, Hong Kong, China
2016 52nd Annual Meeting of the Liver Cancer Study Group of Japan, Hepatocellular Carcinoma: Outcomes beyond Intermediate Stage, Is There a Role for TACE in Advanced HCC? July 1, 2016, Tokyo, Japan
2016 52nd Annual Meeting of the Liver Cancer Study Group of Japan, Hepatocellular Carcinoma Staging Systems around the World: UICC/AJCC, BCLC, Hong Kong and JSGLG, Staging Systems from the Radiology Point of View, July 1, 2016, Tokyo, Japan
2016 International Primary Sclerosing Cholangitis Study Group Annual Workshop, Defining Cholangiocarcinoma, Treatment of Cholangiocarcinoma: The Road Ahead, June 26th, 2016, New Haven, Connecticut
2016 World Conference on Interventional Oncology (WCIO) Annual Meeting, Hepatocellular Carcinoma Evidence-based Debates, Combination Therapies in HCC: Are they Needed? June 11th, 2016, Boston, Massachusetts
2016 World Conference on Interventional Oncology (WCIO) Annual Meeting, Early Career Program, Why we need more Interventional Oncology Research? Opportunities and Challenges, June 9th, 2016, Boston, Massachusetts
2016 World Conference on Interventional Oncology (WCIO) Annual Meeting, Molecular Pathways in Interventional Oncology, Hypoxia and Metabolism, June 9th, 2016, Boston, Massachusetts
2016 World Conference on Interventional Oncology (WCIO) Annual Meeting, General Session, What is Interventional Oncology and what is the Future of Interventional Oncology? June 8th, 2016, Boston, Massachusetts
2016 Rutgers University School of Medicine, Inaugural Radiology Grand Rounds Research Day, How to Get Started in Research? Grants, Clinical Trials and Industry, May 25th, 2016, Newark, New Jersey
2016 Yale University, Sterling Fellows Medical Panel, Tumor Metabolism and its Importance in Cancer, May 6th, 2016, Yale School of Management, New Haven, Connecticut
2016 First Annual School of Gastrointestinal Oncology, Multidisciplinary Management of Liver Metastases, April 23rd, 2016, New York City, New York
2016 First Annual School of Gastrointestinal Oncology, Liver Directed Therapy, April 23rd, 2016, New York City, New York
2016 European Conference on Interventional Oncology 7th Annual Meeting, Guerbet Satellite Symposium, Conventional TACE: Fundamentals and Mechanism of Action, April 19th 2016, Dublin, Ireland
2016 European Conference on Interventional Oncology 7th Annual Meeting, Clinical Focus Session on HCC: an Update, Current Status of Classifying HCC and Tailoring Therapy – An Update on Staging, April 19th 2016, Dublin, Ireland
2016 The 75th Annual Meeting of the Japan Radiological Society, Symposium on Image-guided Therapy of Hepatocellular Carcinoma, Cone Beam CT Imaging for Liver Cancer: See, Reach and Treat, April 15th, 2016, Yokohama, Japan
2016 The 75th Annual Meeting of the Japan Radiological Society, Symposium on Radiology of Hepatocellular Carcinoma Panel Discussion, April 15th, 2016, Yokohama, Japan
2016 The 75th Annual Meeting of the Japan Radiological Society, Keynote Lecture, Non-Surgical Therapies for Liver Malignancies, April 15th, 2016, Yokohama, Japan
2016 Society of Interventional Radiology 42nd Annual Meeting, Meet the Expert Session on Conventional vs. Drug-eluting Beads TACE, April 6th, 2016, Vancouver, Canada
2016 Society of Interventional Radiology 42nd Annual Meeting, Categorical Course on Molecular Oncology, Glycolysis and its Importance in Cancer, April 5th, 2016, Vancouver, Canada
2016 Society of Interventional Radiology 42nd Annual Meeting, Categorical Course on Tumor Response Assessment, How do I do it – Novel Imaging Strategies for Intra-procedural Tumor Response Assessment?, April 4th, 2016, Vancouver, Canada
2016 Society of Interventional Radiology 42nd Annual Meeting, Meet the Expert Session on Regional Liver Tumor Therapy: How do we Put all this Information Together and How does it Translate into Clinical Practice?, April 3rd, 2016, Vancouver, Canada
2016 At the Limits Oncology, Yale University-University College London Annual Scientific Symposium, Image-Guided Management of Liver Cancer, April 1st, 2016, London, United Kingdom
2016 Singapore Congress of Radiology, 25th Annual Scientific Meeting of the Singapore Radiology Society and College of Radiologists Singapore, Keynote Address, New Intraarterial Therapies: The Horizon and Beyond, February 20th, 2016, Singapore
2016 Singapore Congress of Radiology, 25th Annual Scientific Meeting of the Singapore Radiology Society and College of Radiologists Singapore, My Worst Nightmare: Conventional TACE, February 20th, 2016, Singapore
2016 Singapore Congress of Radiology, 25th Annual Scientific Meeting of the Singapore Radiology Society and College of Radiologists Singapore, Singapore Meets WCIO, Conventional TACE: How to Optimise Results Using Advanced Imaging, February 20th, 2016, Singapore
2015 Interventional Oncology in Liver, Pancreas and Biliary Diseases (Italian Congress in Interventional Oncology, New Concepts in Chemoembolotherapy, December 15th, 2015, Milan, Italy
2015 Interventional Oncology in Liver, Pancreas and Biliary Diseases (Italian Congress in Interventional Oncology, New Advances in Embolotherapy Guidance, December 14th, 2015, Milan, Italy
2015 Interventional Oncology in Liver, Pancreas and Biliary Diseases (Italian Congress in Interventional Oncology, Interventional Oncology: The Era of Molecular Targeted Therapy, December 14th, 2015, Milan, Italy
2015 Weill Cornell Medical College-New York-Presbyterian Hospital Weill Cornell Medical Center Department of Radiology Grand Rounds, Interventional Oncology: Towards Molecular Targeting, December 10th 2015, New York City, New York
2015 Radiology Society of North America, 101st Scientific Assembly and Annual Meeting, Interventional Oncology Series, Mechanisms Matter: Basic Science Every IO Should Know, Ischemia-The Prime Mover: Apoptosis, HIF-1 alpha and VEGF Pathways, December 2nd, 2015, Chicago, Illinois
2015 Radiology Society of North America, 101st Scientific Assembly and Annual Meeting, Interventional Oncology Series, Hepatocellular Carcinoma, Tumor Board, November 30th, 2015, Chicago, Illinois
2015 Radiology Society of North America, 101st Scientific Assembly and Annual Meeting, Interventional Oncology Series, Hepatocellular Carcinoma, Transarterial Chemoembolization Technique, Indications and Results: Western Perspective, November 30th, 2015, Chicago, Illinois
2015 Advanced Interventional Management Symposium, 23rd Annual Meeting, Advances in Interventional Oncology, Intermediate Size Hepatocellular Carcinoma: TACE, Ablation and Role of Sorafenib. November 17th, 2015, New York City, New York
2015 Yale Liver Center Grand Rounds, Management of Unresectable Hepatocellular Carcinoma, November 10th, 2015, New Haven, Connecticut
2015 Yale University Biomedical Imaging Sciences Retreat, Targeting Tumor Metabolism: A New Approach against Cancer, October 30th, 2015, Southbury, Connecticut
2015 Digestive Disease Interventions Annual Meeting, Hepatocellular Carcinoma, Hong Kong Staging System: Potential Impact on Management of Hepatocellular Carcinoma, October 23rd, 2015, Boston, Massachusetts
2015 Yale Cancer Center Oncology Grand Rounds, Management of Hepatocellular Carcinoma, October 20th, 2015, New Haven, Connecticut
2015 Yale New Haven Hospital Leadership Kick-off Meeting, Role of Interventional Radiology in Medicine, October 6th, 2015, New Haven, Connecticut
2015 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Satellite Symposium: Casting a New Light on Evidence-Based Medicine Therapy in Interventional Oncology, cTACE Fundamentals and Insight on the Future, September 28th, 2015, Lisbon, Portugal
2015 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Special Session, Management of Intermediate-Advanced Hepatocellular Carcinoma, Combined Therapies in HCC: The Evidence, September 26th, 2015, Lisbon, Portugal
2015 International Liver Cancer Association, Ninth Annual Conference, Advances in Transarterial Treatment of HCC, Targeting Glucose Metabolism – A New Class of Agents for Transarterial Treatment of HCC?, September 5th, 2015, Paris, France
2015 Interventional Radiology 101, Annual Course in Interventional Radiology, Intraarterial Therapies for Primary and Secondary Liver Cancer, August 22nd 2015, Boston, Massachusetts
2015 Asia Pacific liver Cancer Expert Meeting, TACE the real practice in the USA, July 4, 2015, Osaka, Japan.
2015 University of Berlin Charite Hospital, Department of Radiology Grand Rounds, Intraarterial Therapy for Liver Cancer, June 1st, 2015, Berlin, Germany
2015 World Conference on Interventional Oncology (WCIO) 2015 Annual Meeting, WCIO meets APCCVIR, Is There a Role for Combination Therapies in HCC? May 8th, 2015, New York City, New York
2015 World Conference on Interventional Oncology (WCIO) 2015 Annual Meeting, Molecular Oncology, Glycolysis and its Importance in Cancer, May 7th, 2015, New York City, New York
2015 World Conference on Interventional Oncology (WCIO) 2015 Annual Meeting, Early Career Interventional Oncologists Program, Top 5 Practice Tips, DEB-TACE, May 6th, 2015, New York City, New York
2015 Sixth European Conference on Interventional Oncology (ECIO), WCIO meets ECIO, Molecular Oncology and Translation into the Clinic, Tumor Metabolism, April 24th, 2015, Nice, France
2015 Sixth European Conference on Interventional Oncology (ECIO), How to Follow up Patients: Imaging and Clinical, Transarterial Chemoembolization for Hepatocellular Carcinoma, April 22nd, 2015, Nice, France
2015 Sixth China Conference on Interventional Oncology and China Forum on Embolotherapy, Satellite Symposium, Drug-eluting Bead TACE for Liver Cancer: Experience at Johns Hopkins, March 27th, 2015, Tianjin, China
2015 Sixth China Conference on Interventional Oncology and China Forum on Embolotherapy, Opening Session, Drug-eluting Bead TACE for Liver Cancer: Indications, Technique and Results, March 27th, 2015, Tianjin, China
2015 Pan Arab Interventional Radiology Society Annual Meeting, Plenary Session Interventional Oncology, Transarterial Radioembolization of Liver Malignancies, March 12th, 2015, Dubai, United Arab Emirates
2015 Pan Arab Interventional Radiology Society Annual Meeting, Plenary Session Interventional Oncology, Latest Trends in Management of Hepatocellular Carcinoma, March 12th, 2015, Dubai, United Arab Emirates
2015 Society of Interventional Radiology 41st Annual Meeting, Meet the Experts Session: Oncology, March 2nd, 2015, Atlanta, Georgia
2015 Society of Interventional Radiology 41st Annual Meeting, Research and New Horizon in Oncology Plenary Session, Glycolysis and its Importance in Cancer, March 2nd, 2015, Atlanta, Georgia
2015 University of Texas Houston John H. Harris Visiting Professor, Radiology Grand Rounds, Molecular Oncology: The Era of Molecular Targeted Therapy, February 3rd, 2015, Houston, Texas
2015 Seventh Annual Symposium on Clinical Interventional Oncology, Satellite Symposium, See, Reach and Treat: Use of Cone Beam CT Imaging in Interventional Oncology, February 1st, 2015, Miami, Florida
2015 Seventh Annual Symposium on Clinical Interventional Oncology, Drug Eluting Embolics, February 1st, 2015, Miami, Florida
2015 Seventh Annual Symposium on Clinical Interventional Oncology, Coordinator Hepatocellular Carcinoma Tumor Board, January 31st, 2015, Miami, Florida
2015 Johns Hopkins Gastroenterology and Hepatology Program at Sibley Memorial Hospital; Advances in GI Endoscopy and Liver Transplantation, Locoregional Therapies for Primary Liver Cancer, January 17, 2015, Tysons Corner, Virginia
2014 Radiology Society of North America, 100th Scientific Assembly and Annual Meeting, Interventional Oncology Series, Mechanisms Matter: Basic Science Every IO Should Know, Beyond “Just” TACE: Targeting Glycolysis, Apoptosis and the VEGF Pathway, December 3rd, 2014, Chicago, Illinois
2014 Radiology Society of North America, 100th Scientific Assembly and Annual Meeting, Interventional Oncology Series, Hepatocellular Carcinoma, Tumor Board, December 1st, 2014, Chicago, Illinois
2014 Radiology Society of North America, 100th Scientific Assembly and Annual Meeting, Interventional Oncology Series, Hepatocellular Carcinoma, Intraarterial Therapies for Hepatocellular Carcinoma in the US: Where are we?, December 1st, 2014, Chicago, Illinois
2014 The 10th Chinese Conference of Minimally Invasive Therapy in Oncology and the 1st Scientific Meeting of Asia-Pacific Association of Image-guided Therapy in Oncology, Chemoembolization for Primary and Metastatic Liver Cancer, November 6th, 2014, Shanghai, China
2014 Synergy Meeting, Multidisciplinary Approach to Interventional Oncology, Synergy of Chemoembolization and Sorafenib for Patients with HCC, November 14, 2014, Miami, Florida
2014 Centenary Lecture Series, Philips’s History in Medical Imaging and future directions; Image-Guided Therapy for Cancer: Birth of Interventional Oncology, October 23rd 2014, Briarcliff Manor, New York
2014 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Special Session, Combination Therapies of Liver Tumors, Combining Transarterial and Systemic Therapies, September 17th, 2014, Glasgow, United Kingdom
2014 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Satellite Symposium, TheraSphere and DC Bead: Meeting the Needs of Liver Cancer Patients and Physicians, TheraSpheres Y90 Radioembolization: New and Compelling Clinical Outcome in Metastatic Colorectal Cancer, September 14th, 2014, Glasgow, United Kingdom
2014 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Fundamental Course, Basic Principles of Intermediate-Advanced HCC Management, Chemoembolization with Drug-eluting Microspheres, September 14th, 2014, Glasgow, United Kingdom
2014 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Satellite Symposium, Live Image Guidance: Towards Quantifiable and Reproducible Results in Interventional Oncology, Dual Phase CBCT-guided DEB-TACE: See, Reach and Assess, September 13th, 2014, Glasgow, United Kingdom
2014 Oncology Grand Rounds, AZ Kortrijk Hospital, Yttrium 90 TheraSpheres for the Treatment of Patients with Colo-rectal Liver Metastases, September 10th, 2014, Kortrijk, Belgium
2014 Oncology Grand Rounds, Gent Hospital, Yttrium 90 TheraSpheres for the Treatment of Patients with Colo-rectal Liver Metastases, September 9th, 2014, Gent, Belgium
2014 The Fourth Annual Rutgers New Jersey Medical School Multidisciplinary Course on Hepatopancreaticobiliary tumors, Tumor Metabolism and Implications for Therapy, September 6th 2014, Newark, New Jersey
2014 Interventional Radiology 101, Annual Course in Interventional Radiology, Intraarterial Therapies for Primary and Secondary Liver Cancer, August 23rd, 2014, Boston, Massachusetts
2014 Updates in the Multidisciplinary Treatment of Liver Tumors, Johns Hopkins Medicine,
Intraarterial Therapies for Liver Cancer, June 5th 2014, Bethesda, Maryland
2014 World Conference on Interventional Oncology (WCIO) 2014 Annual Meeting, Molecular Oncology, Glycolysis and its Importance in Cancer, May 13th 2014, New York City, New York
2014 World Conference on Interventional Oncology (WCIO) 2014 Annual Meeting, Primary Liver Cancer, Combination Therapies for HCC: Why, When and How? May 12th 2014, New York City, New York
2014 World Conference on Interventional Oncology (WCIO) 2014 Annual Meeting, Imaging, Interventional Oncology Practice, Value of Research/Clinical Trials in Interventional Oncology, May 11th 2014, New York City, New York
2014 World Conference on Interventional Oncology (WCIO) 2014 Annual Meeting, Imaging, Therapy Planning, and Guidance, Guidance, Advanced Techniques, and Endpoint Determination for Chemoembolization, May 11th 2014, New York City, New York
2014 Eastern Cooperative Oncology Group, Annual Spring Meeting, Hepatoma E1208 Update: Randomized Phase III Trial, May 9th, 2014, Chicago, Illinois
2014 59th Annual Philip A. Tumulty Topics in Clinical Medicine, Meet the Professor Session, Interventional Radiology, May 5th 2014, Baltimore, Maryland (2014)
2014 The Wharton Club of Washington DC Innovation Summit, Plenary Session on Healthcare Transformation, Interventional Oncology: The Era of Molecular Targeted Therapies, April 30th, 2014, Washington DC
2014 Fifth European Conference on Interventional Oncology (ECIO), Joint Session with WCIO, How do I do it? Top 5 Clinical Pearls, Drug-eluting Beads Chemoembolization, April 25th, 2014, Berlin, Germany
2014 Fifth European Conference on Interventional Oncology (ECIO), How to Follow up Patients: Imaging and Clinical, Systemic Therapy for Hepatocellular Carcinoma, April 23rd, 2014, Berlin, Germany
2014 Brown University Medical School/Rhode Island Hospital Radiology Grand Rounds, Interventional Oncology: The Era of Molecular Targeted Therapy, April 7th, 2014, Providence, Rhode Island
2014 Society of Interventional Radiology 40th Annual Meeting, Complex TACE Workshop, Case Discussion, March 26th, 2014, San Diego, California
2014 Society of Interventional Radiology 40th Annual Meeting, Categorical Course, Liver Cancer Tumor Board, March 24th, 2014, San Diego, California
2014 Society of Interventional Radiology 40th Annual Meeting, Plenary Session: The Next Big Thing in IR, Molecular Interventional Oncology: New Developments, March 24th, 2014, San Diego, California
2014 Society of Interventional Radiology 40th Annual Meeting, Workshop on the Role of Cone Beam CT in Interventional Radiology, Cone Beam CT for Chemoembolization, March 23rd, 2014, San Diego, California
2014 Society of Interventional Radiology 40th Annual Meeting, Chair, Meet the Professor Session on Interventional Oncology, March 23rd, 2014, San Diego, California
2014 Johns Hopkins University School of Medicine Course on Nuclear Molecular Imaging and Therapy, Therapy of Liver Tumors with Radioactive Microspheres, March 8th, 2014, Turner Auditorium, Baltimore, Maryland
2014 Kuala Lumpur National Cancer Institute, Symposium on Liver Cancer, New Treatments for Liver Cancer: Targeting Tumor Glycolysis, February 7th, 2014, Kuala Lumpur, Malaysia
2014 Kuala Lumpur National Cancer Institute, Symposium on Liver Cancer, Radioembolization for Patients with Liver Cancer, February 7th, 2014, Kuala Lumpur, Malaysia
2014 Kuala Lumpur National Cancer Institute, Symposium on Liver Cancer, Combination Therapies for Hepatocellular Carcinoma, February 7th, 2014, Kuala Lumpur, Malaysia
2014 Kuala Lumpur National Cancer Institute, Symposium on Liver Cancer, Imaging Response after Loco-regional Treatment for Liver Cancer , February 6th, 2014, Kuala Lumpur, Malaysia
2014 Kuala Lumpur National Cancer Institute, Symposium on Liver Cancer, Management of Patients with Liver Cancer, February 6th, 2014, Kuala Lumpur, Malaysia
2014 Sixth Annual Symposium on Clinical Interventional Oncology, Tips and Tricks on Technology, Drug Eluting Embolics, January 19th, 2014, Miami, Florida
2014 Sixth Annual Symposium on Clinical Interventional Oncology, Tumor Board on Liver Cancer, Panel Discussion, January 18th, 2014, Miami, Florida
2014 Americas Hepato-Pancreato-Biliary Association, Society of Surgical Oncology Consensus Conference on the Management of Intrahepatic Cholangiocarcinoma, Panel Discussion on Recommendations, January 15th, 2014, San Francisco, California
2013 13th Annual John Doppman Memorial Lecture for Imaging Sciences, National Institutes of Health, Interventional Oncology: The Era of Molecular Targeted Therapy, December 18th, 2013, Bethesda, Maryland
2013 Italian Conference on Interventional Oncology, Tumor Ablation Beyond Italy, Chemoembolotherapy for Liver Cancer, December 13th, 2013, Milan, Italy
2013 Radiology Society of North America, 99th Scientific Assembly and Annual Meeting, Interventional Oncology Series, Progress, Challenges, and Opportunities, Transcatheter Therapies, December 4th, 2013, Chicago, Illinois
2013 Radiology Society of North America, 99th Scientific Assembly and Annual Meeting, Interventional Oncology Series, Hepatocellular Carcinoma, Tumor Board, December 2nd, 2013, Chicago, Illinois
2013 Radiology Society of North America, 98th Scientific Assembly and Annual Meeting, Interventional Oncology Series, Hepatocellular Carcinoma, Intraarterial Therapies for Hepatocellular Carcinoma in the US: Where are we?, December 1st, 2013, Chicago, Illinois
2013 Advanced Interventional Management Symposium, 21th Annual Meeting, Interventional Oncology, DEB-TACE with or without Sorafenib: How do we Decide? November 18h, 2013, New York City, New York
2013 39th Annual Topics in Gastroenterology and Hepato-biliary Update Conference, Locoregional Therapies for Liver Cancer, Johns Hopkins University School of Medicine, November 6th, 2013, Baltimore, Maryland
2013 Johns Hopkins Medicine Egyptian Delegation Lecture Series, Intraarterial Therapy for Colorectal Liver Metastases, October 31st, 2013, Baltimore, Maryland.
2013 Synergy Meeting, Multidisciplinary Approach to Interventional Oncology, Phase II Trial of Sorafenib and DEB-TACE for Patients with HCC, October 18, 2013, Miami, Florida.
2013 Synergy Meeting, Multidisciplinary Approach to Interventional Oncology, Multidisciplinary Management of HCC, October 18, 2013, Miami, Florida
2013 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Satellite Symposium, DEB-TACE and TheraSphere: Lates Experience and Future Trends in Liver Targeted Therapy, TheraSphere in Metastatic Colorectal Cancer, September 16th, 2013, Barcelona, Spain
2013 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Special Session, Treatment Synergies in Liver Tumors, Chemoembolization and Systemic Treatment in Hepatocellular Carcinoma, September 16th, 2013, Barcelona, Spain
2013 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Satellite Symposium, Live Image Guidance: Towards Quantifiable and Reproducible Results in Interventional Oncology, Dual Phase CBCT-guided DEB-TACE: See, Reach and Assess, September 14th, 2013, Barcelona, Spain
2013 Harvard Medical School, Massachusetts General Hospital Radiology Grand Rounds, Management of Liver Cancer, August 22, 2013, Boston, Massachusetts
2013 Fourth Asia-Pacific Primary Liver Cancer Expert Meeting (2013 APPLE), Satellite Symposium: Overcoming Challenges in the Management of HCC, Heterogeneity in HCC and Redefining Chemoembolization Outcomes, July 6th 2013, Busan, Korea
2013 Third Annual Expert Panel Opinion on Interventions in Hepatocellular Carcinoma (EPOIHCC), Management of TACE Failure, July 4th 2013, Busan, Korea
2013 French Society of Cardiac and Vascular Imaging (SFICV) Annual Meeting, Keynote Address, Management of Liver Cancer, June 21st, 2013, Montpellier, France
2013 Fourth European Conference on Interventional Oncology (ECIO), New Horizons in Interventional Oncology, Tumor Metabolism Inhibitors, June 20th, 2013, Budapest, Hungary
2013 Fourth European Conference on Interventional Oncology (ECIO), Clinical Focus Session: Intermediate-Advanced HCC, Drug-Eluting Microspheres, June 19th, 2013, Budapest, Hungary
2013 American Society of Clinical Oncology Annual Meeting, Meet the Professor Session, Colorectal Liver Cancer: Too Many Non-systemic Options? June 3rd 2013, Chicago, Illinois
2013 Interventional Oncology Sans Frontieres, Creativity, Novelty and Cinical Excellence, Official Therapeutic Guidelines for Hepatocellular Carcinoma: Can we come to an Agreement? May 30th, 2013, Cernobbio, Italy
2013 World Conference on Interventional Oncology (WCIO) 2013 Annual Meeting, Changing Regulatory Pathways for Approval in Interventional Oncology, Drugs: From Lab to Clinic, May 17th 2013, New York City, New York
2013 World Conference on Interventional Oncology (WCIO) 2013 Annual Meeting, New Drugs/New Carriers/New Devices, Tumor Metabolism Inhibitors, May 16th 2013, New York City, New York
2013 World Conference on Interventional Oncology (WCIO) 2013 Annual Meeting, Multidisciplinary State-of-the-Art Session on HCC, Drug-Eluting Beads for HCC, May 16th 2013, New York City, New York
2013 58th Annual Philip A. Tumulty Topics in Clinical Medicine, Johns Hopkins University School of Medicine, Meet the Professor Sessions, May 6-10th, 2013, Baltimore, Maryland
2013 Interdisciplinary Treatment for Liver Tumors, 3rd Annual Meeting, Rationale of Intraarterial Therapies for Treatment of Liver Tumors, April 18-20th, 2013, Essen, Germany
2013 Society of Interventional Radiology 38th Annual Meeting, Categorical Course on Image Guidance/Targeting and Emerging Therapies for Cancer, New Intraarterial Therapies for Cancer, April 13th-18th, 2013, New Orleans, Louisiana
2013 Society of Interventional Radiology 38th Annual Meeting, Categorical Course on Management of Patients with Hepatocellular Carcinoma, Intermediate HCC, April 13th-18th, 2013, New Orleans, Louisiana
2013 Society of Interventional Radiology 38th Annual Meeting, Meet the Professors: Interventional Oncology, April 13th-18th, 2013, New Orleans, Louisiana
2013 Society of Interventional Radiology 38th Annual Meeting, Categorical Course on Academic IR, Moves I am Glad I made and Those I Wish I had not., April 13th-18th, 2013, New Orleans, Louisiana
2013 Society of Interventional Radiology 38th Annual Meeting, Categorical Course on Academic IR, How to Begin and Sustain Animal Research, April 13th-18th, 2013, New Orleans, Louisiana
2013 Society of Interventional Radiology 38th Annual Meeting, Categorical Course, Tumor Board on Hepatocellular Carcinoma and Colorectal Liver Metastases, April 13th-18th, 2013, New Orleans, Louisiana
2013 Society of Interventional Radiology 38th Annual Meeting, Featured Symposium on Interventional Oncology, Intraarterial Therapies for Hepatocellular Carcinoma: Comparison of the Best Evidence, April 13th-18th, 2013, New Orleans, Louisiana
2013 European Congress of Radiology Annual Meeting, Guerbet Satellite Symposium: Maximizing Diagnostic Radiology and Interventional Radiology in Healthcare, Interventional Radiology’s Role in Healthcare is Increasing, March 10th, 2013, Vienna, Austria
2013 European Congress of Radiology Annual Meeting, The Wilhelm Conrad Roentgen Honorary Lecture, Interventional Oncology: The Era of Molecular Targeted Therapy, March 9th, 2013, Vienna, Austria
2013 Fifth Annual Symposium on Clinical Interventional Oncology, Yearbook in Interventional Oncology, Drug-eluting Microspheres, January 19th, 2013, Miami, Florida
2013 Fifth Annual Symposium on Clinical Interventional Oncology, Management of Patients with Colorectal Liver Metastases, Tumor Board, January 18th, 2013, Miami, Florida
2013 Fifth Annual Symposium on Clinical Interventional Oncology, Yearbook, Hepatocellular Carcinoma, January 18th, 2013, Miami, Florida
2012 Molecular Image-guided Interventions Symposium, Johns Hopkins University, Intraarterial Therapies for Cancer, December 14th, 2012, Baltimore, Maryland
2012 Radiology Society of North America, 98th Scientific Assembly and Annual Meeting, Interventional Oncology Series, Liver Metastases, Tumor Board, November 25, 2012, Chicago, Illinois
2012 Radiology Society of North America, 98th Scientific Assembly and Annual Meeting, Interventional Oncology Series, Liver Metastases, Drug-Eluting Embolics for LiverMetastases: Why and When? November 27, 2012, Chicago, Illinois
2012 Radiology Society of North America, 98th Scientific Assembly and Annual Meeting, Bistro RSNA: Liver and Bone, November 27, 2012, Chicago, Illinois
2012 Radiology Society of North America, 98th Scientific Assembly and Annual Meeting, Interventional Oncology Series, Hepatocellular Carcinoma, Tumor Board, November 25, 2012, Chicago, Illinois
2012 Radiology Society of North America, 98th Scientific Assembly and Annual Meeting, Interventional Oncology Series, Hepatocellular Carcinoma, Intraarterial Therapy, November 25, 2012, Chicago, Illinois
2012 Advanced Interventional Management Symposium, 20th Annual Meeting, Interventional Oncology, DEB-TACE has Surpassed Conventional TACE: Where is the Evidence? November 15h, 2012, New York City, New York
2012 Johns Hopkins Medicine 38th Annual Topics in Gastroenterology and Hepato-Biliary Update Conference, Update on Liver Cancer, Locoregional Therapies for Hepatocellular Carcinoma, November 6th, 2012, Baltimore, Maryland
2012 Israel Association for the Study of the Liver, Management of Hepatocellular Carcinoma Symposium, Locoregional Treatment of Hepatocellular Carcinoma, October 30th, 2012, Tel Aviv, Israel
2012 Israel Association for the Study of the Liver, Management of Hepatocellular Carcinoma Symposium, Detection of Hepatocellular Carcinoma, October 30th, 2012, Tel Aviv, Israel
2012 The Second Annual UMDNJ Multidisciplinary Hepatocellular Carcinoma Symposium, Locoregional Therapy is Global, October 7th, 2012, Elizabeth, New Jersey
2012 University of Pennsylvania School of Medicine, Medical Oncology Grand Rounds, Navigating Hepatocellular Carcinoma: Applying Clinical Trials Data to Patient Care, October 3rd, 2012, Philadelphia, Pennsylvania
2012 Dicovery on Target, 10th Annual Meeting, Cancer Cell Metabolism, Molecular Therapy for Liver Cancer by Targeting GAPDH: Thinking the Unthinkable, October 2nd, 2012, Boston, Massachusetts
2012 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Special Session: Synergies between Loco-regional and Systemic Approaches in Cancer Management, Towards Standardization of Image-guided Drug Eluting Beads Chemoembolization (DEB-TACE), September 17th, 2012, Lisbon, Portugal
2012 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Satellite Symposium, Quantifiable and Reproducible Results in Image-guided Interventional Oncology, Targeting Tumor Metabolism with Transcatheter Therapy, September 15th, 2012, Lisbon, Portugal
2012 American Association for the Study of Liver Diseases (AASLD), Emerging Trends Conference in Liver Imaging, Emerging Trends in Interventional Treatments for Hepatocellular Carcinoma, September 8th, 2012, Emory University Conference Center, Atlanta, Georgia
2012 Wilmington Veteral Affairs Medical Center, Internal Medicine Grand Rounds, Navigating Hepatocellular Carcinoma: Applying Clinical Trials Data to Patient Care, July 18th 2012, Wilmington, Delaware
2012 2nd Annual Expert Panel Opinion on Interventions in Hepatocellular Carcinoma (EPOIHCC), Management of TACE Failure, July 8th 2012, Shanghai, China
2012 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (2012 APPLE), Panel Discussion: Improvement of loco-regional and Ablation Therapy, July 8th 2012, Shanghai, China
2012 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (2012 APPLE), Plenary Session: Combination Therapies in Hepatocellular Carcinoma: Sorafenib and TACE, July 7th 2012, Shanghai, China
2012 Pittsburgh Veteran Affairs Health Care Systems, Internal Medicine Grand Rounds, Navigating Hepatocellular Carcinoma: Applying Clinical Trials Data to Patient Care, June 19th 2012, Pittsburgh, Pennsylvania
2012 World Conference on Interventional Oncology (WCIO) 2012 Annual Meeting, Advancing Interventional Oncology, June 14th- June 17th, 2012, Chicago, Illinois
2012 World Conference on Interventional Oncology (WCIO) 2012 Annual Meeting, Fellows Program Symposium: Conventional and Drug Load Chemoembolization, June 15th 2012, Chicago, Illinois
2012 World Conference on Interventional Oncology (WCIO) 2012 Annual Meeting, HCC Tumor Board, June 14th 2012, Chicago, Illinois
2012 World Conference on Interventional Oncology (WCIO) 2012 Annual Meeting, Hepatocellular Carcinoma Plenary Session: Drug Loaded Microspheres: Better than Transarterial Chemoembolization? June 14th 2012, Chicago, Illinois
2012 American Society of Clinical Oncology 2012 Annual Meeting, ASCO/Radiological Society of North America(RSNA) Joint Plenary Session: New and Upcoming Techniques in Interventional Radiology in Oncology, Interventional Radiology in Oncology, June 2nd 2012, Chicago, Illinois.
2012 10th Asia-Pacific Congress of Cardiovascular and Interventional Radiology, Joint Symposium; Hepatocellular Carcinoma; Conventional Transarterial Chemoembolization vs Transarterial Chemoembolization with Drug Eluding Beads, June 1st 2012, Kobe, Japan
2012 10th Asia-Pacific Congress of Cardiovascular Interventional Radiology, Combination Therapy: Targeted Agents and Chemoembolizaiton, May 31st 2012, Kobe, Japan
2012 University of Medicine and Dentistry of New Jersey VA Medical Center Internal Medicine Grand Rounds, Navigating Hepatocellular Carcinoma: Applying Clinical Trials Data to Patient Care, May 22nd 2012, East Orange, New Jersey
2012 Boston Veterans Affairs Medical Center, Internal Medicine Grand Rounds, Management of Hepatocellular Carcinoma, May 21st 2012, Boston, Massachusetts
2012 5th Annual Symposium in Oncology, State of the Art on Combination Therapies between Chemoembolization and Sorafenib, May 12th 2012, Biarritz, France
2012 Global Embolization Symposium and Technologies, Session: TACE for Heptocellular Carcinoma (HCC), Rationale for Combining Anti-angiogenic Agents and TACE for HCC, May 3rd 2012, New York, New York
2012 Global Embolization Symposium and Technologies, Session: TACE for Heptocellular Carcinoma (HCC), Milan Criteria for Transplant Candidates in HCC: Do They Still Apply with Today’s Advanced Imaging?, May 3rd 2012, New York City, New York
2012 Global Embolization Symposium and Technologies, Session: TACE for Heptocellular Carcinoa (HCC), Five-minute Flash Debates: Lipidol Is the Past, May 3rd 2012, New York, New York
2012 Third European Conference on Interventional Oncology (ECIO), ECIO meets WCIO (World Conference on Interventional Oncology), Targeting Tumor Metabolism: A New Approach against Cancer, April 27th 2012, Florence, Italy
2012 Third European Conference on Interventional Oncology (ECIO), Technical Focus Session – Drug delivery in Interventional Oncology, Drug-Eluting Platforms, April 27th 2012, Florence, Italy
2012 Third European Conference on Interventional Oncology (ECIO), Satellite Symposium on DC Bead, What’s New, DC Bead Loaded with Doxorubicin: Results in Vx2 Pre-clinical Model, April 26th 2012, Florence, Italy
2012 Society of Interventional Radiology 37th Annual Meeting, Intraarterial Therapies for Hepatocellular Carcinoma, March 26th -29th 2012, San Francisco, California
2012 Society of Interventional Radiology 37th Annual Meeting, What the Interventional Oncologist Needs to Know, March 29th 2012, San Francisco, California
2012 Society of Interventional Radiology 37th Annual Meeting, Care Changing Clinical Trials, The future is now: Molecular Targetting and Intra-Arterial Therapy for HCC, March 28th 2012, San Francisco, California
2012 Society of Interventional Radiology 37th Annual Meeting, Tumor Board: Hepatobilary Maglignancies, Intermediate/Advanced HCC, March 28th 2012, San Francisco, California
2012 Society of Interventional Radiology 37th Annual Meeting, Oncology IV: Advanced TACE and Portal Vein Embolization, March 27th 2012, San Francisco, California
2012 Society of Interventional Radiology 37th Annual Meeting, Oncology III: TACE and Portal Vein Embolization, March 26th 2012, San Francisco, California
2012 Society of Interventional Radiology 37th Annual Meeting, Interventional Oncology Evolution: Science to Practice, The Next Generation of Interventional Oncology Therapies: A Practical Approach, March 27th, 2012, San Francisco, California
2012 Society of Interventional Radiology 37th Annual Meeting, Interventional Oncology: Technical and Clinicial Controversies – Can Anti-angiogenic Therapy Improve Outcomes of Embolization? March 26th, 2012, San Francisco, California
2012 Yttrium 90 Radioembolization Advanced Users Meeting, Practice Integration – where does TheraSphere Fit?, February 24, 2012, TheraSphere Summit, Denver, Colorado
2012 Yttrium 90 Radioembolization Advanced Users Meeting, Systemic Therapy in HCC – What an Interventional Radiologist Needs to Know, February 24, 2012, TheraSphere Summit, Denver, Colorado
2012 West Virginia University School of Medicine, Medical Oncology Grand Rounds, Therapy for Hepatocellular Carcinoma: The Era of Combination Therapies, February 8th, 2012, Morgantown, West Virginia
2012 Temple University School of Medicine, Gastroenterology Grand Rounds, Therapy for Hepatocellular Carcinoma: The Era of Combination Therapies, February 1st, 2012, Philadelphia, Pennsylvania
2012 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Meet the Professor Session: Modern Day Role of Interventional Radiologist in Metastatic Disease to the Liver, Hepatic-directed Regional Therapies, January 20, 2012, San Francisco, California
2012 International Symposium on Endovascular Therapy (ISET), Plenary Session: Endovascular Medicine 2012-2020: What does the Future hold? Advances in Molecular Therapy, January 16th 2012, Miami, Florida
2012 Fourth Annual Symposium on Clinical Interventional Oncology, Exciting Topics, The Future of Interventional Oncology is in New Biologic Delivery, January 14th, 2012, Miami, Florida
2012 Fourth Annual Symposium on Clinical Interventional Oncology, Treatment of Colorectal Liver Metastases, Transcatheter Therapy for Liver Metastases: How I Decide what to Use? January 14th, 2012, Miami, Florida
2012 Fourth Annual Symposium on Clinical Interventional Oncology, Focus Session on Drug-eluting Embolics, Last Five Cases I Have done with Drug-eluting Embolics, January 14th, 2012, Miami, Florida
2012 Fourth Annual Symposium on Clinical Interventional Oncology, Role of Conventional Chemoembolization Now and in the Future, Panel Discussion, January 14th, 2012, Miami, Florida
2011 Radiology Society of North America, 97th Scientific Assembly and Annual Meeting, Interventional Oncology Series, Hepatocelluar Carcinoma, Intraarterial Therapy, November 27, 2011, Chicago, Illinois
2011 Radiology Society of North America, 97th Scientific Assembly and Annual Meeting, Interventional Oncology Series, Hepatocelluar Carcinoma, Tumor Board, November 27, 2011, Chicago, Illinois
2011 Image-Guided Therapy: Fourth Pillar of Multidisciplinary Cancer Care Symposium University of Utrecht Cancer Center, Chemoembolization of Liver Tumors, November 21st, 2011, Grand Hotel Karel V, Utrecht, the Netherlands
2011 Strategies for the Management of Hepatocellular Carcinoma: Paths to Progress, Surgical and Interventional Radiology Management, November 18th, 2011, New York City, New York
2011 Advanced Interventional Management Symposium, 19th Annual Meeting, Interventional Oncology, Liver Cancer: Tumor Board, November 18th, 2011, New York City, New York
2011 Advanced Interventional Management Symposium, 19th Annual Meeting, Interventional Oncology, Chemoembolization Using DEBs is Best: How do I do it and Value of Periprocedure Anti-angiogenic Therapy, November 17th, 2011, New York City, New York
2011 Advanced Interventional Management Symposium, 19th Annual Meeting, Interventional Oncology, Imaging Strategies to Assess Extent of Disease and Results of Therapy, November17th, 2011, New York City, New York
2011 Expert Panel on the Management of Hepatocellular Carcinoma, Clinical Benefit of Combination Chemoembolization and Targeted Therapy in Selected HCC patients: The Western Perspective, October 9, 2011, Taipei, Taiwan
2011 Taiwan Digestive Disease Week Annual Meeting, Special Lecture, Optimizing Treatment Outcomes of Patients with Intermediate and Advanced Stage Hepatocellular Carcinoma: Importance of Patient Selection and Novel Treatment Strategies, October 9, 2011, Taipei, Taiwan
2011 Special Symposium on the Management of Hepatocellular Carcinoma, Potential Rationale for Systemic Therapy with Antiangiogenic Properties in Intermediate HCC: The Western Perspective, October 7, 2011, Kaohsiung, Taiwan
2011 First UMDNJ Multidisciplinary Hepatocellular Carcinoma Symposium, Emerging Therapies and Clinical Trials in Hepatocellular Carcinoma, September 25th, 2011, Summit, New Jersey
2011 New England Society of Interventional Radiology (NESIR) Guest Speaker, Management of Liver Cancer: The Era of Combination Therapies, September 13th, 2011, Boston, Massachusetts
2011 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Special Session: Film Interpretation Panel, Team Barcelona, September 12th, 2011, Munich, Germany
2011 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Special Session: Oncologic IR under the microscope, Tissue Changes after Tumor Embolization: Does Chemotherapy Truly add to the Cytotoxic Effects? September 12th, 2011, Munich, Germany
2011 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Biocompatibles Symposium on DC Bead in HCC: survival update and combination therapy with Sorafenib, Clinical Results of a Phase II trial of Sorafenib Combined with Drug-Eluting Bead Doxorubicin (DEBDOX) for Patients with Hepatocellular Carcinoma, September 11th, 2011, Munich, Germany
2011 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Bayer Healthcare Symposium on TACE and the Evolving Paradigm in the Management of Intermediate HCC, Advances in the Treatment of Intermediate HCC: Systemic Therapy with Antiangiogenic Properties Used Concomitantly with TACE, September 10th, 2011, Munich, Germany
2011 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Philips Healthcare Symposium on the Innovations in planning, therapy and monitoring in interventional oncology, Intra-arterial Cancer Therapy: See, Reach, Treat and Assess, September 10th, 2011, Munich, Germany
2011 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Special Session: Ongoing Research in IR, Antiangiogenic Drugs and Resorbable Microspheres: What is the Promise?, September 10th, 2011, Munich, Germany
2011 International Liver Cancer Association, Fifth Annual Conference, Key Topics in the Treatment of Hepatocellular Carcinoma in Asia, Potential Rationale for Systemic Therapy with Antiangiogenic Properties in Intermediate HCC: The Western Perspective, September 2, 2011, Hong Kong, China
2011 Asia-Pacific Primary Liver Cancer Expert Meeting, Chemoembolization and Combination Therapies for Hepatocellular Carcinoma, July 3rd, 2011, Osaka, Japan
2011 World Conference in Interventional Oncology, 5th Annual Meeting, Yttrium 90 Symposium: 10 year Experience at Johns Hopkins, June 12h, 2011, New York City, New York
2011 World Conference in Interventional Oncology, 5th Annual Meeting, Enhancing Embolization with Anti-Angiogenic Therapy: Myth or Reality? June 11h, 2011, New York City, New York
2011 American Society of Clinical Oncology, Meet the Professor Session, Non Surgical Strategies of Hepatocellular Carcinoma, June 4th, 2011, Chicago, Illinois
2011 Emory University School of Medicine, Winship Cancer Institute, Gastrointestinal Oncology Grand Rounds, Management of Hepatocellular Carcinoma: Role of Intra-arterial Therapy, May 26th, 2011, Atlanta, Georgia
2011 Global Embolization Symposium and Technologies (GEST) Europe, Chemoembolization with Drug-eluting Beads: Case for a Treatment Standard, April 29th, 2011, Paris, France.
2011 Global Embolization Symposium and Technologies (GEST) Europe, Current Status of Drug Eluting Beads for Hepatocellular Carcinoma, April 29th, 2011, Paris, France
2011 Global Embolization Symposium and Technologies (GEST) Europe, Antiangiogenic Drugs: Before, During or After TACE, April 29th, 2011, Paris, France
2011 Society of Interventional Radiology 36th Annual Meeting, Functional Methods of Response Assessment, Plenary Session on Imaging response after image-guided Therapies: Making Sense of it all, March 30th 2011, Chicago, Illinois
2011 Society of Interventional Radiology 36th Annual Meeting, Commercializing a Therapeutic, Categorical Course on Nanotechnology, March 29th 2011, Chicago, Illinois
2011 Society of Interventional Radiology 36th Annual Meeting, Targeted Therapy in Oncology, Plenary Session on Frontiers in Interventional Oncology, March 28th 2011, Chicago, Illinois
2011 Society of Interventional Radiology 36th Annual Meeting, DEB TACE in 2011: Why, When, How?, Featured Symposium on Practical Interventional Oncology, March 26th 2011, Chicago, Illinois
2011 Philadelphia Angiography and Interventional Radiology Society, Non Surgical Management of Liver Cancer, March 16th, 2011, Philadelphia, Pennsylvania
2011 Arab Health Congress, 10th Middle East Surgery Conference, Role of Interventional Oncology in the Management of Liver Cancer, January 27th, 2011, Dubai, UAE
2011 Korean Liver Cancer Study Group Winter Symposium-Combining Sorafenib with Chemoembolization in Hepatocellular Carcinoma: What is the Rationale? January 14, 2011, Seoul, Korea
2011 Nexavar Hepatocellular Carcinoma Reimbursement Symposium-Key Challenges with TACE in Hepatocellualr Carcinoma: Where do we go from here? January 14, 2011, Seoul, Korea
2011 Severance Hospital Gastroenterology Grand Rounds, Rationale for Combination of Chemeoembolization and Sorafenib in Intermediate Hepatocellular Carcinoma, January 13, 2011, Seoul, Korea
2010 Radiology Society of North America, Interventional Oncology Series, Molecular Targeting and Emerging Clinical Foci in Interventional Oncology: Evolving Clinical Targets for Interventional Oncology Applications, November 30th, 2010, Chicago, Illinois
2010 Radiology Society of North America, Hot Topic, Image-guided Drug Delivery: Transcatheter Intraarterial Image-guided Drug Delivery, November 30th, 2010, Chicago, Illinois
2010 Radiology Society of North America, Interventional Oncology Series, Hepatocellular Carcinoma: Tumor Board Case Discussion, November 29, 2010, Chicago, Illinois
2010 Radiology Society of North America, Interventional Oncology Series, Hepatocellular Carcinoma: Transcatheter Therapies and Factors Affecting Clinical Decision Making, November 29, 2010, Chicago, Illinois
2010 Excellence in Oncology Annual Conference, Current Status of Combination Chemoembolization and Systemic Targeted Therapy for Hepatocellular Carcinoma, November 20th, 2010, Athens, Greece
2010 Advanced Interventional Management Symposium, 18th Annual Meeting, Interventional Oncology, Local Therapy for Hepatocellular Carcinoma: Conventional Chemoembolization vs. Drug-eluting Bead Chemoembolization, November 18th, 2010, New York City, New York
2010 Advanced Interventional Management Symposium, 18th Annual Meeting, Interventional Oncology, Local Therapy for Hepatocellular Carcinoma: Chemoembolization, November 18th, 2010, New York City, New York
2010 Israel Radiological Association Annual Meeting, Current Therapies for Intermediate and Advanced Stage Hepatocellular Carcinoma, October 28th, 2010, Eilat, Israel
2010 Israel Radiological Association Annual Meeting, Keynote Address, Non Surgical Management of Liver Cancer, October 28th, 2010, Eilat, Israel
2010 Indian Society of Vascular and Interventional Radiology, Annual Oration, Chemoembolotherapy and Yttrium 90 Radioembolotherapy for Patients with Liver Cancer, October 23rd, 2010, Chandigarh, India
2010 Indian Society of Vascular and Interventional Radiology, Annual Oration, The Future of Interventional Oncology, October 22nd, 2010, Chandigarh, India
2010 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Special Session: Interventional Oncology at the Cellular Level, Mechanisms of Action of Arterial Embolization in the Liver, October 5th, 2010, Valencia, Spain
2010 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Biocompatibles Symposium on DC Beads in HCC, Chemoembolization: the Case for a Treatment Standard, October 5th, 2010, Valencia, Spain
2010 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Plenary Session on New Frontiers in IR, Interventional Radiology at the Molecular Level, October 4th, 2010, Valencia, Spain
2010 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Philips Healthcare Symposium on New Frontiers in Image-Guided Interventional Therapies, Advanced Imaging Applications in Transarterial Tumor Therapy, October 2nd, 2010, Valencia, Spain
2010 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Bayer Healthcare Symposium on Key Challenges with TACE in HCC, Is There a Potential Role for Systemic Therapy in Patients Suitable for TACE?, October 2nd, 2010, Valencia, Spain
2010 International Liver Cancer Association, Fourth Annual Conference, Locoregional Arterial Therapies for Hepatocellular Carcinoma, September 11, 2010, Montreal, Canada
2010 International Liver Cancer Association, Fourth Annual Conference, Bayer Symposium: The HCC Forum; Key Questions in the Diagnosis and Detection of HCC, Is There a Rationale for Investigating the Combination of TACE and Sorafenib for the Treatment of Intermediate HCC Population and what Supporting Evidence exists to date?, September 11, 2010, Montreal, Canada
2010 European Conference on Interventional Oncology, 2nd Annual Meeting, Targeting Tumor Metabolism: A new Anticancer Strategy, July 22nd, 2010, Florence, Italy
2010 European Conference on Interventional Oncology, 2nd Annual Meeting, Combination of Systemic Targeted Agents and Chemoembolization: Rationale and Results, July 22nd, 2010, Florence, Italy
2010 World Conference in Interventional Oncology, 4th Annual Meeting, Chemoembolization with Doxorubicin-eluting Beads: Clinical results June 10th, 2010, Philadelphia, Pennsylvania
2010 World Conference in Interventional Oncology, 4th Annual Meeting, Can Systemic Agents Improve Outcomes of Embolotherapy? June 10th, 2010, Philadelphia, Pennsylvania
2010 Asia Pacific Congress in Cardiovascular and Interventional Radiology, 9th Annual Meeting, Chemoembolization Using Drug-Eluting Beads, June 3rd, 2010, Seoul, Korea
2010 Asia Pacific Congress in Cardiovascular and Interventional Radiology, 9th Annual Meeting, New Developments in Transcatheter Drug Delivery, June 2nd, 2010, Seoul, Korea
2010 Case Western Reserve University Department of Radiology Grand Rounds, Transcatheter Therapies for Hepatocellular Carcinoma, Kulas Auditorium, May 11th, 2010, Cleveland, Ohio
2010 Global Embolization Symposium and Technologies (GEST), Antiangiogenic Drugs in the Setting of Chemoembolization: Is there a Rationale? May 7th, 2010, San Francisco, California
2010 Global Embolization Symposium and Technologies (GEST), State of Evidence: Drug-eluting Beads Chemoembolotherapy for Liver Cancer, May 7th, 2010, San Francisco, California
2010 Global Embolization Symposium and Technologies (GEST), Drug-eluting Beads: Handling, May 7th, 2010, San Francisco, California
2010 55th Annual Philip A. Tumulty Topics in Clinical Medicine, Intraarterial Treatments for Cancer, May 4th, 2010, Johns Hopkins University School of Medicine, Turner Auditorium, Baltimore, Maryland
2010 Bayer Schering Expert Symposium on Targeted Therapies, Exploring the Next Steps in Intermediate HCC, April 10, 2010, Geneva, Switzerland
2010 Medical Oncology Grand Rounds, Johns Hopkins University School of Medicine, Intraarterial Therapies for Liver Cancer, April 2nd, 2010, Weinberg Auditorium, Johns Hopkins University School of Medicine, Baltimore, Maryland
2010 Society of Interventional Radiology, 35th Annual Scientific Meeting, Plenary Session, Targeted Therapy in Oncology, March 15, 2010, Tampa, Florida.
2010 Regional Cancer Therapies 5th International Symposium, Tumor Board on the Management of Patients with Metastatic Liver Tumors, February 21st, 2010, San Juan, Puerto Rico
2010 Regional Cancer Therapies 5th International Symposium, Intraarterial Therapy for Liver Cancer: Current recommendations and Future Direction, February 21st, 2010, San Juan, Puerto Rico
2010 American Society of Clinical Oncology Gastrointestinal Cancer Symposium, Tumor Board on the Management of Patients with Metastatic Neuroendocrine Tumors, January 23rd, 2010, Orlando World Center Marriott, Orlando, Florida
2010 American Hepato-Pancreato-Biliary Association Consensus Conference on Hepatocellular Carcinoma, The Role of TACE and Emerging Therapies, January 21st, 2010, Orlando, Florida
2010 Gastroenterology Division Grand Rounds, Johns Hopkins University School of Medicine, Transcatheter Therapies for Liver Cancer, January 13th, 2010, Johns Hopkins University School of Medicine, Baltimore, Maryland
2009 Radiology Society of North America, Interventional Oncology Symposium, Hepatocellular Carcinoma, Tumor Board, November 29, 2009, Chicago, Illinois
2009 Radiology Society of North America, Interventional Oncology Symposium, Hepatocellular Carcinoma, Advances in Transcatheter Interventional Oncology Therapies: Critical Review of the Data, November 29, 2009, Chicago, Illinois
2009 Advanced Interventional Management Symposium, 17th Annual Meeting, Oncology Session: Primary and Secondary Liver Cancer, The Future of interventional Oncology, November 20th, 2009, New York City, New York
2009 Advanced Interventional Management Symposium, 17th Annual Meeting, Oncology Session: Chemoembolization and Yttrium 90, November 19th, 2009, New York City, New York
2009 Advanced Interventional Management Symposium, 17th Annual Meeting, Oncology Session: Multidisciplinary Approach Yields the Best Approach, November 19th, 2009, New York City, New York
2009 American Association for the Study of Liver Diseases, 60th Annual Meeting, University of Florida Satellite Symposium, Taking Stock of the Current Research in Hepatocellular Carcinoma, Standards in Imaging and Intervention in Liver Cancer: What are the Best Tools?, November 1st, 2009, Boston, Massachusetts
2009 Nexavar Investigator Forum, Hepatocellular Carcinoma, Transcatheter and Combination Therapies for Hepatocellular Carcinoma, October 8th, 2009, Chicago, Illinois
2009 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Plenary Session Future Technology, The Future of Catheter-Guided Cancer Therapy, September 23, 2009, Lisbon, Portugal
2009 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Bayer Schering Satellite Symposium, Current Treatment of Intermediate-stage Hepatoma, September 22, 2009, Lisbon, Portugal
2009 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Philips Medical Systems Satellite Symposium, Imaging Innovations for Liver Embolotherapy, September 19, 2009, Lisbon, Portugal
2009 World Conference on Interventional Oncology (WCIO) 4th Annual Meeting, Chemoembolization and Radioembolization for Liver Metastases, June 27, 2009, Beijing, China
2009 World Conference on Interventional Oncology (WCIO) 4th Annual Meeting, Chemoembolization with Drug-eluting Beads, June 26, 2009, Beijing, China
2009 University of Utrecht Cancer Center Grand Rounds (Visiting Professor), Interventional Oncology for Liver Tumors, June 9th, 2009, Utrecht, The Netherlands
2009 19th Annual Robin C. Watson Memorial Lecture, Memorial Sloan-Kettering Cancer Center, Department of Radiology, New Therapies for Liver Cancer, May 5th, 2009, New York City, New York
2009 Global Embolization Symposium and Technologies (GEST), Drug-eluting Beads: Current Options, April 16th, 2009, Paris, France
2009 Global Embolization Symposium and Technologies (GEST), Radioembolization: TheraSpheres, April 15th, 2009, Paris, France
2009 Second Israeli Conference on Interventional Oncology, Chemoembolization for Liver Cancer: Conventional and Drug-eluting beads, April 2nd, 2009, Tel Aviv, Israe
2009 Society of Interventional Radiology, 34th Annual Scientific Meeting, Plenary Session, Cancer Therapies: Biologic Lead, March 11, 2009, San Diego, California
2009 Society of Interventional Radiology, 34th Annual Scientific Meeting, Categorical Course on the Management of Hepatocellular Carcinoma, Review and Rationale for Palliative Options (TACE/Y90/Bland): Critical Review, March 8, 2009, San Diego, California
2009 Society of Interventional Radiology, 34th Annual Scientific Meeting, Plenary Session: Research to Practice, Forum, March 9, 2009. San Diego, California
2009 Society of Surgical Oncology 62nd Annual Meeting, Emerging Therapeutic Approaches for Hepatocellular Carcinoma: Intra-arterial Regional Therapy for Hepatocellular Carcinoma: Where do we Stand? March 5th, 2009, Phoenix, Arizona
2009 University of Miami School of Medicine Division of Hepatology Grand Rounds, New Paradigms in Liver Cancer Therapies, February 19, 2009, Miami, Florida
2009 Eighth Annual Intensive Course for Interventional Radiology (IICIR), Seoul National University Hospital, Transcatheter Management of Liver Cancer: Research and Experience in the US, February 10, 2009, Seoul, Republic of Korea
2009 Arab Health Conference, Imaging Symposium, Future of Medicine: Image-guide Therapy, January 27, 2009, Dubai, United Arab Emirates
2008 Hepatocellular Carcinoma: Eastern and Western Experiences, 6th International Meeting, New Transarterial Agents for Hepatocellular Carcinoma, December 8th, 2008, Seoul, Korea.
2008 Radiology Society of North America, Interventional Oncology Symposium, Advances in Transcatheter Interventional Oncology Therapies, December 4th, 2008, Chicago, Illinois
2008 Radiology Society of North America, Interventional Oncology Symposium, Hepatocellular Carcinoma: Patient Management Algorithms, November 30th, 2008, Chicago, Illinois
2008 Radiology Society of North America, Interventional Oncology Symposium, Hepatocellular Carcinoma: Transarterial Chemoembolization, November 30th, 2008, Chicago, Illinois
2008 Sixteenth Annual Advanced Interventional Management Symposium (AIMS), Drug-eluting Microspheres: Tecjhniques and Results, November 21, 2008, New York City, New York
2008 Johns Hopkins University School of Medicine Hepato-biliary Update (14th Annual Meeting), Hepatocellular Carcinoma: Loco-regional Therapy, November 16th, 2008, Baltimore, Maryland
2008 Southeastern Angiography Society, Annual Meeting, Role of Physician Extenders in Interventional Oncology, Martha Washington Inn, October 9, 2008, Abingdon, Virginia
2008 Southeastern Angiography Society, Annual Meeting, Emerging Therapies in Oncology, Martha Washington Inn, October 9, 2008, Abingdon, Virginia
2008 Southeastern Angiography Society, Annual Meeting, Chemoembolization of Liver Cancer, Martha Washington Inn, October 9, 2008, Abingdon, Virginia
2008 Imperial College Symposium on Hepato-biliary Cancer, Chemoembolization and Drug-eluting Microspheres for Liver Cancer, October 1st, 2008, Hammersmith Hospital, London, United Kingdom
2008 Fourth Annual Oncology Congress, Multidisciplinary Approach to Primary and Metastatic Liver Cancer, Loco-regional Therapies: To Whom and With What? September 26th, 2008, San Francisco, California
2008 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Plenary Session Controversies in Non-vascular Interventions, Role of Combination Intraarterial and Targeted Therapies, September 14, 2008, Copenhagen, Denmark
2008 Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Plenary Session Foundation Course: Interventional Oncology on Hepatocellular Carcinoma, Intraarterial Therapy for Hepatocellular Carcinoma, September 13, 2008, Copenhagen, Denmark
2008 The Korean Liver Cancer Study Group 11th Symposium, The 21st Century Paradigm Shift in the Management of Hepatocellular Carcinoma, New Transcatheter Treatments for Hepatocellular Carcinoma, June 28, 2008, Seoul, Korea
2008 World Conference on Interventional Oncology (WCIO) 3nd Annual Meeting, Chemoembolization with Drug-eluting Beads, June 23, 2008, Los Angeles, California
2008 World Conference on Interventional Oncology (WCIO) 3nd Annual Meeting, Chair, Satellite Symposium on Multidisciplinary Management of Hepatocellular Carcinoma, Hepatocellular Carcinoma: A Worldwide Problem, June 22, 2008, Losa Angeles, California
2008 World Conference on Interventional Oncology (WCIO) 3nd Annual Meeting, New Intraarterial Chemotherapeutics, June 22, 2008, Los Angeles, California
2008 Global Embolization Symposium and Technologies (GEST), Drug-eluting Microspheres for Liver Cancer: Results Point to the Future, June 7, 2008, Barcelona, Spain
2008 Global Embolization Symposium and Technologies (GEST), Chemoembolization for Liver Cancer: Top Tips, June 6, 2008, Barcelona, Spain
2008 Oncology Symposium at the Gustave Roussy Cancer Institute, Radioembolization for Liver Cancer: Indications and Results, May 23, 2008, Paris, France
2008 Philips Multidisciplinary Oncology Symposium, Intraarterial
Interventional Therapies for Liver Cancer, April 24th, 2008, Washington DC
2008 European Conference on Interventional Oncology, Plenary Session on New Ablation Devices and Transarterial Agents, Intraarterial Therapies Using Tumor Metabolism Inhibitors, April 10 2008, Florence, Italy
2008 European Conference on Interventional Oncology, Plenary Session on Intermediate-advanced Hepatocellular carcinoma, Chemoembolization with Drug-eluting Beads, April 10, 2008, Florence, Italy
2008 Society of Interventional Radiology, 33rd Annual Scientific Meeting, Symposium, Drug Delivery: Drug Delivery via Catheter, March 20, 2008, Washington DC
2008 Society of Interventional Radiology, 33rd Annual Scientific Meeting, Categorical Course, Interventional Oncology Case Discussions, March 19, 2008, Washington DC
2008 Society of Interventional Radiology, 33rd Annual Scientific Meeting, Plenary Session, Review of Image-guided Transvascular Therapy for HCC, March 19, 2008, Washington DC
2008 Society of Interventional Radiology, 33rd Annual Scientific Meeting, Categorical Course, Drug –Eluting Beads, March 16, 2008, Washington DC
2008 Society of Interventional Radiology, 33rd Annual Scientific Meeting, Plenary Session, Should IO Split from the SIR? Pro: Let’s Get a New Home, March 16, 2008, Washington DC
2008 Society of Interventional Radiology, 33rd Annual Scientific Meeting, Plenary Session, Cellular Delivery, March 16, 2008, Washington DC
2008 Johns Hopkins University School of Medicine, Nuclear Oncology: From Genotype to Phenotype to Targeted Therapy, Y90 Microspheres for Liver Tumors, March 14, 2008, Baltimore, Maryland
2008 University of Michigan School of Medicine Department of Radiology,
Visiting Professor, Grand Rounds, Intraarterial Targeted Therapy for Liver Cancer, February 13th, 2008, Ann Arbor, Michigan
2008 Wake Forest University School of Medicine Department of Radiology Visiting Professor, Grand Rounds, Intraarterial Therapy for Liver Cancer, February 5th, 2008, Winston-Salem, North Carolina
2008 Georgetown University School of Medicine Department of Radiology Visiting Professor, Grand Rounds, Targeted Intraarterial Therapies for Liver Cancer, January 11, 2008, Washington DC
2007 Radiology Society of North America/National Cancer Institute, Interventional Oncology Symposium, New Horizons in Transcatheter Therapies (Drug Delivery Systems, Radiotherapy, Genes, Biologics), November 30, 2006, Chicago, Illinois
2007 Fifteen Annual Advanced Interventional Management Symposium (AIMS), Chemoembolization: Indications and Techniques, Including New Absorbing Beads and Drugs, November 12, 2007, New York City
2007 First Annual State-of-the-Art Imaging and Interventional Forum, University of California Los Angeles, Future Developments: Future Developments in Transarterial Chemoembolization, November 1st, 2007, Santa Barbara, California
2007 First Annual State-of-the-Art Imaging and Interventional Forum, University of California Los Angeles, Oncology: Drug Eluting Beads, November 1st, 2007, Santa Barbara, California
2007 First Israeli Conference on Interventional Oncology, Comprehensive Management of Hepatocellular Carcinoma, October 9th, 2007, Tel Aviv, Israel
2007 First Israeli Conference on Interventional Oncology, Overview on Vascular Interventions, October 9th, 2007, Tel Aviv, Israel
2007 Symposium on Loco-Regional Treatment of Hepatocellular Carcinoma, Royal Free Hospital, Smart Beads and Nano-particles: What is the Future of Chemoembolization?, September 21st, 2007, London, United Kingdom
2007 Cardiovascular and Interventional radiology Society of Europe Annual Meeting, Plenary Special Session: Controversies in Interventional Radiology, Con: Bland Embolization is all you need for hepatocellular carcinoma, September 9th, 2007, Athens, Greece
2007 Onco-Interventional Radiology Congress, University of the Free State, Transarterial Chemoembolization for Liver Cancer Including Drug-Eluting Bead, August 5th, 2007, Bloemfontein, South Africa
2007 Onco-Interventional Radiology Congress, University of the Free State, Yttrium 90 Microspheres for Liver Cancer, August 5th, 2007, Bloemfontein, South Africa
2007 Onco-Interventional Radiology Congress, University of the Free State, Portal Vein Embolization, August 5th, 2007, Bloemfontein, South Africa
2007 Japanese Society of Interventional Radiology, 36th Annual Meeting, New Intraarterial Therapies for Hepatocellular Carcinoma (Keynote Address), May 25th, 2007, Kanazawa, Japan
2007 Japanese Society of Interventional Radiology, 36th Annual Meeting, Transarterial Hepatic Chemoembolization in the United States (Plenary Session), May 25th, 2007, Kanazawa, Japan
2007 American College of Radiology, Interventional Oncology Symposium, Transarterial Therapy for Primary and Secondary Liver Cancer, May 18, 2007, Washington DC
2007 American College of Radiology, Interventional Oncology Symposium, Principles of Intraarterial Therapy, May 18, 2007, Washington DC
2007 National Cancer Institute Workshop on Interventional Oncology, Eastern Cooperative Oncology Group (ECOG) Trial of Drug-eluting Microspheres Chemoembolotherapy in Patients with Hepatocellular Carcinoma, May 17, 2007, Washington DC
2007 World Conference on Interventional Oncology (WCIO) 2nd Annual Meeting, Chemoembolization for Hepatocellular Carcinoma, May 16, 2007, Washington DC
2007 World Conference on Interventional Oncology (WCIO) 2nd Annual Meeting, Biological Aspects of Transarterial Therapy, May 15, 2007, Washington DC
2007 Global Embolization Symposium and Technologies (GEST), Chemoembolization for Hepatocellular Carcinoma: Results of Western Experience, April 25th, 2007, Barcelona, Spain
2007 Global Embolization Symposium and Technologies (GEST), Drug Eluting Particles for Interventional Pharmacology, April 25th, 2007, Barcelona, Spain
2007 Anodolu Medical Center/Johns Hopkins Medicine International Conference on Gastrointestinal Cancer, Percutaneous Ablative Techniques for Liver Cancer, March 23rd, 2007, Istanbul, Turkey
2007 Anodolu Medical Center/Johns Hopkins Medicine International Conference on Gastrointestinal Cancer, Intraarterial Therapy for HCC, March 23rd, 2007, Istanbul, Turkey
2007 Society of Interventional Radiology 32nd Annual Meeting, Plenary Session on Interventional Oncology. Transcatheter Therapies for Hepatocellular Carcinoma: Clinical Outcomes. March 6, 2007, Seattle, Washington
2007 Society of Interventional Radiology 32nd Annual Meeting, Plenary Session. CRC/Mets: Chemoembolization: Critical Assessment of the Data. March 5, 2007, Seattle, Washington
2007 Society of Interventional Radiology 32nd Annual Meeting, Plenary Session. HCC: Chemoembolization: A Critical Assessment of the Data. March 5, 2007, Seattle, Washington
2007 Society of Interventional Radiology 32nd Annual Meeting, Plenary Session, Targeting Tumor Metabolism with Intraarterial therapy. March 2, 2007, Seattle, Washington
2007 Stanford University School of Medicine, 9th Annual Techniques in Interventional Radiology, Drug-eluting Beads for Liver Cancer, February 24, 2007, Squaw Valley, California.
2007 Stanford University School of Medicine, 9th Annual Techniques in Interventional Radiology, CT vs. MR Imaging for Hepatocellular Carcinoma, February 23, 2007, Squaw Valley, California.
2007 Seventh National Forum on Biomedical Imaging in Oncology, Oncologic Image-guided Interventions: Opportunities for Collaboration, Case Analysis Clinical Trial-Principal Investigator Perspective, February 1st, 2007, Bethesda, Maryland
2007 Sixth Annual Intensive Course for Interventional Radiology (IICIR), Seoul National University Hospital, Transcatheter Management of Liver Cancer: Research and Experience in the US, January 30th, 2007, Seoul, Republic of Korea.
2007 Johns Hopkins University School of Medicine Department of Radiology Grand Rounds, Intraarterial Therapy for Liver Cancer, January 11, 2007, Baltimore, Maryland
2006 Royal Free Hospital Department of Surgery Lecture Series, Targeted Therapy for Liver Cancer, December 22nd, 2006, London, United Kingdom
2006 Radiology Society of North America, Interventional Oncology Symposium, Outcomes of Transcatheter Treatment Options in Hepatocellular Carcinoma, November 30, 2006, Chicago, Illinois
2006 Sixteen Annual Advanced Interventional Management Symposium (AIMS), Chemoembolization vs. Radiation Bead Embolization, November 14, 2006, New York City
2006 Congress of Brazilian Society of Interventional Radiology and Endovascular Surgery (SOBRICE IX), Intraarterial Thearpy for Liver Cancer, November 10, 2006, Maksoud Plaza Hotel, Sao Paulo, Brazil
2006 Congress of Brazilian Society of Interventional Radiology and Endovascular Surgery (SOBRICE IX), Percutaneous Therapy for Liver Tumors, November 10, 2006, Maksoud Plaza Hotel, Sao Paulo, Brazil
2006 Southeastern Angiography Society and Emory University School of Medicine Image Guided Intervention 2006, Practice Development in Interventional Oncology, October 20, 2006, The Greenbrier, White Sulphur Springs, West Virginia
2006 Southeastern Angiography Society and Emory University School of Medicine Image Guided Intervention 2006, Management of the Patient with Liver Cancer, October 20, 2006, The Greenbrier, White Sulphur Springs, West Virginia
2006 Southeastern Angiography Society and Emory University School of Medicine Image Guided Intervention 2006, Intraarterial Therapy for Liver Cancer, October 20, 2006, The Greenbrier, White Sulphur Springs, West Virginia
2006 Southeastern Angiography Society and Emory University School of Medicine Image Guided Intervention 2006, Targeted Therapy for Cancer, October 20, 2006, The Greenbrier, White Sulphur Springs, West Virginia
2006 University of Utah Huntsman Cancer Institute, Intraarterial Therapy for Liver Cancer, October 11th, 2006, Salt Lake City, Utah
2006 Advanced Cardiac and Endovascular Therapies (ACE), Chemoembolization of Hepatic Malignancies, October 10th, 2006, New York City, New York
2006 Advanced Cardiac and Endovascular Therapies (ACE), Chemoembolization for Liver Tumors: How I Do It, October 9th, 2006, New York City, New York
2006 Vascular Interventional Advances (VIVA), Chemoembolization for Primary and Metastatic Liver Cancer: Do we Have the Data to Overcome the Resistance of Oncologists? September 25th, Mandalay Bay Resort, Las Vegas, Nevada
2006 Second Congress of Vascular and Interventional Radiology Foundation, Multi-disciplinary Approach to Clinical Management of Hepatocellular carcinoma, Transcatheter Arterial Chemoembolization, September 24th, 2006, Hong Kong Polytechnic University, Hong Kong, China
2006 International Congress of Radiology, 24th Annual Meeting, Intraarterial Therapy for Liver Cancer, August 13th, 2006, Capetown, South Africa
2006 International Congress of Radiology, 24th Annual Meeting, Future of Interventional Radiology, August 12th, 2006, Capetown, South Africa
2006 Hot Topics at Sea: Multidisciplinary Management of Hepatic, Pancreatic and Biliary Malignancies, Pancreatectomy: Role of the Interventional Radiologist in Managing Patients and Complications. August 19, 2006, Cruise to Alaska, Vancouver, Canada
2006 Hot Topics at Sea: Multidisciplinary Management of Hepatic, Pancreatic and Biliary Malignancies, Molecular Imaging and Novel Methods of Assessing Response to Therapy. August 18, 2006, Cruise to Alaska, Vancouver, Canada
2006 Hot Topics at Sea: Multidisciplinary Management of Hepatic, Pancreatic and Biliary Malignancies, Treatment of Liver Cancer with Yttrium 90 Microspheres. August 15, 2006, Cruise to Alaska, Vancouver, Canada
2006 Hot Topics at Sea: Multidisciplinary Management of Hepatic, Pancreatic and Biliary Malignancies, Chemoembolization: What are the Goals? What are the Limits? August 14, 2006, Cruise to Alaska, Vancouver, Canada.
2006 Union of International Cancer Conferences, Plenary Session, Tumor Board on Liver Cancer, July 9th, 2006, Washington DC.
2006 World Conference on Interventional Oncology, Plenary Session, Emerging Transcatheter Therapies: New drugs and Concepts, June 13th, 2006, Como, Italy.
2006 World Conference on Interventional Oncology, Plenary Session, Review of Available Transvascular Therapies, June 12th, 2006, Como, Italy.
2006 University of Medicine and Dentistry of New Jersey Department of Radiology Grand Rounds, Non-Surgical Management of Liver Cancer, May 24th, 2006, Newark, New Jersey.
2006 St Vincent Medical Center 150th Anniversary Symposium “On the Edge of Innovation”, Shaping the Future of Medicine by Radiology, May 6th, 2006, Los Angeles, California.
2006 University of Massachusetts School of Medicine Department of Radiology Grand Rounds, Intraarterial Targeted Therapy for Liver Cancer, May 1st, 2006, Worcester, Massachusetts.
2006 Society of Interventional Radiology, 31st Annual Scientific Meeting, Plenary Session, Chemoembolization: Hepatocellular Carcinoma, April 3, 2006, Toronto, Ontario, Canada.
2006 Society of Interventional Radiology, 31st Annual Scientific Meeting, Categorical Course, Providing Continuity in Follow-up, April 4, 2006, Toronto, Ontario, Canada.
2006 Colorado Angiography Society, Liver Cancer: Treatment with Chemoembolotherapy, March 14, 2006, Denver, Colorado
2006 New York University School of Medicine Radiology Research Seminar, Targeted Therapy for Liver Cancer, February 23, 2006, New York City.
2006 Stanford University School of Medicine, 8th Annual Techniques in Interventional Radiology, New Cancer Therapies, February 17, 2006, Squaw Valley, California.
2006 Stanford University School of Medicine, 8th Annual Techniques in Interventional Radiology, Intra-arterial Therapy for Liver Cancer, February 17, 2006, Squaw Valley, California.
2006 Korean Society of Interventional Radiology, Seoul National University Hospital, Research on Liver Cancer: Drug Delivery and Targeted Therapy, February 14, 2006, Seoul, Republic of Korea.
2006 Fifth Annual Intensive Course for Interventional Radiology (IICIR), Seoul National University Hospital, Management of Patients with Liver Cancer: Research and Experience in the US, February 13, 2006, Seoul, Republic of Korea.
2005 Radiology Society of North America, Interventional Oncology Symposium, Intraarterial Delivery of Drug-eluting Beads, December 2, 2005, Chicago, Illinois
2005 Radiology Society of North America, Interventional Oncology Symposium, Drug Delivery in Interventional Oncology, December 1st, 2005, Chicago, Illinois
2005 Advanced Cardiac and Endovascular Therapies Symposium, (ACE), Highly Targeted Oncology: Putting the Chemotherapy Where it Belongs, November 21, 2005, New York City
2005 Advanced Coronary and Endovascular Demonstrations Symposium, (ACE), Advances in Chemoembolization, November 21, 2005, New York City
2005 Fifteen Annual Advanced Interventional Management Symposium (AIMS), Chemoembolization,Bland Embolization or Radiation Bead Embolization: Which is Best?, November 15, 2005, New York City
2005 Fifteen Annual Advanced Interventional Management Symposium (AIMS), Hepatic Embolization and Chemoembolization: Principles, Controversies, Patient selection, Techniques, and Results, November 15, 2005, New York City
2005 Chesapeake Interventional Radiology Society, Chemoembolotherapy of Liver Cancer: An Update, November 10, 2005, Washington DC
2005 Philadelphia Angiography Society, Chemoembolization for Liver Cancer: Current Management and Future Trends, November 9, 2005, Philadelphia, Pennsylvania
2005 Society of Interventional Radiology Multimodality Symposia, Interventional Oncology, Treatment for Hepatocellular Carcinoma: Chemoembolization, October 29, 2005, Tyson’s Corner, Virginia
2005 Department of Gastroenterology Research Conference, Targeted Therapy for Liver Cancer, Johns Hopkins School of Medicine, October 25, 2005, Baltimore, Maryland
2005 French Society of Radiology Annual Meeting, The Embolization of the Future, Plenary Session on Interventional Oncology, October 16, 2005, Paris, France.
2005 New England Society of Interventional Radiology Grand Rounds (Brigham and Women’s Hospital), New Targeted Therapies for Liver Cancer, September 20, 2005, Boston, Massachusetts.
2005 Cardiovascular and Interventional Radiology Society of Europe, Plenary Session, New Agents for Chemoembolization, September 14, 2005, Nice, France.
2005 Cardiovascular and Interventional Radiology Society of Europe, Plenary Session, Oncology Interventions in the Liver Transplant Patient, September 12, 2005, Nice, France.
2005 Cardiovascular and Interventional Radiology Society of Europe, Plenary Session, Targeted Chemotherapy in Cancer, September 12, 2005, Nice, France.
2005 Yonsei Liver Cancer Special Clinic Second Anniversary Symposium on Therapeutic Experiences for Hepatocellular Carcinoma (Special Lecture), Treatment of Liver Cancer with Drug-eluting Beads and New Anti-cancer Agents, July 9, 2005, Seoul, Republic of Korea.
2005 Johns Hopkins University School of Medicine, Department of Medical Oncology Grand Rounds, Intraarterial Therapy for Liver Cancer with Yttrium 90 Microspheres, June 10, 2005, Baltimore, Maryland
2005 American Roentgen Ray Society, Instructional Course, Catheter-Directed Interventional Oncology: Chemoembolization and Radioisotope Embolization-New Agents and New Strategies, May 17, 2005, New Orleans, Louisiana.
2005 Japanese Society of Angiography and Interventional Radiology/International Society of Interventional Radiology Annual Meeting, Techniques and Embolic Agents in Transarterial Hepatic Chemoembolization, (Plenary session), Hyogo, Japan (2005).
2005 Japanese Society of Angiography and Interventional Radiology/International Society of Interventional Radiology Annual Meeting, Current Status of Transcatheter Arterial Chemoembolization for Patients with Hepatocellular Carcinoma in the US, Hyogo, Japan (2005).
2005 Japanese Society of Angiography and Interventional Radiology/International Society of Interventional Radiology Annual Meeting, Clinical Trials in Oncologic Intervention, Hyogo, Japan (2005).
2005 International Symposium on Image-Guided Therapy for Cancer, Emerging Therapies for Liver Cancer, May 2nd, 2005, London, United Kingdom.
2005 International Symposium on Image-Guided Therapy for Cancer, Chemoembolization for Hepatocellular Carcinoma, May 2nd, 2005, London, United Kingdom.
2005 Philips Medical Systems Symposium on New Frontiers in Interventional Radiology, Applications in interventional oncology, April 29, 2005, Paris, France.
2005 Indiana Interventional Radiology Lecture Series, Intrarterial Therapy for liver cancer. April 14, 2005, Indianapolis, Indiana
2005 Johns Hopkins International Symposium, Interventional Oncology, April 13, 2005, Toronto, Canada.
2005 Society of Interventional Radiology Plenary Session. Emerging Oncologic Interventions, Update on Chemoembolotherapy and Drug Delivery. April 4, 2005, New Orleans, Louisiana
2005 Society of Interventional Radiology Research Symposium, Foundation Support. March 31, 2005, New Orleans, Louisiana
2005 XVth SIMI (Week of Minimally Invasive Interventions), Eneri Medical Institute, Oncologic Interventions, March 14-16, 2005, Buenos Aires, Argentina
2005 Food and Drug Administration (FDA) and Society of Interventional Radiology Symposium on Interventional Oncology, Intraarterial Therapy for Liver Cancer, January 31st, 2005, Rockville, Maryland
2005 Johns Hopkins University School of Medicine, Department of Comparative Medicine Grand Rounds, New intraarterial therapeutic approaches for Liver Cancer, February 18, 2005, Baltimore, Maryland
2005 Seoul National University Hospital, Transcatheter management of hepatic tumors: Research and experience in the US, January 17, 2005, Seoul, Republic of Korea.
2004 Columbia University School of Medicine Symposium on Image-guided Tumor Therapy, Chemoembolization of liver cancer: current practice and new trends, December 16-17, 2004, New York City, New York
2004 MD Anderson Cancer Center, University of Texas, Radiology Grand Rounds, Intraarterial therapy for liver cancer: Molecular targets and drug delivery, November 3-4, 2004, Houston, Texas.
2004 Image-guided Ablation Therapies of Neoplastic Diseases, New intraarterial therapy for liver cancer, October 16, 2004, Milan, Italy
2004 French Society of Radiology, Annual Meeting, Intraarterial Therapy in Oncology, October 2, 2004, Paris, France
2004 Cardiovascular and Interventional Radiology Society of Europe, Satellite Symposium on Drug Delivery for Liver Tumors, Drug-eluting beads – Review of Pre-clinical data, September 26, 2004, Barcelona, Spain
2004 Tenth Annual Hepato-Biliary Update, Palliation of liver and bile duct cancer, September 6-7, 2003, Cambridge, Maryland
2004 Keynote Lecture, “Image-guided Therapy of Hepatocellular Carcinoma: The New and the True”, 6th World Congress of the International Hepato-Pancreato-Biliary Association, June 2-6, 2004, Washington DC
2004 Johns Hopkins University School of Medicine, Seminar in International Health “The Future is Here: Managing Change in Clinical Care”, Recent Developments in Image-Guided Interventional Therapies, May 12, 2004, Baltimore, Maryland
2004 Johns Hopkins University School of Medicine, Department of Pathology Grand Rounds, Intraarterial Therapy for Liver Cancer, Baltimore, Maryland
2004 American Roentgen Ray Society, Instructional Course, Percutaneous Management in Oncology: Chemoembolization, May 6, 2004, Miami, Florida
2004 National Institutes of Health (NIH/NIDDK) Symposium on Hepatocellular Carcinoma, Intraarterial Therapy with Yttrium 90 Microspheres, April 3rd, 2004, Bethesda, Maryland
2004 Society of Interventional Radiology Plenary Session. The world of Intervention: IR in oncology, Transarterial Therapies in the US. March 27, 2004, Phoenix, Arizona
2004 International Symposium on Endovascular Therapy (ISET), Chemoembolization of liver tumors. January 29, 2004, Miami, Florida
2004 University of Texas MD Anderson Cancer Center, Oncologic Interventional Radiology: A Multidisciplinary Approach. January 22-24, 2004, Houston, Texas
2003 Radiology Society of North America, Refresher Course on Functional Image-guided Therapy of Hepatic Malignancies, Assessment of Chemoembolization for Liver Cancer. December 1-5, 2003, Chicago, Illinois
2003 Radiology Society of North America, Plenary Session on Interventional Oncology: A New Field for the New Era of Image-guided Therapy, New Intraarterial Therapies for Liver Cancer. December 1-5, 2003, Chicago, Illinois
2003 Columbia University School of Medicine Symposium on Image-guided Tumor Therapy, Chemoembolization of liver cancer: current status and future trends, November 3-4, 2003, New York City, New York
2003 Society of Interventional Radiology Symposium on Interventional Oncology: Current Practice and Future Trends, Chemoembolization for Hepatocellular Carcinoma, October 17th, 2003, San Francisco, California
2003 29th Topics in Gastroenterology and Liver Disease, Image-guided therapy for liver cancer, September 22-24, 2003, Baltimore, Maryland
2003 American Association for the Study of Liver Disease, Clinical Research Single Topic Conference, Systematic evaluation of local ablation, September 20-21, 2003, Emory Conference Center, Atlanta, Georgia
2003 Northwestern University School of Medicine, Chicago Angiographic Society, Intraarterial therapy for liver cancer: Current practice and future, September 10, 2003, Chicago, Illinois
2003 Ninth Annual Hepato-Biliary Update, Does non-surgical management of unresectable HCC improve the life expectancy or quality of life? September 6-7, 2003, Cambridge, Maryland
2003 RSNA Media Briefing on Image-guided Therapies, Chemoembolization helps patients with liver cancer live longer, June 19, 2003, New York City, New York
2003 First French-American Meeting in Interventional Oncology, Johns Hopkins Medicine/Institut Gustave Roussy, New intraarterial therapy against liver cancer. May 14-16, 2003, Villejuif, France
2003 First French-American Meeting in Interventional Oncology, Johns Hopkins Medicine/Institut Gustave Roussy, Chemoembolization for Hepatocellular Carcinoma. May 14-16, 2003, Villejuif, France
2003 Johns Hopkins University School of Medicine Biennial Meeting, Interventional radiology and image-guided interventions: The new frontier. May 2nd, 2003, Baltimore, Maryland.
2003 Association of Vascular and Interventional Radiographers, Annual Meeting, Chemoembolization of liver tumors. March 30th, 2003, Salt Lake City, Utah.
2003 Columbia University School of Medicine, Department of Radiology Grand Rounds, Intraarterial therapy for liver cancer. March 5th, 2003, New York, New York.
2003 Chinese University of Hong Kong, Prince of Wales Hospital, Departments of Medicine and Radiology Grand Rounds, Targeting energy metabolism in liver cancer. January 2nd, 2003, Hong Kong, China.
2002 Hong Kong Society of Interventional Radiology, Assessment of tumor response following chemoembolization of liver tumors. December 30, 2002, Hong Kong, China
2002 Radiology Society of North America, Categorical Course, Functional image-guided therapy of hepatic malignancies. December 1-6, 2002, Chicago, Illinois
2002 28th Topics in Gastroenterology and Liver Disease, Hepatocellular carcinoma: choosing the right weapon, October 2-4, 2002, Baltimore, Maryland
2002 Society of Interventional Radiology Symposium on the Multidisciplinary Management of Liver Cancer: A Team Approach, Animal Models of Liver Cancer, September 20th, 2002, Tysons Corner, Virginia
2002 Society of Interventional Radiology Symposium on the Multidisciplinary Management of Liver Cancer: A Team Approach, Chemoembolization for Patients with Hepatocellular Carcinoma, September 20th, 2002, Tysons Corner, Virginia
2002 Eighth Annual Hepato-Biliary Update, Treatment of HCC: What is new? September 1-2, 2002, Ocean City, Maryland
2002 American Roentgen Ray Society, Instructional Course, Treatment of Liver Cancer: The New and the True, April 28-May 2, 2002, Atlanta, Georgia
2002 Society of Cardiovascular and Interventional Radiology, Categorical Course, New Horizons in Interventional Oncology, April 6-11, 2002, Baltimore, Maryland
2002 Japanese Radiological Society, Treatment for Liver Cancer Symposium, April 4-7, 2002, Kobe, Japan
2002 Johns Hopkins University School of Medicine, Targeted Radionuclide Therapy Symposium, March 15-16, 2002, Baltimore, Maryland
2001 Chesapeake Interventional Radiology Society, Non-surgical Management of Liver Cancer, November 22, 2001, Bethesda, Maryland
2001 27th Topics in Gastroenterology and Liver Disease, Intra-arterial therapy of Liver Cancer, October 3-5, 2001, Baltimore, Maryland
2001 Seventh Annual Hepato-Biliary Update, Non-surgical Management of Biliary Strictures, September 15-16, 2001, Ocean City, Maryland.
2001 26th Annual Eugene P. Pendergrass Lecture and Symposium, Department of Radiology, University of Pennsylvania, Oncologic Interventions, June 15, 2001, Philadelphia, Pennsylvania.
2001 Society of Cardiovascular and Interventional Radiology Advisory Board Meeting, Role of Interventional Radiology in Oncology, June 12, 2001, Washington D.C.
2001 Society of Cardiovascular and Interventional Radiology Symposium on Advances in the Treatment of Liver Cancer: A Multimodality and Multidisciplinary Approach, Chemoembolotherapy for Patients with Hepatocellular Carcinoma, June 8th, 2001, Boston, Massachusetts
2001 Society of Cardiovascular and Interventional Radiology, Categorical Course on Cancer Therapy, March 3-8, 2001, San Antonio, Texas
2001 Indo-American Conference and Workshop on Hepatobiliary Diseases and Liver Transplantation, January 15-17, 2001, Amrita Institute of Medical Sciences, Cochin, India
2001 International Update on Hepatobiliary Diseases, January 12-14, 2001, Bangalore, India
2001 International Symposium on the Management of Hepatobiliary Diseases,
Johns Hopkins Singapore, January 8-10, 2001, Singapore
2001 Radiological Society of Singapore Keynote Address, January 8, 2001, Singapore
2001 National University of Singapore, Departments of Radiology, Gastroenterology and Surgery Grand Rounds, January 10, 2001, Singapore
2000 Biomedical Research Institute, Food and Drug Administration, Symposium on Embolotherapy, December 11-12, 2000, Laurel, Maryland
2000 Department of Surgery Grand Rounds, December 15, 2000, St Agnes Hospital, Baltimore, Maryland
2000 Eastern Cooperative Oncology Group Semi-Annual Conference, November 18-20, 2000, Miami, Florida
2000 Keynote Speaker: Symposium on intratumoral injection of IntraDose: Results of clinical trials for liver and head and neck cancers. Sponsored by Matrix Pharmaceuticals. 5th International Conference on Head and Neck Cancer, July 26, 2000, San Francisco, California
2000 Seventh Annual Penn-Hopkins Conference on Interventional Radiology, June 9-11, 2000, Harbourtowne Resort, Maryland
2000 Second Annual Hepato-biliary Diseases for Practitioners, Baltimore, Maryland
2000 Department of Medical Oncology Grand Rounds, Therapy for Liver Cancer, Marshfield Clinic, Marshfield, Wisconsin
2000 University of California San Francisco, Department of Radiology Lecture Series
2000 Matrix Pharmaceuticals, Annual Guest Lecture, Fremont, California
2000 Department of Medical Oncology Grand Rounds, The Johns Hopkins Hospital, Non Surgical Management of Liver Cancer, Baltimore, Maryland
2000 Chesapeake Interventional Radiology Society, Chemoembolization for Liver Cancer, Bethesda, Maryland
1999 University of Paris School of Medicine, Cochin Hospital 

Department of Surgery Grand Rounds, Intraarterial Therapy for Liver Cancer, Paris, France
1999 Sixth Annual Penn-Hopkins Conference on Interventional Radiology, May 21-23, 1999, Wye Plantation, Maryland
1999 The Johns Hopkins Hospital Department of Vascular Surgery Grand Rounds
1999 Baltimore Interventional Radiology Technologist Society, Baltimore, Maryland
1999 Department of Gastroenterology Grand Rounds, The Johns Hopkins Hospital, Non Surgical Therapy for Liver Cancer, Baltimore, Maryland
1997 Department of Radiology Grand Rounds, The Johns Hopkins Hospital,
Assessment of Myocardial Viability Using MR Imaging, Baltimore, Maryland

Professional Service

Peer Review Groups/Grant Study Sections:

2019-present Grant Reviewer, Israel Science Foundation
2018-present Abstract Reviewer, Cardiovascular and Interventional Radiology Society of Europe
2017-present Abstract Reviewer, European Conference on Interventional Oncology
2011-2019 Grant Reviewer, Society of Interventional Radiology Foundation
2005-2011 Grant Reviewer, Research Grant Council of Hong Kong
2005-2009 NIH grant reviewer (Tumor Cell Biology, Tumor Microenvironment, Digestive Diseases and Developmental Therapeutics Study Sections)
2004-2008 Grant Reviewer, Society of Interventional Radiology (SIR) Foundation
2004-2013 Abstract Reviewer, American Roentgen Ray Society Annual Meeting
2000-2003 Abstract Reviewer, Society of Vascular and Interventional Radiology Annual Meeting.
1998-2002 Abstract Reviewer, American Heart Association.

Journal Service:
Editor/Associate Editor
2020-present Member, Editorial Board, Gastroenterology Insight
2020-present Member, Editorial Board, Diagnostics
2013-2017 Member Editorial Board, Journal of Hepatocellular Carcinoma
2012-2017 Member Editorial Board, Liver Cancer
2012-2017 Consultant to the Editor, Radiology
2011-2017 Member Editorial Board, Anticancer Research
2010-2012 Deputy Editor, Radiology
2010-2014 Editorial Board Member, Interventional Oncology Today
2009-2015 Editor, Vascular and Interventional Radiology Section, Academic Radiology
2009-2011 Editor, Interventional Oncology Section of the Journal of Vascular and Interventional Radiology
2008-2012 Member, Editorial Board, Journal of Interventional Oncology
2008-2017 Member, Editorial Board, Cardiovascular and Interventional Radiology
2006-2017 Member, Editorial Board, World Journal of Gastroenterology
2004-2017 Member, Editorial Board, Techniques in Vascular and Interventional Radiology
2003-2009 Member, Editorial Board, Journal of Vascular and Interventional Radiology

Reviewer
2012-present Reviewer, Molecular Cancer Therapeutics and Journal of the National Cancer Institute
2012-present Reviewer, Liver Cancer
2009-present Reviewer, Hepatology
2008-present Reviewer, Journal of Clinical Oncology
2008-present Reviewer, Lancet Oncology
2007-present Reviewer, Annals of Surgical Oncology
2007-present Reviewer, Annals of Oncology
2007-present Reviewer, Clinical Gastroenterology and Hepatology
2006-present Reviewer, Cancer Biotherapy and Radiopharmaceuticals
2005-present Reviewer, Clinical Cancer Research
2004-present Reviewer, Urology
2004-present Reviewer, Journal of Clinical Oncology
2004-present Reviewer, Journal of Hepatology
2004-present Reviewer, American Journal of Cancer
2004-present Reviewer, American Journal of Roentgenology
2003-present Reviewer, Expert Opinion on Pharmacotherapy
2003-present Reviewer, Lancet Oncology
2003-present Reviewer, Journal of Pediatric Hematology/Oncology
2002-present Reviewer, Cancer
2002-present Reviewer, Journal of Clinical Gastroenterology
2000-present Reviewer, Academic Radiology.
2000-present Reviewer, Journal of Vascular and Interventional Radiology.

Professional Service for Professional Organizations:

2015-17 Chair, World Conference on Interventional Oncology Board of Directors
2014-17 Chair, Program Committee on Interventional Oncology, Radiology Society of North America (RSNA)
2014-15 Named Principal Investigator, ECOG 1208 NCI/CTEP Clinical Trial “A Randomized Phase III Trial of Chemoembolization and Sorafenib in the Treatment of Patients with Unresectable Hepatocellular Carcinoma”
2014-15 Vice-Chair World Conference on Interventional Oncology Board of Directors
2013-14 Course Director, Interventional Radiology 101 (course for IR fellows)
2013 Coordinator, Categorical Courses on Interventional Oncology for 38th Annual Meeting, Society of Interventional Radiology (SIR)
2011-2017 Member of the World Conference on Interventional Oncology Board of Directors
2009-2017 Co-Chair, ECOG 1208 Randomized Trial of Sorafenib and Chemoembolization for Patients with Hepatocellular Carcinoma
2009-2013 Member, Executive Council Society of interventional Radiology
2009-2017 Member, Steering Committee World Congress on Interventional Oncology
2009-2017 Member, Scientific Program Committee, European Congress of Interventional Oncology, Cardiovascular and Interventional Society of Europe
2009-2017 Chair, Interventional Oncology Series on Hepatocellular Carcinoma Radiology Society of North America Annual Meeting
2008-2017 Member, American College of Radiology Liver Imaging Reporting and Data Systems (LIRADS)
2008 Workshop Chair, Hepatocellular Carcinoma State of the Science Meeting, National Cancer Institute/Cancer Therapy Evaluation Program, Washington DC
2008 Chair, Symposium on Interventional Oncology: Hepatocellular Carcinoma, Radiology Society of North America, Annual Meeting, Chicago, Illinois
2007 NIH study Section on Quick Trials in Image-guided Interventions (ZRG 1 SBIB-Q)
2007-2017 Member, Hepatobiliary Task Force, Gastrointestinal Steering Committee, National Cancer Institute/Cancer Therapy Evaluation Program (CTEP)
2007 Coordinator/Chair, Plenary session on Interventional Oncology, Society of Interventional Radiology 32nd Annual Meeting, Seattle, Washington
2006-2007 American Roentgen Ray Society Scientific Program Subcommittee Chair (Vascular and Interventional Radiology Section), American Roentgen Ray Society Annual Meeting, Orlando, Florida, May 2007
2006-2007 Program Chairman, World Conference on Interventional Oncology, 2nd Annual Meeting, Washington DC, May 14-18, 2007
2006 Program Co-Chairman, World Conference on Interventional Oncology, 1st Annual Meeting, Como, Italy, June 12-16, 2006
2006-2017 Program and Steering Committees, World Conference on Interventional Oncology
2006-2009 NIH Study Sections on Tumor Cell Biology and Tumor Microenvironment (TME)
2006-2008 NIH Study Section on Digestive Diseases
2006-2009 Society of Interventional Radiology Foundation Board Member
2005-2008 NIH Study Section on Developmental Therapeutics
2005-2008 Member, Strategic Planning Committee, Society of Interventional Radiology
2004-2015 Member, Society of Interventional Radiology/FDA panel
2004-2009 Member, Scientific Program Committee, American Roentgen Ray Society
2004 Course Director, “Image-guided Tumor Therapy Workshop”, Johns Hopkins University School of Medicine, June 7, 2004, Baltimore, MD.
2004-2008 Member, Oncology Task Force, Society of Interventional Radiology
2003 Course Director, “Interventional Oncology: Current practice and future trends”, Society of Interventional Radiology. October 17-18, 2003, San Francisco, CA.
2003 Course Director, “First French-American Meeting in Interventional Oncology”, Johns Hopkins Medicine/Institut Gustave Roussy. May 14-16, 2003, Villejuif, France.
2003 Vascular and Interventional Radiology Foundation, Board Member, Hong Kong, China
2003 Member, Educational Program Committee, Society of Interventional Radiology
2002 Course Director, “Multi disciplinary management of liver cancer: a team approach”, Society of Interventional Radiology. September 20-21, 2002, Ritz-Carlton Tysons Corner, Tysons Corner, VA
2002 Faculty Development Program, Association of University Radiologists
2001 Vice-Chairman, Program’s Committee,
Society of Cardiovascular and Interventional Radiology
2001 Member, Executive Committee, Council on Cardiovascular Radiology,
American Heart Association
2001 Course Director, “Advances in the treatment of liver cancer: A multimodality and multi disciplinary approach”, Society of Cardiovascular and Interventional Radiology. June 8-9, 2001, The Westin Copley Place, Boston, MA
2000 Moderator, “Percutaneous renovascular interventions: Indications, techniques and outcomes”. American Heart Association, 73rd Annual Scientific Session.
Member, Research Committee, Society of Cardiovascular and Interventional Radiology.
2000 Member, MDS Nordion Inc. Advisory Panel on the Treatment of Liver Cancer Using Radioactive Microspheres (Therasphere).
2000 Member, Editorial News, Society of Cardiovascular and Interventional Radiology.
2000 Member, Selection Committee, Melvin Judkins Young Clinical Investigator Award, American Heart Association.
Moderator, “Sonographic indices of vascular disease”.
American Heart Association, 72nd Annual Scientific Session.
1999 Coordinator, Legs for Life Program National Screening Program for peripheral vascular disease Society of Cardiovascular and Interventional Radiology.
1998-2000 Member, Council on Cardiovascular Radiology
American Heart Association.

University Service:

2009-2015 Johns Hopkins Department of Radiology Research Committee
2006-2014 Johns Hopkins Department of Radiology Ad Hoc Advisory Committee
2005-2015 Johns Hopkins Medicine, Central Venous Lines Task Force
2004-2015 Member, Johns Hopkins Department of Radiology Space Committee
2004-2015 Coordinator, Liver Tumor Board (weekly)
2003-2013 Co-chairman Interventional Services, “Planning and Strategy Committee for the Cardiovascular and Critical Care Tower-Interventional Services”, Johns Hopkins University School of Medicine
2002-2015 Member, Radiology Executive and Research Committees, Johns Hopkins University School of Medicine, Department of Radiology
2002 Member, Cardiology Division Chief Search Committee,
Johns Hopkins University School of Medicine
2001 Resident Selection Committee, Department of Radiology,
The Johns Hopkins University School of Medicine

Bibliography:
Google Scholar H-index 84

Peer-Reviewed Original Research
1. Prentki M, Glennon MC, Geschwind JF, Matschinsky F, Corkey B. Cyclic AMP raises cytosolic Ca2+ and promotes Ca2+ influx in a clonal pancreatic B-cell line (HIT-T15). FEBS lett. 1987; 220:103-107.
2., Hiriart M, Glennon MC, Corkey B, Matschinsky F, Prentki M. Selective activation of Ca2+ influx by extracellular ATP in a pancreatic B-cell line (HIT). Biochemica et Biophysica Acta 1989; 1012:107-115.
3. Corkey B, Geschwind JF, Deeney J, Hale D, Douglas S, Kilpatrick L. Ca2+ responses to Interleukin-1 and tumor necrosis factor in cultured human fibroblasts: possible implications for Reye Syndrome. J Clin Inv. 1990; 87:778-786.
4. Geschwind JF, Wendland MF, Saeed M, Lauerma K, Derugin N, Higgins CB. Identification of myocardial cell death in reperfused myocardial injury using dual mechanism of contrast enhanced MRI. Association of University Radiologists Annual Memorial Award. Acad Radiol 1994;1:319-325.
5. Sakuma H, Wendland MF, Saeed M, Geschwind JF, Derugin N, Lauerma K, Mintorovitch J, Cavagna F, Higgins CB. Multi-slice measurement of first pass transit of Gd-BOPTA/dimeg in ischemic myocardium in dogs. Acad Radiol 1995; 2:864-870.
6. Saeed M, Wendland MF, Sakuma H, Geschwind JF, Derugin N, Cavagna F, Higgins CB. Detection of experimental coronary artery stenosis using contrast enhanced magnetic resonance imaging. Radiology 1995; 196:79-84.
7. Saeed M, Wendland MF, Sakuma H, Geschwind JF, Derugin N, Cavagna FM, Higgins CB. Coronary artery stenosis: detection with contrast-enhanced MR imaging in dogs. Radiology 1995 Jul:196(1): 79-84.
8. Cavagna FM, Saeed M, Wendland MF, Sakuma H, Geschwind JF, Derugin N, Higgins CB. Names for gadobenate dimeglumine. Radiology 1996 Mar; 198(3):908.
9. Higgins CB, Saeed M, Wendland MF, Sakuma H, Geschwind JF. Identification of regional myocardial ischemia using contrast-enhanced dynamic MR imaging in an experimental canine model of hemodynamically significant coronary arterial stenosis. Acad Radiol 1996 Aug; 3:S392-394.
10.Wendland MF, Saeed M, Geschwind JF, Mann J, Brasch R, Higgins CB. Distribution of intracellular, extracellular and intravascular MR contrast media in hearts subjected to reperfused myocardial infarction. Acad Radiol 1996 Aug; 3:S402-404.
11.Geschwind JF, Saeed M, Wendland MF, Szolar D, Derugin N, Higgins CB. Acute hemodynamic effects of newly developed monomer and dimer magnetic resonance imaging contract media: a comparative study. Acad Radiol 1996 Aug; 3:667-677.
12. Saeed M, Wendland MF, Szolar D, Geschwind JF, Sakuma H, Globits S, Derugin N, Higgins CB. Quantification of the extent of area at risk with fast contrast-enhanced magnetic resonance imaging in experimental coronary artery stenosis. Am Heart J 1996 Nov; 132:921-32.
13. Huncharek M, Muscat J, Geschwind JF. Planned preoperative radiation therapy in muscle invasive bladder cancer: results of a meta-analysis. Anticancer Research 1998 May-Jun; 18(3B):1931-4.
14. Geschwind JF, Saeed M, Wendland MF, Szolar D, Derugin N, Higgins CB. Depiction of
reperfused myocardial infarction using contrast-enhanced spin echo and gradient echo MR
imaging: influence of dose of MR contrast media. Investigative Radiology 1998 Jul; 33:386-
392.
15. Savader SJ, Lynch FC, Radvany MG, Kudryk BT, Andrews RT, Geschwind JF, Singh H, and Hamet MR.. Single specimen bile cytology: a prospective study in 80 patients with obstructive jaundice. J Vasc Interv Radiol 1998 Sep-Oct; 9(5):817-21.
16. Andrews RT, Geschwind JF, Savader SJ, Venbrux AC. Entrapment of J-tip guidewires by Venatech and stainless-steel Greenfield vena cava filters during central venous catheter placement: percutaneous management in four patients. Cardiovasc Interv Radiol 1998 Sep-Oct; 21(5):424-8.
17. Huncharek M, Muscat J, Geschwind JF. Multi-drug versus single agent chemotherapy for high grade astrocytoma; results of a meta-analysis. Anticancer Res. 1998 Nov-Dec;18(6B): 4693-7.
18. Geschwind JF, Price DC, Laberge J, Mulvihill SJ. Intraoperative localization of jejuna bleeding due to Dieulafoy’s disease using Tc-99m RBC. Clin Nucl Med. 1998 Dec; 23(12):839-41.
19. Geschwind JF, Price D, Mulvihill S, LaBerge J. Identification of Dieulafoy lesion using intra-operative RBC scan. Clinical Nuclear Medicine 1998; 23:839-860.
20. Andrews RT, Geschwind JF, Savader SJ, Osterman FA Jr. Management of guidewires entrapped by vena cava filters during central venous placement. Cardiovasc Interv Radiol 1998; 21:424-428.
21. Wyttenbach R, Saeed M, Wendland MF, Geschwind JF, Bremerich J, Arheden H, Higgins CB. Detection of acute myocardial ischemia using first pas dynamics of MnDPDP on inversion recovery echo planar imaging. JMRI 1999 Feb; 9(2):209-14.
22. Huncharek M, Muscat J, Geschwind JF. K-ras oncogene mutation as a prognostic marker
in non small cell lung cancer; a combined analysis of 881 cases. Carcinogenesis 1999 Aug;
20(8):1507-1510.
23. Huncharek M, Wheeler L, McGarry R, and Geschwind JF. Chemotherapy response rates in
recurrent/progressive pediatric glioma. Anticancer Research 1999 Jul-Aug; 19(4C):3569-74.
24. Huncharek M, Geschwind JF, Lambert D, Adcock D, and Wheeler L. Intravesical
chemotherapy prophylaxis in primary superficial bladder cancer: a metaanalysis of 3703 patients from 11 randomized trials. J Clin Epidemiology 2000; 53(7):676-680.
25. Huncharek M, Kupelnick B, and Geschwind JF. Prognostic significance of p53 mutations in
non-small cell lung cancer: a metaanalysis of 829 cases from eight published studies. Cancer
Letters 2000; 153(1-2):219-226.
26. Saeed M, Geschwind JF, Higgins CB, and Wendland MF. T1-relaxation kinetics of extracellular intracellular, and intravascular MR contrast agents in normal and acutely reperfused infarcted
myocardium using echoplanar MR imaging. Eur Radiology 2000; 10(2), 310-318.

27. Savader SJ, Geschwind JF, Lund GB, and Sheel PJ. Percutaneous radiologic placement of peritoneal dialysis catheters. J Vasc Interv Radiol 2000; 11:965-970.
28. Geschwind JF, Artemov D, Abraham S, Omdal D, Huncharek M, Arepally A,
Lambert D, MacGee C, Venbrux AC, and Lund GB. 2000 Gary J. Becker Young Investigator
Award: Chemoembolization of liver tumor in a rabbit model: Assessment of tumor cell death with diffusion-weighted MRI and histologic analysis. J Vasc Interv Radiol 2000; 11:1245-1255.
29. Hofmann LV, Razavi M, Arepally A, Reginelli JP, Resar J, Geschwind JF, Corl F. GPllb-llla receptor inhibitors: what the interventional radiologist needs to know. Cardiovasc Intervent Raiol. 2001 Nov-Dec; 24(6):361-7.
30. Geschwind JF, and Hamet M. Use of percutaneous drain insertion in the management of
advanced pyomyositis: case report and a review of the literature. Orthopedics 2001;
24(2):187-189.
31. Lim J, Andrews RT, and Geschwind JF. Balloon tamponade: a novel technique for
visualizing and catheterizing the common bile duct following partial transection.
J Vasc Interv Radiol 2001; 12:117-120.
32. Thuluvath P, Geschwind JF, Johnson P, Heneghan M, and O’ Grady J. Management of hepatoma using cisplatin/epinephrine gel in patients awaiting orthotopic liver transplantation. Transplant Proc. 2001 Feb-March; 33(1-2):1359-60.
33. Gelber AC, Schachna L, Mitchell L, Schwartzman G, Hartnell G, and Geschwind JF.
Behcet’s disease complicated by pyelephlebitis and hepatic abscesses. Clin Exp Rheumatol 2001;
19(Suppl. 24):S59-61.
34. Arepally A, Hofmann L, Kim K, Geschwind JF, Kirkwood S, Oechsle D, and Perler B. Weight-based rt-PA thrombolysis protocol for acute native arterial and bypassgraft occlusions. J Vasc Interv Radiol 2002 Jan; 13:45-50.
35. Geschwind JF, Dagli MS, Vogel-Claussen J, Arepally AA, Venbrux AC. Percutaneous removal of fractured endostent remnant from the portal vein. Cardiovasc Intervent Radiol 2002 Mar-Apr; 25(2):152-4.
36. Konyaris L, Geschwind JF, and Sitzman A. Can alcohol therapies injure the bile ducts?
Hepatogastroenterology 2003; 50(49):69-72.
37. Geschwind JF, Ramsey D, Cleffken B, Kobeiter H, van der Wal B, Juluru K, Hartnell G,
and Choti M. Chemoembolization of liver tumors: Effects of embolization material on
subsequent vessel patency. Cardiovasc Interv Radiol 2003; 26:111-117.
38. Ko YH, Pedersen PL, and Geschwind JF. Glucose catabolism in the rabbit VX2 tumor model
for liver cancer: Characterization and targeting hexokinase. Cancer Letters 2001; 173:83-91
39. Georgiades C, Ramsey D, Solomon S, and Geschwind JF. New non-surgical therapies in the
treatment of hepatocellular carcinoma. Tech Vasc Interv Rad 2001; 4(3):193-199.
40. Geschwind JF, Dagli M, Morris J, and Choti M. Treatment of focal nodular hyperplasia
with selective transcatheter arterial embolization using iodized oil and polyvinyl alcohol.
Cardiovasc Interv Radiol 2002; 25(4):340-1.
41. Georgiades CS , and Geschwind JF. Percutaneous peritoneal dialysis catheter placement
for the management of end-stage renal disease: Technique and comparison with the surgical
approach. Tech Vasc Interv Radiol. 2002; 5(2):103-7.
42. Ramsey DE, and Geschwind JF. New interventions for liver tumors. Semin Roentgenol.
2002; 37(4):303-11.
43. Salem R, Thurston KG, Carr BI, Goin JE, and Geschwind JF. Yttrium 90 microspheres:
Radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 2002; 13(9
Suppl):S223-9.
44. Ramsey D, Kernagis L, Soulen M, and Geschwind JF. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 2002; 13(9 Suppl):S211-21.

45. Pedersen Pl, Mathupala S, Rempel A, Geschwind JF, and Ko YH. Mitochondrial bound
Type II hexokinase. Biochemica et Biophysica Acta, 2002; 1555(1-3):14-20.
46. Geschwind JF, Ko YH, Torbenson MS, McGee C, and Pedersen PL. Rapid therapy for liver cancer by direct intraarterial injection of a potent inhibitor of ATP production. Cancer
Research 2002; 62(14):3909-13.
Geschwind JF, Kaushik S, Ramsey D, Choti M, Fishman E, and Kobeiter H. Influence of a
new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization of liver tumors. J Vasc Interv Radiol 2002; 13(11):1163-6.
Geschwind JF, Rilling WS. Hepatocellular carcinoma: obligation and opportunity for
interventional radiology. J Vasc Interv Radiol. 2002; 13(9 Suppl):S167. Editorial.
Geschwind JF. Chemoembolization for hepatocellular carcinoma: where does the truth lie?
J Vasc Interv Radiol. 2002; 13(10):991-4. Commentary.
50. Ramsey DE, and Geschwind JF. Chemoembolization of hepatocellular carcinoma-what to
tell the skeptics: Review and meta-analysis. Tech Vasc Interv Radiol. 2002; 5(3):122-6.

51. Mudrick D, Arepally A, Geschwind JF, Ronsivalle JA, Lund GB, and Sheel P.
Spontaneous renal artery dissection: treatment with coil embolization. J Vasc Interv Radiol.
2003; 14(4):497-500.
52. Geschwind JF, Dagli M, Vogel-Claussen J, Seifter E, and Huncharek M. Metastatic breast
carcinoma presenting as a large pulmonary embolism: A case report and review of the
literature. Am. J. Clin. Oncol. 2003; 26(1):89-91.
53. Leung TWT, Yu S, Johnson PJ, Geschwind JF, Vogl TJ, Englemann K, Gores GJ,
Giovannini M, O’ Grady J, Heneghan M, Stewart M, Orenberg EK, and Thuluvath PJ. Phase II study of the efficacy and safety of Cisplatin-Epinephrine injectable gel administered to patients with unresecatble hepatocellular carcinoma. J Clin Oncol. 2003; 21(4): 652-658.
54. McCarthy DM, Haas M, Thuluvath PJ, Geschwind JF, Hutchins GM, and Westra WH.
Pulmonary embolization of bovine collagen. Arch Pathol Lab Med. 2003; 127(2):E67-9.
55. Sohn TA, Yeo CJ, Cameron JL, Geschwind JF, Mitchell SE, Venbrux AC, and Lillemoe
KD. Pancreaticoduodenectomy. Role of interventional radiologists in managing patients and
complications. J Gastrointest Surg. 2003; 7(2):209-19.
56. Huncharek M, Geschwind JF, and Kopelnik B. Perineal application of cosmetic talc and
risk of invasive epithelial ovarian cancer: a meta-analysis of 11,933 subjects from sixteen
observational studies. Anticancer Res. 2003; 23(2C):1955-60.
57. Geschwind JF, Ramsey D, Thuluvath P, Choti M, and Huncharek M. Chemoembolization
of hepatocellular carcinoma: results of a metaanalysis. Am. J. Clin. Oncol. 2003; 26(4):344-349.
58. Kamel IH, Bluemke D, Ramsey D, Abusedera M, Torbenson M, Eng J, Szarf G, and
Geschwind JF. Role of Diffusion-Weighted Imaging in Estimating Tumor Necrosis After
Chemoembolization of Hepatocellular Carcinoma. AJR 2003; 181:708-710.
59. Geschwind JF, Dagli MS, Lambert DL, and Kobeiter H. Thrombolytic therapy in the setting of arterial line-induced ischemia. J Endovasc Ther. 2003 May-Jun;10(3):590-4.
60. Tatsumi M, Nakamoto Y, Traughber B, Marshall LT, Geschwind JF, and Wahl RL. Initial
Experience in Small Animal Tumor Imaging with a Clinical Positron Emission Tomography/Computed Tomography Scanner Using 2-[F-18]Fluoro-2-deoxy-D-glucose.
Cancer Res. 2003 Oct 1;63(19):6252-7.
61. Yoo HY, Patt CH, Geschwind JF, and Thuluvath PJ. The outcome of liver transplantation
in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-
year survival has improved significantly with time. J Clin Oncol. 2003 Dec 1;21(23):4329-
35.
62. Misra S, Melton GB, Geschwind JF, Venbrux AC, Cameron JL, and Lillemoe KD.
Percutaneous management of bile duct strictures and injuries associated with laparoscopic
cholecystectomy: a decade of experience. J Am Coll Surg. 2004 Feb;198(2):218-26.

63. Geschwind JF, Georgiades CS, Ko YH, and Pedersen PL. Recently elucidated energy
catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma. Expert Rev. Anticancer Ther. 2004; 4(3):449-457.
64. Agrawal N, Bettegowda C, Cheong I, Geschwind JF, Drake CG, Hipkiss EL, Tatsumi M,
Dang LH, Diaz LA Jr, Pomper M, Abusedera M, Wahl RL, Kinzler KW, Zhou S, Huso DL, and Vogelstein B. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A. 2004; Oct 7.
65. Geschwind JF, Salem R, Carr BI, Soulen MC, Thurston KG, Goin KA, Van Buskirk M,
Roberts CA, and Goin JE. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004 Nov;127(5 Suppl 2):S194-205.
66. Hindley J, Gedroyc WM, Regan L, Stewart E, Tempany C, Hynnen K, Macdanold N, Inbar
Y, Itzchak Y, Rabinovici J, Kim K, Geschwind JF, Hesley G, Gostout B, Ehrenstein T, Hengst S, Sklair-Levy M, Shushan A, Jolesz F. MRI guidance of focused ultrasound therapy of uterine fibroids: early results. AJR Am J Roentgenol. 2004 Dec;183(6):1713-9.
67. Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF, Goin K, Van Buskirk
M, Thurston K. Treatment of unresectable hepatocellular carcinoma with intrahepatic
yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol. 2005
Feb;16(2):205-13.
Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF, Goin K, Van Buskirk
M, Thurston K. Treatment of unresectable hepatocellular carcinoma with intrahepatic
yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol. 2005
Feb;16(2):195-203.
Burger I, Hong K, Shulick R, Georgiades C, Thuluvath P, Choti M, Kamel I, and
Geschwind JF. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: Initial experience in a single instititution. J Vasc Interv Radiol. 2005 Mar 16(3):353-61.
Hong K, Liapi E, Georgiades CS, and Geschwind JF. Case-controlled Comparison of a
Percutaneous Collagen Arteriotomy Closure Device versus Manual Compression after Liver Chemoembolization. J Vasc Interv Radiol. 2005 Mar 16(3):339-45.
Geschwind JF, and Liapi E. Is radiofrequency ablation an effective long-term treatment for
early-stage hepatocellular carcinoma? Nat clin pract gatroenterol hepatol. 2005 July;2(7):302-3.
Liapi E, Hong K, Georgiades CS, and Geschwind JF. Three-dimensional Rotational
Angiography: Introduction of an Adjunctive Tool for Successful Transarterial Chemoembolization. J Vasc Interv Radiol. 2005 Sep 16(9):1241-5.
Lewandowski RJ, Thrurston KG, Goin JE, Wong CY, Gates VL, Van Buskirk M,
Geschwind JF, and Salem R. 90Y Microsphere (TheraSphere) Treatment for Unresectable Colorectal Cancer Metastases of the Liver: Response to Treatment at Targeted Doses of 135-150 Gy as Measured by [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomographic Imaging. J Vasc Interv Radiol. 2005 Dec;16(12):1641-51.
Georgiades CS, Hong K, D’Angelo M, and Geschwind JF. Safety and Efficacy of
Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma
and Portal Vein Thrombosis. J Vasc Interv Radiol. 2005 Dec 16(12):1653-9.
Hong K, Georgiades CS, Kobeiter H, Torbenson M, and Geschwind JF. Effects of the type
of embolization particles on carboplatin concentration in liver tumors following transcatheter
arterial chemoembolization in a rabbit model of liver cancer (Vx-2). J Vasc Interv Radiol. 2005 Dec 16(12):1711-7.
Goldberg SN, Bonn J, Dodd G, Dupuy D, Geschwind JF, Hicks M, Hume KM, Lee FT,
Lewis CA, Lencioni RA, Omary RA, Rundback JH, Silverman S, and Dorfman GS.
Society of interventional radiology interventional oncology task force: interventional
oncology research vision statement and critical assessment of the state of research affairs.
J Vasc Interv Radiol. 2005 Oct;16(10):1287-94.
Brown D, Geschwind JF, Soulen MC, Millward SF, and Sacks D. Society of interventional
radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv
Radiol. 2006 Feb;17(2):217-23.
Kamel IR, Bluemke DA, Eng J, Liapi E, Messersmith W, Reyes DK, and Geschwind JF. The Role of Functional MR Imaging in the Assessment of Tumor Response after
Chemoembolization in Patients with Hepatocellular Carcinoma. J Vasc Interv Radiol. 2006 Mar;17(3):505-12.
Hong K, Khwaja A, Liapi E, Torbensen M, Georgiades C, and Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res. 2006 Apr 15;12(8):2563-7.
80. Hong K, Georgiades C, and Geschwind JF. Technology Insight: image-guided therapies for
hepatocellular carcinoma-intra-arterial and ablative techniques. Nat Clin Pract Oncol. 2006
Jun;3(6):315-24.
Georgiades C, Liapi E, Frangakis C, Park JU, Kim HW, Hong K, and Geschwind JF. Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular
carcinoma treated with transarterial chemoembolization. J Vasc Interv Radiol. 2006 Oct;17(10):1619-24.
82. Vali M, Liapi E, Kowalski J, Hong K, Khwaja A, Torbenson, M, Georgiades C and Geschwind JF. Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate) in an animal model of liver cancer: Identification of therapeutic dose and method of injection. J Vasc Interv Radiol 2007; 18:95-102.
83. Kamel I, Reyes D, Liapi E, Bluemke D and Geschwind JF. Functional MR
imaging assessment of tumor response following Therasphere treatment in patients with
unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2007; 18:49-56.
84. Dorfman JD, Shulick R, Chota MA, Geschwind JF, Kamel I, Torbenson M, and Thuluvath
P. Differences in characteristics of patients with and without known risk factors for
hepatocellular carcinoma in the United States. World J Gastroenterol. 2007 Feb
7;13(5):781-4.
85. Liapi E, and Geschwind JF. Transcatheter and ablative therapeutic approaches for solid
malignancies. J Clin Oncol. 2007 Mar 10;25(8):978-86.
86. Kobeiter H, Georgiades C, Leakakos T, Torbenson M, Hong K, and Geschwind JF.
Targeted transarterial therapy of Vx-2 rabbit liver tumor with yttrium-90 labeled ferromagnetic particles using an external magnetic field. Anticancer Research 2007; 27:755-760.
87. Lewandowski RJ, Sato KT, Atassi B, Ryu PK, Nemcek AA Jr., Kulik L, Geschwind JF,
Murthy R, Rilling W, Liu D, Bester L, Bilbao JL, Kennedy AS, Omary RA, and Salem R.
Radioembolization with (90)Y Microspheres: Angiographic and Technical Considerations. Cardiovasc Intervent Radiol. 2007 May 22.
88. Hong K, Georgiades C, Hebert J, Wahlin T, Mitchell SE, and Geschwind JF. Incorporating
physician assistants and physician extenders in the contemporary interventional oncology
practice. Tech Vasc Interv Radiol. 2006 Sep;9(3):96-100.
89. Georgiades C, Hong K, and Geschwind JF. Pre- and postoperative clinical care of patients
undergoing interventional oncology procedures: a comprehensive approach to preventing
and mitigating complications. Tech Vasc Interv Radiol. 2006 Sep;9(3):113-24.
90. Buijs M, Kamel I, Vossen J, Georgiades C, Hong K, and Geschwind JF. Assessment of
Metastatic Breast Cancer Response to Chemoembolization with Contrast Agent enhanced
and Diffusion-weighted MR Imaging. J Vasc Interv Radiol. 2007 Aug;18(8):957-63.
91. Georgiades CS, Hong K, Geschwind JF, Liddell R, Syed L, Kharlip J, and Arepally A.
Adjunctive Use of C-Arm CT May Eliminate Technical Failure in Adrenal Vein Sampling.
J Vasc Interv Radiol. 2007 Sep;18(9):1102-5.

92. Liapi E, Georgiades CS, Hong K, and Geschwind JF. Transcatheter arterial
chemoembolization: Current technique and future promise. Tech Vasc Interv Radiol. 2007 Mar;10(1):2-11.
93. Brown DB, Gould JE, Gervais DA, Goldberg SN, Murthy R, Millward SF, Rilling WS,
Geschwind JF, Salem R, Vedantham S, Cardella JF, and Soulen MC. Transcatheter therapy for hepatic malignancy: Standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2007 Dec; 18(12):1469-78.

94. Liapi E, Geschwind JF, Vossen J, Buijs M, Hong K, Georgiades CS, Bluemke D, and
Kamel I. Functional MR imaging evaluation of tumor response in patients with
neuroendocrine hepatic metastases treated with transcatheter arterial chemoembolization. AJR Am J Roentgenol. 2008 Jan; 190(1):67:73.
95. Georgiades C, Hong K, and Geschwind JF. Radiofrequency ablation and
chemoembolization for hepatocellular carcinoma. Cancer J 2008 Mar-Apr;14(2):117-22.
96. Vossen J, Buijs M, Kamel I, Georgiades C, Hong K, and Geschwind JF. Role of functional
MR imaging in assessing metastatic leiomyosarcoma response to chemoembolization. JCAT
2008 May-Jun;32(3):347-52.
97. Buijs M, Vossen JA, Geschwind JF, Ishimori T, Engles JM, Acha-Ngwodo, Wahl RL, and
Vali M. Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG
uptake in a rat model of breast cancer. Invest New Drugs. 2008 Jun 14.
98. Buijs M, Vossen JA, Hong K, Georgiades CS, Geschwind JF, and Kamel I.
Chemoembolization of hepatic metastases from ocular melanoma: assessment of response
with contrast-enhanced and diffusion-weighted MRI. AJR Am J Roentgenol. 2008
Jul;191(1):285-9.
99. Liapi E, Lee KH, Georgiades CS, Hong K, and Geschwind JF. Drug-eluting particles for
interventional pharmacology. Tech Vasc Interv Radiol. 2007 Dec;10(4):261-9.
100. Lee KH, Liapi E, Ventura VP, Buijs M, Vossen JA, Vali M, and Geschwind JF.
Evaluation of Different Calibrated Spherical Polyvinyl Alcohol Microspheres in
Transcatheter Arterial Chemoembolization: VX2 Tumor Model in Rabbit Liver.
J Vasc Interv Radiol. 2008 Jul;19(7):1065-1069.

101. Vali M, Vossen JA, Buijs M, Engles JM, Liapi E, Prieto-Ventura V, Khwaja A, Acha-
Ngwodo O, Wahl RL, and Geschwind JF. Targeting of VX2 rabbit liver tumor by
selective delivery of 3-bromopyruvate: a biodistribution and survival study. J Pharmacol
Exp Ther. 2008 Jun 30.
102. Assumpcao L, Cameron JL, Wolfgang CL, Edil B, Choti MA, Herman JM, Geschwind JF,
Hong K, Georgiades C, Schulick RD, Pawlik TM. Incidence and Management of Chyle
Leaks Following Pancreatic Resection: A High Volume Single-Center Institutional
Experience. J Gastrointest Surg. 2008 Aug 7.
103. Buijs M, Vossen, JA, Frangakis C, Hong K, Georgiades CS, Chen Y, Liapi E, and
Geschwind JF. Nonresectable hepatocellular carcinoma: long-term toxicity in patients
treated with transarterial chemoembolization–single-center experience.
Radiology 2008 Oct; 249(1):346-54
104. El-Khouli RH, Geschwind JF, Bluemke DA, and Kamel IR. Solitary fibrous tumor
of the liver: magnetic resonance imaging evaluation and treatment with transarterial chemoembolization. J Comput Assist Tomogr. 2008 Sep-Oct;32(5):769-71.
105. Lee KH, Liapi E, Buijs M, Vossen J, Hong K, Georgiades C, and Geschwind JF. Considerations for implantation site of Vx-2 carcinoma into rabbit liver. J Vasc Interv Radiol. 2009 Jan;20(1):113-7.

106. Taguchi K, Funama Y, Zhang M, Fishman EK, and Geschwind JF. Quantitative measurement of iodine concentration in the liver using abdominal C-arm computed tomography. Acad Radiol. 2009 Feb;16(2):200-8.
107. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, and Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology. 2009 Feb;250(2):466-73.
108. Jain A, Smith C, Geschwind JF, and Pawlik TM. Image of the month: Gastrohepatic fistula following TACE for hepatocellular carcinoma. Arch Surg. 2009 Mar;144(3):285-6.
109. Liapi E, and Geschwind J.F. Interventional oncology: new options for interstitial
treatments and intravascular approaches. Targeting tumor metabolism via a loco-regional approach: A new therapy against liver cancer. J Hepatobiliary Pancreat Surg. 2009
110. Ganapathy-Kanniappan S, Geschwind J.F., Kunjithapatham R, Buijs M, Vossen J,
Tchernyshyov I, Cole R, Syed L, Rao P, Ota S, Vali M. Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH) is Pyruvylated during 3-Bromopyruvate Mediated Cancer Cell Death. Anticancer Res. 2009 Dec;29(12):4909-4918.
111. Reyes DK, Vossen JA, Kamel IR, Azad N, Wahlin T, Torbenson M, Choti MA, and
Geschwind JF. Single Centre Phase II Trial of Transarterial Chemoembolization with Drug Eluting Beads for Patients with Unresectable Hepatocellular Carcinoma: Initial Experience in the USA. Cancer Journal 2009 ; 15:526-532.
112. Liapi E and Geschwind JF. Chemoembolization for primary and metastatic liver cancer.
Cancer J. 2010 Mar-Apr;16(2):156-62. Review.PMID: 20404613
113. Hong K and Geschwind JF. Locoregional intra-arterial therapies for unresectable
intrahepatic cholangiocarcinoma. Semin Oncol. 2010 Apr;37(2):110-7. Review.PMID:
20494703
114. Golzarian J, Sapoval MR, Kundu S, Hunter DW, Brountzos EN, Geschwind JF, Murphy TP, Spies JB, Wallace MJ, de Baere T, and Cardella JF; Society of Interventional Radiology (SIR); Cardiovascular and Interventional Radiological Society of Europe (CIRSE); Canadian Interventional Radiology Association (CIRA). Guidelines for Peripheral and Visceral Vascular Embolization Training: joint writing groups of the Standards of Practice Committees for the Society of Interventional Radiology (SIR), Cardiovascular and Interventional Radiological Society of Europe (CIRSE), and Canadian Interventional Radiology Association (CIRA). J Vasc Interv Radiol. 2010 Apr;21(4):436-41. No abstract available. PMID: 20346881
115. Loffroy R, Gergele F, Rao P,and Geschwind JF. Endovascular management of a posttraumatic pseudoaneurysm of the common carotid artery with superselective coil embolization. J Vasc Surg. 2010 May 25. [Epub ahead of print] No abstract available. PMID: 20510566
116. Liapi E, and Geschwind JF. Intra-arterial therapies for hepatocellular carcinoma: where do
we stand? Ann Surg Oncol. 2010 May;17(5):1234-46. Epub 2010 Apr 20. Review.PMID: 20405328
117. Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Syed LH, Rao PP,
Ota S, and Vali M. The pyruvic acid analog 3-bromopyruvate interferes with the tetrazolium reagent MTS in the evaluation of cytotoxicity. Assay Drug Dev Technol. 2010 Apr;8(2):258-62.PMID: 20085459
118. Loffroy R, Rao P, Kwak BK, Ota S, De Lin M, Liapi E, and Geschwind JF. Transcatheter
arterial embolization in patients with kidney diseases: an overview of the technical aspects and clinical indications. Korean J Radiol. 2010 May-Jun;11(3):257-68. Epub 2010 Apr 29. Review.PMID: 20461179
119. Schwarz RE, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R, and Venook AP.
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford). 2010 Jun;12(5):313-20.PMID: 20590905

120. Lee KH, Liapi EA, Cornell C, Reb P, Buijs M, Vossen JA, Ventura VP, Geschwind JF.
Doxorubicin-loaded QuadraSphere microspheres: plasma pharmacokinetics and intratumoral drug concentration in an animal model of liver cancer. Cardiovasc Intervent Radiol. 2010 Jun;33(3):576-82. Epub 2010 Jan 20.PMID: 20087738
121. Loffroy R, Rao P, Ota S, and Geschwind JF. Renal artery embolisation prior to radical
nephrectomy for renal cell carcinoma: when, how and why? Br J Radiol. 2010 Jul;83(991):630; author reply 631-2. No abstract available. PMID: 20603414
122. De Jong MC, Farnell MB, Sclabas G, Cunningham SC, Cameron JL, Geschwind JF,
Wolfgang CL, Herman JM, Edil BH, Choti MA, Schulick RD, Nagorney DM, and Pawlik TM. Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. Ann Surg. 2010 Jul;252(1):142-8.PMID: 20531007
123. Ganapathy-Kanniappan S, Vali M, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S,
Kwak BK, Loffroy R, and Geschwind JF. 3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy. Curr Pharm Biotechnol. 2010 Aug;11(5):510-7. Review.PMID: 20420565
124. Loffroy R, Rao P, Ota S, De Lin M, Kwak BK, Krause D and Geschwind JF. Packing
technique for endovascular coil embolisation of peripheral arterial pseudo-aneurysms with preservation of the parent artery: safety, efficacy and outcomes. Eur J Vasc Endovasc Surg. 2010 Aug;40(2):209-15.PMID: 20399122
125. Liapi E and Geschwind JF. Interventional oncology: new options for interstitial treatments
and intravascular approaches: targeting tumor metabolism via a loco-regional approach: a new therapy against liver cancer. J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):405-6.
126. Liapi E and Geschwind JF. Transcatheter Arterial Chemoembolization for Liver Cancer:
Is It Time to Distinguish Conventional from Drug-Eluting Chemoembolization? Cardiovasc Intervent Radiol. 2010 Nov 12.
127. Lin M, Loffroy R, Noordhoek N, Taguchi K, Radaelli A, Blijd J, Balguid A, and
Geschwind JF. Evaluating tumors in transcatheter arterial chemoembolization (TACE) using dual-phase cone-beam CT. Minim Invasive Ther Allied Technol. 2010 Nov 17:
128. Frangakis C, Geschwind JF, Kim D, Chen Y, Koteish A, Hong K, Liapi E, and Georgiades
CS. Chemoembolization Decreases Drop-Off Risk of Hepatocellular Carcinoma Patients on the Liver Transplant List. Cardiovasc Intervent Radiol. 2010 Dec 30:
129. Loffroy R, Rao P, Ota S, De Lin M, Kwak BK, and Geschwind JF. Embolization of acute
nonvariceal upper gastrointestinal hemorrhage resistant to endoscopic treatment: results and predictors of recurrent bleeding. Cardiovasc Intervent Radiol. 2010 Dec;33(6):1088-100. Epub 2010 Mar 16.
130. Kwak BK, Geschwind JF, Rao P, Ota S, Loffroy R, Lin M, Ganapathy S, Kunjithapatham R, Buijs M, Syed L, Liapi E, Chacko VP, and Vali M. High-resolution Ultarsound in Research of Mouse Orthotopic Glioma and Ultrasound-guided Cell Implant. Advances in Molecular Imaging 2011; 1(2):24-32.
131. Liapi E, Geschwind JF, Vali M, Khwaja A, Ventura VP, Buijs M,Vossen J, Ganapathy S, and Wahl R. Assessment of Tumoricidal Efficacy and Response to Treatment with F-FDG PET/CT After Intraarterial Infusion with the Antiglycolytic Agent 3-Bromopyruvate in the VX2 Model of Liver Tumor. J Nucl Med 2011; 52:225–230.
132. Ye SL, Takayama T, Geschwind JF, Marrero JA, Bronowicki JP. Current approaches to the treatment of early hepatocellular carcinoma. Oncologist. 2010;15 Suppl 4:34-41. Review. PubMed PMID: 21115579.

133. Bonekamp D, Reyes DK, Bonekamp S, Wahlin TA, Geschwind JF, Fishman EK, Kamel IR. Complications of loco-regional therapy in the liver-spectrum of imaging findings by CT and MRI. Emerg Radiol. 2011 Feb 16. [Epub ahead of print] PubMed PMID: 21327446.
134. Loffroy R, Lin M, Rao P, Bhagat N, Noordhoek N, Radaelli A, Blijd J, Geschwind JF. Comparing the Detectability of Hepatocellular Carcinoma by C-Arm Dual-Phase Cone-Beam Computed Tomography During Hepatic Arteriography With Conventional Contrast-Enhanced Magnetic Resonance Imaging. Cardiovasc Intervent Radiol. 2011 Feb 17. [Epub ahead of print] PubMed PMID: 21328023.
135. Salem R, Lewandowski RJ, Gates VL, Nutting CW, Murthy R, Rose SC, Soulen MC, Geschwind JF, Kulik L, Kim YH, Spreafico C, Maccauro M, Bester L, Brown DB, Ryu RK, Sze DY, Rilling WS, Sato KT, Sangro B, Bilbao JI, Jakobs TF, Ezziddin S, Kulkarni S, Kulkarni A, Liu DM, Valenti D, Hilgard P, Antoch G, Muller SP, Alsuhaibani H, Mulcahy MF, Burrel M, Real MI, Spies S, Esmail AA, Raoul JL, Garin E, Johnson MS, Benson AB 3rd, Sharma RA, Wasan H, Lambert B, Memon K, Kennedy AS, Riaz A; Technology Assessment Committee; Interventional Oncology Task Force of the Society of Interventional Radiology. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol. 2011 Mar;22(3):265-78. PubMed PMID: 21353979.
136. Bonekamp S, Shen J, Salibi N, Lai HC, Geschwind JF, Kamel IR. Early response of hepatic malignancies to locoregional therapy-value of diffusion-weighted magnetic resonance imaging and proton magnetic resonance spectroscopy. J Comput Assist Tomogr. 2011 Mar-Apr;35(2):167-73. PubMed PMID: 21412085.
137. Liapi E, Geschwind JF. Medium-Sized HCC: Achieving Effective Local Tumor Control with Combined Chemoebolization and Radiofrequency Ablation. Ann Surg Oncol. 2011 Jun;18(6):1527-8. PubMed PMID: 21431403.
138. Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology. 2011 Jun;259(3):641-57. PubMed PMID: 21602502
139. Buijs M, Vossen JA, Geschwind JF, Salibi N, Pan L, Ventura VP, Liapi E, Lee KH, Kamel IR. Quantitative proton MR spectroscopy as a biomarker of tumor necrosis in the rabbit VX2 liver tumor. J Vasc Interv Radiol. 2011 Aug;22(8):1175-80. Epub 2011 May 28. PubMed PMID: 21620723
140. Mayo SC, de Jong MC, Bloomston M, Pulitano C, Clary BM, Reddy SK, Clark Gamblin T, Celinski SA, Kooby DA, Staley CA, Stokes JB, Chu CK, Arrese D, Ferrero A, Schulick RD, Choti MA, Geschwind JF, Strub J, Bauer TW, Adams RB, Aldrighetti L, Mentha G, Capussotti L, Pawlik TM. Surgery Versus Intra-arterial Therapy for Neuroendocrine Liver Metastasis: A Multicenter International Analysis. Ann Surg Oncol. 2011 Jun 17. PubMed PMID: 21681380.
141. Demirjian A, Peng P, Geschwind JF, Cosgrove D, Schutz J, Kamel IR, Pawlik TM. Infiltrating Hepatocellular Carcinoma: Seeing the Tree through the Forest. J Gastrointest Surg. 2011 Jul 2. PubMed PMID: 21725699
142. Pellerin O, Geschwind JF. [Intra-arterial treatment of liver metastases from
colorectal carcinoma]. J Radiol. 2011 Sep;92(9):835-41. Epub 2011 Sep 1. French.
PubMed PMID: 21944243.
143. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma. J Clin Oncol. 2011 Sep 12. PubMed PMID: 21911714.
144. Schaefer NG, Geschwind JF, Engles J, Buchanan, JW, Wahl RL. Systemic
Administration of 3-bromopyruvate in Treating Disseminated Aggressive Lymphoma. Transl Res. 2012 Jan;159(1):51-7. Pub Med PMID:22153810
145.Kneuertz PJ, Cosgrove DP, Cameron AM, Kamel IR, Geschwind JF, Herman JM,
Pawlik TM. Multidisciplinary Management of Recurrent Hepatocellular Carcinoma
Following Liver Transplantation. J Gastrointest Surg. 2011 Oct 6.
PubMed PMID: 21975686.
146. Lencioni R, de Baere T, Burrel M, Caridi JG, Lammer J, Malagari K, Martin RC,
O’Grady E, Real MI, Vogl TJ, Watkinson A, Geschwind JF. Transcatheter Treatment of Hepatocellular Carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): Technical Recommendations. Cardiovasc Intervent Radiol. 2011 Oct 19. PubMed PMID: 22009576.
147. Ray CE Jr, Haskal ZJ, Geschwind JF, Funaki BS. The use of transarterial
chemoembolization in the treatment of unresectable hepatocellular carcinoma: a
response to the Cochrane Collaboration review of 2011. J Vasc Interv Radiol. 2011
Dec;22(12):1693-6. PubMed PMID: 22035882.
148. Janne d’Othée B, Sofocleous CT, Hanna N, Lewandowski RJ, Soulen MC, Vauthey
JN, Cohen SJ, Venook AP, Johnson MS, Kennedy AS, Murthy R, Geschwind JF, Kee ST. Development of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panel. J Vasc Interv Radiol. 2012 Feb;23(2):153-63. PubMed PMID: 22264550.
149. Ganapathy-Kanniappan S, Kunjithapatham R, Torbenson MS, Rao PP, Carson KA,
Buijs M, Vali M, Geschwind JF. Human hepatocellular carcinoma in a mouse model: Assessment of tumor response to percutaneous ablation by using
glyceraldehyde-3-phosphate dehydrogenase antagonists. Radiology. 2012
Mar;262(3):834-45. PubMed PMID: 22357885; PubMed Central PMCID: PMC3285229.
150. Kneuertz PJ, Demirjian A, Firoozmand A, Corona-Villalobos C, Bhagat N, Herman
J, Cameron A, Gurakar A, Cosgrove D, Choti MA, Geschwind JF, Kamel IR, Pawlik TM. Diffuse Infiltrative Hepatocellular Carcinoma: Assessment of Presentation, Treatment, and Outcomes. Ann Surg Oncol. 2012 Apr 3; PMID: 22476754.

151. Bhagat N, Reyes DK, Lin M, Kamel I, Pawlik TM, Frangakis C, Geschwind JF.
Phase II Study of Chemoembolization with Drug-eluting Beads in Patients with
Hepatic Neuroendocrine Metastases: High Incidence of Biliary Injury. Cardiovasc
Intervent Radiol. 2012 Jun 22. [Epub ahead of print] PMID: 22722717
152. Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J,
Geschwind JF, de Guevara LL, Papandreou C, Sanyal AJ, Takayama T, Yoon SK,
Nakajima K, Cihon F, Heldner S, Marrero JA. First interim analysis of the
GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma
and of its treatment with sorafeNib) non-interventional study. Int J Clin Pract. 2012
Jul;66(7):675- 83. doi: 10.1111/j.1742-1241.2012.02940.x. PMID: 22698419
153.Halappa VG, Bonekamp S, Corona-Villabos, CP, Li Z, Mensa M, Reyes D, Eng J,
Bhagat N, Pawlik TM, Geschwind JF, Kamel IR. Intrahepatic Cholangiocarcinoma
Treated with Local-Regional Therapy: Quantitative Volumetric Apparent Diffusion
Coefficient Maps for Assessment of Tumor Reponse. Radiology. 2012 Jul 2;
PMID: 22627601.
154. Li Z, Bonekamp S, Halappa VG, Corona-Villalobos CP, Pawlik T, Bhagat N, Reyes
D, Lai H, Geschwind JF, Kamel IR. Islet cell liver metastases: assessment of
volumetric early response with functional MR imaging after transarterial
chemoembolization. Radiology. 2012 Jul 2; PMID: 22627601.
155.Peng PD, Hyder O, Bloomston M, Marques H, Corona-Villalobos C, Dixon E,
Pulitano C, Hirose K, Schulk RD, Aldrighetti L, Choti M, Shen F, Kamel I,
Geschwind JF, Pawlik T. Sequential Intra-Arterial Therapy and Portal
Vein Embolization is Feasible and Safe in Patients with Advanced Hepatic
Malignancies. HBP. 2012 Aug 14; PMID 22762400.
156.Georgiades C, Geschwind JF, Harrison N, Hines-Peralta A, Liapi E, Hong K, Wu Z,
Kamel I, Frangakis C. Lack of Response after Initial Chemoembolization for
Hepatocellular Carcinoma: Does it Predict Failure of Subsequent Treatment?
Radiology. 2012 Aug 13; PMID 22891361.

157. Bridges JF , Joy SM , Gallego G , Blauvelt BM, Geschwind JF, Pawlik, TM. Priorities
for Hepatocellular Carcinoma (HCC)Control: A Comparison of Policy Needs in Five
European Countries, Journal of Comparative Policy Analysis: Research and Practice, 2012
Aug 14:4, 352-368.
158. Schafer D, Lin M, Rao P, Loffroy R, Liapi E, Noordhoek N, Eshuis P, Radaelli A,
Grass M and Geschwind JF. Breathing Motion Compensated Reconstruction for C-
arm Cone Beam CT Imaging: Initial Experience Based on Animal Data. Proc. SPIE
8313, Medical Imaging 2012: Physics of Medical Imaging; 831354 D1-D6.
159. Pellerin O, Lin M, Bhagat N, Ardon R, Mory B, Geschwind JF. Comparison of
Semi-automatic Volumetric VX2 Hepatic Tumor Segmentation from Cone Beam
CT and Multi-detector CT with Histology in Rabbit Models. Acad Radiol. 2012 Sep
1. [Epub ahead of print] PMID: 22947274
160. Ganapathy-Kanniappan S, Kunjithapatham R, Geschwind JF. Glyceraldehyde-3-
Phosphate Dehydrogenase: A Promising Target for Molecular Therapy in
Hepatocellular Carcinoma. Oncotarget. 2012 Sep 7. [Epub ahead of print] PMID:
22964488
161.Mayo SC, Herman JM, Cogrove D, Bhagat N, Kamel I, Geschwind JF, Pawlik TM.
Emerging Approaches in the Management of Patients with Neuroendocrine Liver
Metastasis: Role of Liver-Directed and Sytemic Therapies. J Am Coll Surg. 2012
Oct 11. [Epub ahead of print] PMID: 23063263
162. Kneuertz PJ, Malla M, Cosgrove DP, Herman JM, Kamel IR, Geschwind JF,
Cameron AM, Pawlik TM. Image of the Month. Recurrent Metastatic HCC. Arch
Surg. 2012 Oct 14. PMID: 23070415
163. Buijs M, Reyes DK, Pawlik TM, Blackford AL, Salem R, Messersmith WA,
Weekes CD, Mulcahy M, Kamel IR, Geschwind JF. Phase 2 Trial of Concurrent
Bevacizumab and Transhepatic Arterial Chemoembolization in Patients with
Unresectable Hepatocellular Carcinoma. Cancer. 2012 Nov 6. [Epub ahead of
print] PMID: 23132335
164. Loffroy R, Lin M, Rao PP, Bhagat N, Noordhoek N, Radaelli A, Blijd J, Liapi E,
Geschwind JF. Intraprocedural C-Arm Dual-Phase Cone-Beam CT: Can It Be
Used to Predict Short-Term Response to TACE with Drug-Eluting Beads in Patients
With Hepatocellular Carcinoma? Radiology. 2012 Nov 9. [Epub ahead of print]
165. Liapi E, Geschwind JF. Combination of Local Transcatheter Arterial Chemoembolization
and Systemic Anti-Angiogenic Therapy for Unresectable Hepatocellular Carcinoma. Liver
Cancer. 2012 Nov; 1(3-4):201-215. Review. PubMed PMID: 24159585
166. Lin M, Pellerin O, Bhagat N, Rao PP, Loffroy R, Ardon R, Mory B, Reyes DK, Geschwind
JF. Quantitative and Volumetric European Association for the Study of the Liver and
Response Evaluation Criteria in Solid Tumors measurements: Feasibility of a
Semiautomated Software Method to Assess Tumor Reponse After Transcatheter Arterial
Chemoembolization. J Vasc Interv Radiol. 2012 Dec 23. PMID: 23177109
167. Buijs M, Geschwind JF, Syed LH, Ganapathy-Kanniappan S, Kunjithapatham R,
Wijlemans JW, Koo Kwak B, Ota S, Vali M. Spontaneous Tumor Regression in a
Syngeneic Rat Model of Liver Cancer: Implications for Survival Studies. J Vasc Interv.
Radiol. 2012 Dec 23. PMID: 2317711
168. Gowdra Halappa V, Corona-Villalobos CP, Bonekamp S, Li Z, Reyes D, Cosgrove D,
Pawlik TM, Diaz LA, Bhagat N, Eng J, Geschwind JF, Kamel IR. Neuroendocrine Liver
Metastasis Treated By Using Intraarterial Therapy: Volumetric Functional Imaging
Biomarkers of Early Tumor Response and Survival. Radiology. 2013 Feb. PMID:
23192780
169. Ganapathy-Kanniappan S, Kunjithapatham R, Geschwind JF. Statins Impair Glucose
Uptake In Tumor Cells. Cancer Biol Ther. 2013 Feb. PMID: 23254955
170. Ganapathy-Kanniappan S, Kunjithapatham R, Geschwind JF. Anticancer Efficacy of the
Metabolic Blocker 3-Bromopyruvate: Specific Molecular Targeting. Anticancer Res. 2013
Jan. PMID: 23267123
171. Park JW, Amarapukar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M,
Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T,
Teng G, Cheng AL. Consensus Recommendations and Review by an International Expert
Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). Liver Int. 2013 Mar.
PMID: 23331661
172. Pellerin O, Lin M, Bhagat N, Shao W, Geschwind JF. Can C-Arm Cone CT Detect a
Micro-Embolic Effect After TheraSphere Radioembolization of Neuroendocrine and
Carcinoid Liver Metastasis? Cancer Biother Radiopharm. 2013 Mar. PMID: 23484809
173. Buijs M, Wijelmans JW, Kook Kwak B, Ota S, Geschwind JF. Antigylcolytic Therapy
Combined with an Image-Guided Minimally Invasive Delivery Strategy for the Treatment
Of Breast Cancer. J Vasc Interv Radiol. 2013 Mar. PMID: 23489770
174. Tacher V, Lin M, Chao M, Gjesteby L, Bhagat N, Mahammedi A, Ardon R, Mory B,
Geschwind JF. Semiautomatic Volumetric Tumor Segmentation for Hepatocellular
Carcinoma: Comparison Between C-Arm Cone Beam Computed Tomography and MRI.
Acad Radiol. 2013 Apr. PMID: 23498985
175. Ota S, Geschwind JF, Bujis M, Wijlemans JW, Kwak BK, Ganapathy-Kanniappan S.
Ultrasound-Guided Direct Delivery of 3-Bromopyruvate Blocks Tumor Progression in an
Orthotopic Mouse Model of Human Pancreatic Cancer. Target Oncol. 2013 Mar.
PMID: 23529644
176. Zhang J, Mavros MN, Cosgrove D, Hirose K, Herman JM, Smallwood-Massey S, Kamel I,
Gurakar A, Anders R, Cameron A, Geschwind JF, Pawlik TM. Impact of a Single-Day
Multidisciplinary Clinic on the Management of Patients with Liver Tumors. Curr Oncol.
2013 Apr PMID: 23559879
177. Bonekamp S, Li Z, Geschwind JF, Halappa VG, Corona-Villalobos CP, Reyes D, Pawlik
TM, Bonekamp D, Eng J, Kamel IR. Unresectable Hepatocellular Carcinoma: MR Imaging
After Intraarterial Therapy. Part I. Identification and Validation of Volumetric Functional
Response Criteria. Radiology. 2013 Apr. PMID: 23616631
178. Bonekamp S, Halappa VG, Geschwind JF, Li Z, Corona-Villalobos CP, Reyes D, Bhagat
N, Cosgrove DP, Pawlik TM, Mezey E, Eng J, Kamel IR. Unresectable Hepatocellular
Carcinoma: MR Imaging After Intraarterial Therapy. Part II. Response Stratification Using
Volumetric Functional Criteria After Intraarterial Therapy. Radiology. 2013 Apr.
PMID: 23616632
179. Wild AT, Gandhi N, Chettiar ST, Aziz K, Gajula RP, Williams RD, Kumar R, Taparra K,
Zeng J, Cades JA, Velarde E, Menon S, Geschwind JF, Cosgrove D, Pawlik TM, Maitra
A, Wong J, Hales RK, Torbenson MS, Herman JM, Tran PT. Concurrent Versus
Sequential Sorafenib Therapy In Combination With Radiation For Hepatocellular
Carcinoma. PLoS One. 2013 Jun. PMID: 23762417
180. Benson AB 3rd, Geschwind JF, Mulcahy MF, Rilling W, Siskin G, Wiseman G,
Cunningham J, Houghton B, Ross M, Memon K, Andrews J, Fleming CJ, Herman J,
Nimeiri H, Lewandowski RJ, Salem R. Radioembolization for Liver Metastases: Results
From a Prospective 151 Patient Multi-Institutional Phase II Study. Eur J Cancer. 2013
Oct;49(15):3122-30 PMID: 23777743
181. Stacy S, Hyder O, Cosgrove D, Herman JM, Kamel I, Geschwind JF, Gurakar A, Anders
R, Cameron A, Pawlik TM. Patterns of Consultation and Treatment of Patients with
Hepatocellular Carcinoma Presenting to a Large Medical Center in the US. J Gastointest.
Surg. 2013 Jun. PMID: 23780638

182. Tacher V, Bhagat N, P Rao P, Lin M, Schafer D, Noodhoek N, Eshuis P, Radaelli A,
Liapi E, Grass M, Geschwind JF. ImageQuality Improvements in C-Arm CT (CACT) for
Liver Oncology Applications: Preliminary Study in Rabbits. Minim Invasive Ther Allied
Technol. 2013 Jul. PMID: 23837536
183. Hyder O, Marsh JW, Salem R, Petre EN, Kalva S, Liapi E, Cosgrove D, Neal D, Kamel I,
Zhu AX, Sofocleous CT, Geschwind JF, Pawlik TM. Intra-Arterial Therapy for Advanced
Intrahepatic Cholangiocarcinoma: A Multi-Institutional Analysis. Ann Surg Oncol. 2013
Jul. PMID: 23846786

184. Kunjithapatham R, Geschwind JF, Rao PP, Boronina TN, Cole RN, Ganapathy-
Kanniappan S. Systemic Administration of 3-Bromopyruvate Reveals Its Interaction with
Serum Proteins in a Rat Model. BMC Res. Notes. 2013 Jul. PMID: 23866825
185. Dodson RM, Weiss MJ, Cosgrove D, Herman JM, Kamel I, Anders R, Geschwind JF,
Pawlik TM. Intrahepatic Cholangiocarcinoma Management Options and Emerging
Therapies. J Am Coll Surg. 2013 Jul. PMID: 23890842
186. Hyder O, Dodson RM, Weiss M, Cosgrove DP, Herman JM, Geschwind JF, Kamel IR,
Pawlik TM. Trends and Patterns of Utilization in Post-Treatment Surveillance Imaging
Among Patients Treated for Hepatocellular Carcinoma. J Gastrointest Surg. 2013 Aug.
PMID: 23943387
187. Hyder O, Dodson RM, Nathan H, Herman JM, Cosgrove D, Kamel I, Geschwind JF,
Pawlik TM. Referral Patterns and Treatment Choices for Patients with Hepatocellular
Carcinoma: A US Population-Based Study. J Am Coll Surg. 2013 Sep.
PMID: 24041557
188. Dodson RM, Firoozmand A, Hyder O, Tacher V, Cosgrove DP, Bhagat N, Herman JM,
Wolfgang CL, Geschwind JF, Kamel IR, Pawlik TM. Impact of Sarcopenia on Outcomes
Following Intra-Arterial Therapy of Hepatic Malignancies. J Gastrointest Surg. 2013 Sep.
PMID: 24065364
189. Chen R, Geschwind JF, Wang Z, Tacher V, Lin M. Quantitative Assessment of Lipiodol
Deposition after Chemoembolization: Comparison Between Cone-Beam Computed
Tomography and Multidetector Computed Tomography. J Vasc Interv. Radiol. 2013 Oct.1
PMID: 24094672
190. Chapiro J, Tacher V, Geschwind JF. Intraarterial Therapies for Primary Liver Cancer:
State of the Art. Expert Rev Anticancer Ther. 2013 Oct; 13 (10): 1157-67.
PMID: 2409962
191. Bonekamp S, Bonekamp D, Geschwind JF, Corona-Villalobos CP, Reyes DK, Pawlik
TM, Kamel IR. Response Stratification and Survival Analysis of Hepatocellular Carcinoma
Patients Treated with Intra-Arterial Therapy Using MR Imaging-Based Arterial
Enhancement Fraction. J Magn Reson Imaging. 2013 Nov 8. PMID: 24214827
192. Lencioni R, Kudo M, Ye SK, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind
JF, de Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R,
Heldner S, Sanyal AJ. GIDEON (Global Investigation of therapeutic Decisions in
hepatocellular carcinoma and Of its treatment with sorafeNib: second interim analysis.
Int J Clin Pract. 2014 May; 68 (5): 609-17. Epub 2013 Nov 28. PMID: 24283303
193. Tacher V, Lin M, Bhagat N, Abi Jaoudeh N, Radaelli A, Noordhoek N, Carlesen B,
Wood BJ, Geschwind JF. Dual-phase-cone-beam Computed Tomography to See, Reach,
and Treat Hepatocellular Carcinoma During Drug-Eluting Beads Transarterial Chemo-
Embolization. J Vis Exp. 2013 Dec 2; (82): 50795. PMID: 24326874
194. Bonekamp D, Bonekamp S, Halappa VG, Geschwind JF, Eng J, Corona-Villalobos CP,
Pawlik TM, Kamel IR. Interobserver Agreement of Semi-Automated and Manual
Measurements of Functional MRI Metrics of Treatment Response in Hepatocelluar
Carcinoma. Eur J. Radiol. 2014 Mar; 83(3):487-96. Epub 2013 Dec. 3 PMID: 24387824

195. Cheng AL, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M,
Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng
G, Park JW. Re-Evaluating Transarterial Chemoembolization for the Treatment of Hepato-
Cellular carcinoma: Cosensus Recommendations and Review by an International Expert
Panel. Liver Int. 2014 Feb; 24(2):174-83. Epub 2013 Nov. 20. PMID: 24251922
196. Ganapathy-Kanniappan S, Geschwind JF. Tumor Glycolysis as a Target for Cancer
Therapy: Progress and Prospects. Mol. Cancer. 2013 Dec 3; 12:152. PMID: 24298908
197. Karthikeyan S, Geschwind JF, Ganapathy-Kanniappan S. Tumor Cells and Memory
Converge at Glycolysis: Therapeutic Implications. Cancer Biol Ther. 2014 May;15(5):
483-5. Epub 2014 Feb 20. PMID: 24556820
198. Wang Z, Lin M, Lesage D, Chen R, Chapiro J, Gu T, Tacher V, Duran R, Geschwind JF.
Three-Dimensional Evaluation of Lipiodol Retention in HCC After Chemoembolization:
A Quantitative Comparison Between CBCT and MDCT. Acad Radiol. 2014 Mar; 21(3):
393-9. PMID: 24507426
199. Chapiro J, Geschwind JF. Hepatocellular Carcinoma: Have We Finally Found the
Ultimate Staging System for HCC? Nat Rev Gastroenterol Hepatol. 2014 Jun;11(6):
334-6. Epub May 6. PMID: 24798199
200. Ganapathy-Kanniappan S, Karthikeyan S, Geschwind JF, Mezey E. Is the Pathway of
Energy Metabolism Modified in Advanced Cirrhosis? J. Hepatol. 2014 Aug; 61(2):452.
Epub 2014 May 6. PMID: 24810232.
201. Chapiro J, Duran R, Geschwind JF. Combination of Intra-Arterial Therapies and
Sorafenib: Is There A Clinical Benefit? Radiol Med. 2014 Jul; 119(7):476-82. Epub 2014
Jun 4. PMID: 24894921.
202. Duran R, Chapiro J, Frangakis C, Lin M, Schlachter TR, Schernthaner RE, Wang Z, Savic
LJ, Tacher V, Kamel IR, Geschwind JF. Uveal Melanoma Metastatic to the Liver: The
Role of Quantitative Volumetric Contrast-Enhanced MR Imaging in the Assessment of
Early Tumor Response after Transarterial Chemoembolization. Transl Oncol. 2014 Aug;
7(4): 447-55/ Epub 2014 Jun 20. PMID: 24953419.
203. Floridi C, Radaelli A, Abi-Jaoudeh N, Grass M, De Lin M, Chiaradia M, Geschwind JF,
Kobeiter H, Squillaci E, Maleux G, Giovagnoni A, Brunese L, Wood B, Carrafiello G,
Rotondo A. C-Arm Cone-Beam Computed Tomographuy in Interventional Oncology:
Technical Aspects and Clinical Applications. Radiol Med. 2014 Jul; 119(7): 521-32. Epub
2014 Jul 11. PMID: 25012472.
204. Chapiro J, Wood LD, Lin M, Duran R, Cornish T, Lesage D, Charu V, Schernthaner R,
Wang Z, Tacher V, Savic LJ, Kamel IR, Geschwind JF. Radiologic-Pathological Analysis
Of Contrast-Enhanced and Diffusion-Weighted MR Imaging in Patients with HCC After
TACE: Diagnostic Accuracy of 3D Quantitative Image Analysis. Radiology 2014 Jul15:
140033. PMID: 25028783.
205. Li L, Masica D, Ishida M, Tomuleasa C, Umegaki S, Kalloo AN, Georgiades C, Singh VK,
Khashab M, Amateau S, Li Z, Okolo P, Lennon AM, Saxena P, Geschwind JF, Schlachter
T, Hong K, Pawlik TM, Canto M, Law J, Sharaiha R, Weiss CR, Thuluvath P, Goggins M,
Shin EJ, Peng H, Kumbhari V, Huftless S, Zhou L, Mezey E, Meltzer SJ, Karchin R, Selaru
FM. Human Bile Contains MicroRNA-laden Extracellular Vesicles That Can Be Used for
Cholangiocarcinoma Diagnosis. Hepatology. 2014 Sep;60(3):896-907. Epub 2014 Jul25.
PMID: 24497320.
206. Floridi C, Radaelli A, Abi-Jaoudeh N, Grass M, Lin M, Chiaradia M, Geschwind JF,
Kobeiter H, Squillaci E, Maleux G, Giovagnoni A, Brunese L, Wood B, Carrafiello G,
Rotondo A. Erratum to: C-Arm Cone-Beam Computed Tomography in Interventional
Oncology: Technical and Clinical Applications. Radiol Med. 2014 Aug 7. PMID: 25100305.
207. Corona-Villalobos CP, Halappa VG, Geschwind JF, Bonekamp S, Reyes D, Cosgrove
D, Pawlik TM, Kamel IR. Volumetric Assessment of Tumour Response Using Functional
MRI Imaging in Patients with Hepatocellular Carcinoma Treated with a Combination of
Doxorubicine-Eluting Beads and Sorafenib. Eur Radiol. 2014 Sep 17. Epub ahead of
print. PMID: 25226843.
208. Kunjithapatham R, Karthikeyan S, Geschwind JF, Kieserman E, Lin M, Fu DX,
Ganapathy-Kanniappan S. Reversal of Anchorage-Independent Multicellular Spheroid
Into a Monolayer Mimics a Metastatic Model. Sci Rep. 2014 Oct 29;4;6816.
PMID: 25351825.
209. Chapiro J, Lin M, Duran R, Schernthaner RE, Geschwind JF. Assessing Tumor Response
After Loco-Regional Liver Cancer Therapies: The Role of 3D MRI. Expert Rev
Anticancer Ther. 2014 Nov. 5:1-7. PMID: 25371052
210. Chapiro J, Wood LD, Lin M, Duran R, Cornish T, Lesage D, Charu V, Schlernthaner R,
Wang Z, Tacher V, Savic LJ, Kamel IR, Geschwind JF. Radiologic-Pathologic Analysis
Of Contrast-Enhanced and Diffusion-Weighted MRI Imaging in Patients with HCC
After TACE: Diagnostic Accuracy of 3D Quantitative Image Analysis. Radiology. 2014.
Dec. 273(3): 746-58. PMID: 25028783
211. Schernthaner RE, Lin M, Duran R, Chapiro J, Wang Z, Geschwind JF. Delayed-Phase
Cone-Beam CT Improves Detectability of Intrahepatic Cholangiocarcinoma During
Conventional Transarterial Chemoembolization. Cardiovasc. Intervent Radiol. 2014
Dec. 5 PMID: 25476872
212. Chapiro J, Dyran R, Lin M, Mungo B, Schlachter T, Schernthaner R, Gorodetski B, Wang
Z, Geschwind JF. Transarterial Chemoembolization in Soft-Tissue Sarcoma Metastases
to the Liver – The Use of Imaging Biomarkers as Predictors of Patient Survival. Eur J
Radiol. 2014 Dec 13. PMID: 25542065
213. Chapiro J, Sur S, Savic LJ, Ganapathy-Kanniappan S, Reyes J, Duran R,
Thiruganasambandam SC, Moats CR, Lin M, Luo W, Tran PT, Herman JM, Semenza
GL, Ewald AJ, Vogelstein B, Geschwind JF. Systemic Delivery of Microencapsulated
3-Bromopyruvate for the Therapy of Pancreatic Cancer. Clin Cancer Res. 2015 Dec. 15
(24):6406-17. PMID: 25326230
214. Chapiro J, Duran R, Lin M, Schernthaner RE, Wang Z, Gorodetski B, Geschwind JF.
Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial
Chemoemboilzation: Comparison of Three-Dimensional Quantitative Versus Non-
Three-Dimensional Imaging Markers. Radiology. 2014 Dec 19: 141180
PMID: 25531387

215. Fu D, Geschwind JF, Karthikeyan S, Miller E, Kunjithapatham R, Wang Z, Ganapathy-Kanniappan S.Oncoimmunology. Metabolic perturbation sensitizes human breast cancer to NK cell mediated cytotoxicity by increasing the expression of MHC class I chain-related A/B. 2015 Jan 14;4(3):e991228. PMID: 25949910
216. Chapiro J, Lin M, Duran R, Schernthaner RE, Geschwind JF. Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI. Expert Rev Anticancer Ther. 2015 Feb;15(2):199-205. PMID: 25371052
217. Tacher V, Radaelli A, Lin M, Geschwind JF. How I do it: Cone-beam CT during transarterial chemoembolization for liver cancer. Radiology. 2015 Feb; 274(2):320-34. PMID: 25625741
218. Chapiro J, Duran R, Lin M, Mungo B, Schlachter T, Schernthaner R, Gorodetski B, Wang Z, Geschwind JF. Transarterial chemoembolization in soft-tissue sarcoma metastases to the liver – the use of imaging biomarkers as predictors of patient survival. Eur J Radiol. 2015 Mar;84(3):424-30. PMID: 25542065
219. Lee H, Chapiro J, Schernthaner R, Duran R, Wang Z, Gorodetski B, Geschwind JF, Lin M.
How I do it: a practical database management system to assist clinical research teams with data collection, organization, and reporting. Acad Radiol. 2015 Apr; 22(4):527-33. PMID: 25641319
220. Chapiro J, Duran R, Lin M, Schernthaner RE, Wang Z, Gorodetski B, Geschwind JF. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers. Radiology. 2015 May; 275(2):438-47. PMID: 25531387
221. Chapiro J, Duran R, Lin M, Werner JD, Wang Z, Schernthaner R, Savic LJ, Lessne ML, Geschwind JF, Hong K. Three-Dimensional Quantitative Assessment of Uterine Fibroid Response after Uterine Artery Embolization Using Contrast-Enhanced MR Imaging. J Vasc Interv Radiol. 2015 May; 26(5):670-678. PMID 25638750
222. Schernthaner RE, Chapiro J, Sahu S, Withagen P, Duran R, Sohn JH, Radaelli A, van der Bom IM, Geschwind JF, Lin M. Feasibility of a Modified Cone-Beam CT Rotation Trajectory to Improve Liver Periphery Visualization during Transarterial Chemoembolization. Radiology. 2015 May: 142821. PMID: 26000642
223. Schernthaner RE, Duran R, Chapiro J, Wang Z, Geschwind JF, Lin M. A new angiographic imaging platform reduces radiation exposure for patients with liver cancer treated with transarterial chemoembolization. Eur Radiol. 2015 May. PMID: 25956933
224. Lafaro KJ, Cosgrove D, Geschwind JF, Kamel I, Herman JM, Pawlik TM. Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management.Gastroenterol Res Pract. May 2015:860861. PMID: 26089873
225. Wang Z, Chen R, Duran R, Zhao Y, Yenokyan G, Chapiro J, Schernthaner R, Radaelli A, Lin M, Geschwind JF. Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2015 May. PMID: 26001366
226. Chockalingam A, Duran R, Sohn JH, Schernthaner R, Chapiro J, Lee H, Sahu S, Nguyen S, Geschwind JF, Lin M. Radiologic-pathologic analysis of quantitative 3D tumour enhancement on contrast-enhanced MR imaging: a study of ROI placement. Eur Radiol. 2015 May. PMID: 25994198
227. Cosgrove DP, Reyes DK, Pawlik TM, Feng AL, Kamel IR, Geschwind JF. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results. Radiology. 2015 Jun 11:142481. PMID: 26069923
228. Tacher V, Lin M, Duran R, Yarmohammadi H, Lee H, Chapiro J, Chao M, Wang Z, Frangakis C, Sohn JH, Maltenfort MG, Pawlik T, Geschwind JF. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach. Radiology. 2015 Jul :142951. PMID: 26131913
229. Schneider T, Chapiro J, Lin M, Geschwind JF, Kleinberg L, Rigamonti D, Jusué-Torres I, Marciscano AE, Yousem DM. 3D quantitative assessment of response to fractionated stereotactic radiotherapy and single-session stereotactic radiosurgery of vestibular schwannoma. Eur Radiol. 2015 Jul PMID: 26139318
230. Wang Z, Chapiro J, Schernthaner R, Duran R, Chen R, Geschwind JF, Lin M. Multimodality 3D Tumor Segmentation in HCC Patients Treated with TACE. Acad Radiol. 2015 Jul;22(7):840-5. PMID: 25863795
231. Chapiro J, Duran R, Lin M, Schernthaner R, Lesage D, Wang Z, Savic LJ, Geschwind JF. Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver. Eur Radiol. 2015 Jul;25(7):1993-2003. PMID:25636420
232. Schernthaner RE, Lin M, Duran R, Chapiro J, Wang Z, Geschwind JF. Delayed-Phase Cone-Beam CT Improves Detectability of Intrahepatic Cholangiocarcinoma During Conventional Transarterial Chemoembolization. Cardiovasc Intervent Radiol. 2015 Aug; 38(4):929-36. PMID:25476872
233. Chapiro J, Geschwind JF. Science to Practice: The Changing Face of Local Tumor Therapies-Do We Have to Think Systemically When Treating Cancer Locally? Radiology. 2015 Aug. 276 (2):315-7. PMID: 26203703
234. Spolverato G, Vitale A, Ejaz A, Kim Y, Cosgrove D, Schlacter T, Geschwind JF, Pawlik TM. Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: A Markov decision model. Surgery. 2015 Aug; 158(2):339-48. PMID: 25999251
235. Abou-Alfa GK, Geschwind JF, Choti M, d’Angelica MI. Consensus Conference on Intrahepatic Cholangiocarcinoma. HPB (Oxford). 2015 Aug; 17(8):661-3. PMID: 26172131
236. Duran R, Chapiro J, Schernthaner RE, Geschwind JF. Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. Br J Radiol. 2015 Aug; 88(1052):20140564. PMID: 25978585
237. Savic LJ, Lin MD, Duran R, Schernthaner RE, Hamm B, Geschwind JF, Hong K, Chapiro J.Three-Dimensional Quantitative Assessment of Lesion Response to MR-guided High-Intensity Focused Ultrasound Treatment of Uterine Fibroids. Acad Radiol. 2015 Sep; 22 (9):1199-205. PMID: 26160057
238. de Baere T, Arai Y, Lencioni R, Geschwind JF, Rilling W, Salem R, Matsui O, Soulen MC. Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion. Cardiovasc Intervent Radiol. 2015 Sep 21. [Epub ahead of print] PMID 26390875
239. Locoregional Therapy for Patients With Hepatocellular Carcinoma. JF. Gastroenterol Hepatol. 2015 Oct;11 (10):698-700. PMID: 27330497
240. Karthikeyan S, Potter JJ, Geschwind JF, Sur S, Hamilton JP, Vogelstein B, Kinzler KW, Mezey E, Ganapathy-Kanniappan S. Deregulation of Energy Metabolism Promotes Antifibrotic Effects in Human Hepatic Stellate Cells and Prevents Liver Fibrosis in a Mouse Model. Biochem Biophys Res Commun. 2015 Oct 22. pii: S0006-291X(15)30801-9. doi: 10.1016/j.bbrc.2015.10.101. PMID: 26525850
241. Hickey R, Lewandowski RJ, Prudhomme T, Ehrenwald E, Baigorri B, Critchfield J, Kallini JR, Gabr A, Gorodetski B, Geschwind JF, Abbott A, Shridhar R, White SB, Rilling WS, Boyer B, Kauffman S, Kwan S, Padia SA, Gates VL, Mulcahy M, Kircher S, Nimeiri H, Benson AB, Salem R. Y90 Radioembolization of Colorectal Hepatic Metastases using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study. J Nucl Med. 2015 Dec 3. pii: jnumed.115.166082. [Epub ahead of print] PMID: 26635340
242. Tacher V, Duran R, Lin M, Sohn JH, Sharma KV, Wang Z, Chapiro J, Gacchina Johnson C, Bhagat N, Dreher MR, Schäfer D, Woods DL, Lewis AL, Tang Y, Grass M, Wood BJ, Geschwind JF. Multimodality Imaging of Ethiodized Oil-loaded Radiopaque Microspheres during Transarterial Embolization of Rabbits with VX2 Liver Tumors. Radiology. 2015 Dec 141624. PMID: 26678453
243. Duran R, Sharma K, Dreher MR, Ashrafi K, Mirpour S, Lin M, Schernthaner RE, Schlachter TR, Tacher V, Lewis AL, Willis S, den Hartog M, Radaelli A, Negussie AH, Wood BJ, Geschwind JF. A Novel Inherently Radiopaque Bead for Transarterial Embolization to Treat Liver Cancer – A Pre-clinical Study. Theranostics. 2016 Jan 1;6(1):28-39. doi: 10.7150/thno.13137. eCollection 2016. PMID: 26722371
244. Savic LJ, Chapiro J, Duwe G, Geschwind JF. Targeting glucose metabolism in cancer: new class of agents for loco-regional and systemic therapy of liver cancer and beyond? Hepat Oncol. 2016 Jan 1;3(1):19-28. PMID: 26989470
245. Geschwind JF, Kudo M, Marrero JA, Venook AP, Chen XP, Bronowicki JP, Dagher L, Furuse J, Ladrón de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Ye SL, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R. TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. Radiology. 2016 Jan 8:150667. PMID: 26744927
246. Fleckenstein FN, Schernthaner RE, Duran R, Sohn JH, Sahu S, Zhao Y, Hamm B, Gebauer B, Lin M, Geschwind JF, Chapiro J. 3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival. Eur Radiol. 2016 Jan 13. PMID: 26762942
247. Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology. 2016 Jan 13. doi: 10.1002/hep.28453. PMID: 26765068
248. Gholamrezanezhad A, Mirpour S, Geschwind JF, Rao P, Loffroy R, Pellerin O, Liapi EA. Evaluation of 70-150-μm doxorubicin-eluting beads for transcatheter arterial chemoembolization in the rabbit liver VX2 tumour model. Eur Radiol. 2016 Jan 15. PMID: 26780638
249. Dhir M, Melin AA, Douaiher J, Lin C, Zhen WK, Hussain SM, Geschwind JF, Doyle MB, Abou-Alfa GK, Are C. A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma. Ann Surg. 2016 Jan 21. PMID: 26813914
250. Kudo M, Lencioni R, Marrero JA, Venook AP, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Ladrón de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Ye SL. Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study. Liver Int. 2016 Feb 22. doi: 10.1111/liv.13096. PMID: 26901163
251. Wang Z, Hansis E, Chen R, Duran R, Chapiro J, Sheu YR, Kobeiter H, Grass M, Geschwind JF, Lin M. Automatic bone removal for 3D TACE planning with C-arm CBCT: Evaluation of technical feasibility. Minim Invasive Ther Allied Technol. 2016 Jun;25(3):162-70. doi: 10.3109/13645706.2015.1129970. 2016 Feb 29. PMID: 26923140
252. Geschwind JF. Locoregional therapy for patients with hepatocellular carcinoma.
Clin Adv Hematol Oncol. 2015 Oct;13(10):660-2. Review. No abstract available. PMID: 27058570
253. De Feyter HM, Behar KL, Rao JU, Madden-Hennessey K, Ip KL, Hyder F, Drewes LR, Geschwind JF, de Graaf RA, Rothman DL. A ketogenic diet increases transport and oxidation of ketone bodies in RG2 and 9L gliomas without affecting tumor growth. Neuro Oncol. 2016 May 3. PMID: 27142056
254. Levy EB, Krishnasamy VP, Lewis AL, Willis S, Macfarlane C, Anderson V, van der Bom IM, Radaelli A, Dreher MR, Sharma KV, Negussie A, Mikhail AS, Geschwind JF, Wood BJ.
First Human Experience with Directly Image-able Iodinated Embolization Microbeads. Cardiovasc Intervent Radiol. 2016 Aug;39(8):1177-86. doi: 10.1007/s00270-016-1364-8. Epub 2016 May 20. PMID: 27206503
255. Gorodetski B. Chapiro J, Schernthaner R, Duran R, Lin M, Lee H, Lenis D, Stuart E, Nonyane, B, Pekurovsky V, Tamrazi A, Gebauer B, Schlachter T, Pawlik TM, Geschwind JF. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. Eur Radiol. 2016 Jun 8. PMID: 27277261.
256. Geschwind JF. Locoregional Therapy for Patients with Hepatocellular Carcinoma.
Gastroenterol Hepatol (N Y). 2015 Oct;11(10):698-700. PMID: 27330497
257. Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology. 2016 Jul;64(1):106-16. doi: 10.1002/hep.28453. Epub 2016 Mar 7. PMID: 26765068
258. Schernthaner RE, Haroun RR, Duran R, Lee H, Sahu S, Sohn JH, Chapiro J, Zhao Y, Gorodetski B, Fleckenstein F, Smolka S, Radaelli A, van der Bom IM, Lin M, Geschwind JF. Improved Visibility of Metastatic Disease in the Liver During Intra-Arterial Therapy Using Delayed Arterial Phase Cone-Beam CT. Cardiovasc Intervent Radiol. 2016 Jul 5. PMID: 27380872
259. Duran R, Mirpour S, Pekurovsky V, Ganapathy-Kanniappan S, Brayton CF, Cornish TC, Gorodetski B, Reyes J, Chapiro J, Schernthaner RE, Frangakis C, Lin M, Sun JD, Hart CP, Geschwind JF. Preclinical Benefit of Hypoxia-Activated Intraarterial Therapy with Evofosfamide in Liver Cancer. Clin Cancer Res. 2016 Jul 20. pii: clincanres.0725.2016. PMID:
27440271
260. Chapiro J, Geschwind JF. Science to Practice: Systemic Implications of Ablative Tumor Therapies-Reality Uncovered and Myths Exposed? Radiology. 2016 Aug; 280(2):329-31. doi: 10.1148/radiol.2016160505. PMID: 27429140
261. Chapiro J, Goldberg SN, Galun E, Geschwind JF.
Response. Radiology. 2016 Apr; 279(1):323. PMID: 27437552
262. Geschwind JF, Chapiro J. Sorafenib in Combination with Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma. Clin Adv Hematol Oncol. 2016 Aug;14(8):585-7. PMID: 27487101.
263. Fan KY, Wild AT, Halappa VG, Kumar R, Ellsworth S, Ziegler M, Garg T, Rosati LM, Su Z, Hacker-Prietz A, Pawlik TM, Cosgrove DP, Hong KK, Kamel IR, Geschwind JF, Herman JM.
Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization. Contemp Clin
Trials. 2016 Sep 50:143-9. doi: 10.1016/j.cct.2016.08.001. Epub 2016 Aug 9. PMID: 27520932
264. Fleckenstein FN, Schernthaner RE, Duran R, Sohn JH, Sahu S, Marshall K, Lin M, Gebauer B, Chapiro J, Salem R, Geschwind JF. Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis. Transl Oncol. 2016 Sep 12:9 (5):377-383. doi: 10.1016/j.tranon.2016.07.005. PMID: 27641641
265. Zhao Y, Duran R, Chapiro J, Sohn JH, Sahu S, Fleckenstein F, Smolka S, Pawlik TM, Schernthaner R, Zhao L, Lee H, He S, Lin M, Geschwind JF. Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma. J Gastrointest Surg. 2016 Oct 6. PMID: 27714643
266. Sohn JH, Duran R, Zhao Y, Fleckenstein F, Chapiro J, Sahu S, Schernthaner RE, Qian T, Lee H, Zhao L, Hamilton J, Frangakis C, Lin M, Salem R, Geschwind JF. Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy. Clin Gastroenterol Hepatol. 2016 Nov 12. pii: S1542-3565(16)31049-7. doi: 10.1016/j.cgh.2016.10.036. PMID: 27847278
267. Sahu S, Schernthaner R, Ardon R, Chapiro J, Zhao Y, Sohn JH, Fleckenstein F, Lin M, Geschwind JF, Duran R. Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival? Radiology. 2017 Jun;283(3):883-894. doi: 10.1148/radiol.2016160838. Epub 2016 Nov 10. PMID: 27831830
268. Mu L, Chapiro J, Stringam J, Geschwind JF. Interventional Oncology in Hepatocellular Carcinoma: Progress Through Innovation. Cancer J. 2016 Nov/Dec;22(6):365-372. PMID: 27870678
269. Stroehl YW, Letzen BS, van Breugel JM, Geschwind JF, Chapiro J. Intra-arterial therapies for liver cancer: assessing tumor response. Expert Rev Anticancer Ther. 2017 Feb;17(2):119-127. doi: 10.1080/14737140.2017.1273775. Epub 2016 Dec 27. Review. PMID: 27983883
270. Pesapane F, Nezami N, Patella F, Geschwind JF. New concepts in embolotherapy of Hepatocellular Carcinoma. Med Oncol. 2017 Apr;34(4):58. doi: 10.1007/s12032-017-0917-2. Epub 2017 Mar 16. PMID: 28299645
271. Martin RC 2nd, Bruenderman E, Cohn A, Piperdi B, Miksad R, Geschwind JF, Goldenberg A, Sanyal A, Zigmont E, Babajanyan S, Foreman P, Mantry P, McGuire B, Gholam P. Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry. Am J Surg. 2017 Apr;213(4):688-695. doi: 10.1016/j.amjsurg.2016.10.006. Epub 2016 Nov 18. PMID: 28318501
272. Savic LJ, Chapiro J, Geschwind JF. Science to Practice: Killing Dormant Cells-Is Targeting Autophagy the Key to Complete Tumor Response in Transarterial Chemoembolization?
Radiology. 2017 Jun;283(3):621-623. doi: 10.1148/radiol.2017170358. PMID: 28514219
273. Smolka S, Chapiro J, Manzano W, Treilhard J, Reiner E, Deng Y, Zhao Y, Hamm B, Duncan JS,
Gebauer B, Lin M, Geschwind JF. The impact of antiangiogenic therapy combined with
Transarterial Chemoembolization on enhancement based quantitative tumor response assessment
in patients with hepatocellular carcinoma. Clin Imaging. 2017 Jun 7;46:1-7. doi:
10.1016/j.clinimag.2017.05.007. [Epub ahead of print]. PMID: 28668723.
274. Do Minh D, Chapiro J, Gorodetski B, Huang Q, Liu C, Smolka S, Savic LJ, Wainstejn D, Lin M,
Schlachter T, Gebauer B, Geschwind JF. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. Eur Radiol. 2017 Dec;27(12):4995-5005. doi: 10.1007/s00330-017-4856-2. Epub 2017 Jul 4. PMID: 28677067.
275. Adam LC, Murali N, Chapiro J, Geschwind JF. Science to Practice: Molecular-targeted Drug Delivery in Combination with Radiofrequency Ablation of Liver Cancer: A Magic Bullet? Radiology. 2017 Nov;285(2):333-335. doi: 10.1148/radiol.2017171527. PMID: 29045226
276. Zhao Y, Duran R, Bai W, Sahu S, Wang W, Kabus S, Lin M, Han G, Geschwind JF. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL? Cardiovasc Intervent Radiol. 2017 Oct 30. doi: 10.1007/s00270-017-1829-4. [Epub ahead of print]. PMID: 29086058
277. Murali N, Laage-Gaupp FM, Chapiro J, Geschwind JF. Science to Practice: Decrypting the Enigma of Ablation-induced Off-Target Effects-Is Network Pathway Analysis the Final Piece of the Puzzle? Radiology. 2018 Feb;286(2):405-408. doi: 10.1148/radiol.2017171779.
278. Abajian A, Murali N, Savic LJ, Laage-Gaupp FM, Nezami N, Duncan JS, Schlachter T, Lin M, Geschwind JF, Chapiro J. Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning-An Artificial Intelligence Concept. J Vasc Interv Radiol. 2018 Jun;29(6):850-857.e1. doi: 10.1016/j.jvir.2018.01.769. Epub 2018 Mar 14. PMID: 29548875
279. Abajian A, Murali N, Savic LJ, Laage-Gaupp FM, Nezami N, Duncan JS, Schlachter T, Lin M, Geschwind JF, Chapiro J. Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma. J Vis Exp. 2018 Oct 10;(140). doi: 10.3791/58382. PMID: 30371657
280. Fereydooni A, Letzen B, Ghani MA, Miszczuk MA, Huber S, Chapiro J, Schlachter T, Geschwind JF, and Georgiades C. Irinotecan-Eluting 75-150-μm Embolics Lobar Chemoembolization in Patients with Colorectal Cancer Liver Metastases: A Prospective Single-Center Phase I Study. J Vasc Interv Radiol. 2018 Dec;29(12):1646-1653.e5. doi: 10.1016/j.jvir.2018.08.010. Epub 2018 Oct 15. PMID: 30337148
281. van Breugel JMM, Geschwind JF, Mirpour S, Savic LS, Zhang X, Duran R, De Lin M,
Miszczuk M, Liapi E, and Chapiro J. Theranostic application of lipiodol for transarterial
chemoembolization in a VX2 rabbit liver tumor model. Theranostics 2019; 9(13): 3674-3686. doi: 10.7150/thno.32943
282. Miszczuk MA, Chapiro J, Geschwind JF, et al. Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer [published online ahead of print, 2020 Feb 21]. Transl Oncol. 2020;13(3):100742. doi:10.1016/j.tranon.2020.01.003
283. Nezami N, Geschwind JF. Predicting Patient Survival in Oncology: Is it Time to Take a New Path? Cardiovasc Intervent Radiol. 2020 Aug;43(8):1173-1174. doi: 10.1007/s00270-020-02553-y. PMID: 32529335
284. Geschwind JF, and Nezami N. Combining Chemotherapy and Radiation Therapy for Liver Cancer: Is the Solution an Intraarterial Approach? Cardiovasc Intervent Radiol. 2020 Oct;43(10):1538-1539. doi: 10.1007/s00270-020-02592-5. Epub 2020 Aug 11. PMID: 32783143
285. Borde T, Laage Gaupp F, Geschwind JF, Savic LJ, Miszczuk M, Rexha I, Adam L, Walsh JJ, Huber S, Duncan JS, Peters DC, Sinusas A, Schlachter T, Gebauer B, Hyder F, Coman D, van Breugel JMM, Chapiro. Idarubicin-Loaded ONCOZENE Drug-Eluting Bead Chemoembolization in a Rabbit Liver Tumor Model: Investigating Safety, Therapeutic Efficacy, and Effects on Tumor Microenvironment. J Vasc Interv Radiol. 2020 Oct 31(10):1706-1716.e1. doi: 10.1016/j.jvir.2020.04.010. Epub 2020 Jul 17. PMID: 32684417
286. Savic LJ, Chapiro J, Funai E, Bousabarah K, Schobert IT, Isufi E, Geschwind JF, Stark S, He P, Rudek MA, Perez Lozada JC, Ayyagari R, Pollak J, Schlachter T. Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies. Eur Radiol. 2021 May;31(5):3002-3014. doi: 10.1007/s00330-020-07380-w. Epub 2020 Oct 15. PMID: 33063185
287. Korn R, Burkett A, Geschwind JF, Zygadlo D, Brodie T, Cridebring D, Von Hoff D, and Demeure M. Can Imaging Using Radiomics and Fat Fraction Analysis Detect Early Tissue Changes on Historical CT Scans in the Regions of the Pancreas Gland That Subsequently Develop Adenocarcinoma? Diagnostics, 2023 Mar; 13(5): 941. Published online 2023 Mar 1. doi: 10.3390/diagnostics13050941

Chapters, Books, Reviews

1. Saeed M, Geschwind JF, Wendland MF, Higgins CB. Advances in the assessment of ischemic heart disease using contrast-enhanced magnetic resonance imaging. In: Kern MJ and Geschwind HJ, Eds. Manual of Coronary Diagnostic Techniques: Endovascular Imaging and Physiology for Coronary Artery Disease, First edition. New York: Futura Editions, 1996.
2.Geschwind JF. Interventional radiology in the diagnosis and management of cancer. In: De Vita VT, Rosenberg SA and Hellman S, Eds. Cancer: Principles and practice of oncology, 6th edition. Philadelphia: Lippincott-Raven, 2000.
3. Venbrux AC, Ignatio EA, Soltes AP, Washington SB, and Geschwind JF. Transjugular
Intrahepatic Porto-systemic shunt. In: Cameron JL, Ed. Current Surgical Therapy, 8th
edition. Philadelphia: Elsevier-Mosby, 2004.
4. Heneghan M, and Geschwind JF. Ethanol and Other Percutaneous Injection Modalities in
the Treatment of Liver Tumors. In: Clavien PA, Ed. Malignant Liver Tumors: Current and Emerging Therapies, Second edition. Sudbury: Jones and Bartlett Publishers, 2004.
5. Georgiades C, and Geschwind JF. Non-cirrhotic Portal Hypertension. In: Bayless T and
Diehl AM, Eds. Advanced Therapy in Gastroenterology and Liver Disease, Fifth edition.
B.C. Becker Publishers, 2005.
6. Liapi E and Geschwind JF. Image-guided Interventions for Treatment of Hepatocellular
Carcinoma: Intra-arterial and Locoregional Ablative Techniques. In: American Society of Clinical Oncology Educational Book; Perry M, Ed. ASCO 41st Annual Meeting, 2005.
7. Georgiades C, and Geschwind JF. Chemoembolization for Liver Cancer. In: Golzarian J,
Sun S, and Sharafuddin M, Eds. Vascular Embolotherapy: A comprehensive Approach, First edition. Springer-Verlag Publishers, 2006.
8. Georgiades C, Salem R, and Geschwind JF. Radioactive Microspheres for the Treatment of
HCC. In: Golzarian J, Sun S, and Sharafuddin M, Eds. Vascular Embolotherapy: comprehensive Approach, First edition. Springer-Verlag Publishers, 2006.
9. Salem R, Thurston KG, and Geschwind JF. Yttrium-90 Radioembolization for the Treatment of Liver Metastases. In: Golzarian J, Sun S, and Sharafuddin M, Eds. Vascular Embolotherapy: A comprehensive Approach, First edition. Springer-Verlag Publishers, 2006.
10. Liapi E and Geschwind JF. Research and Future Directions in Oncology Embolotherapy. In: Golzarian J, Sun S, and Sharafuddin M, Eds. Vascular Embolotherapy: A comprehensive Approach, First edition. Springer-Verlag Publishers, 2006.
11. Liapi E and Geschwind JF. Transhepatic Interventions for Obstructive Jaundice.
In: Cameron JL, Ed. Current Surgical Therapy, 9th edition. Philadelphia: Elsevier-Mosby, 2007.
12. Liapi E and Geschwind JF. Radioembolization for Hepatocellular Carcinoma. In: Mauro M,
Murphy K, Thomson K, Venbrux A, and Zollikofer C, Eds. Abdominal Vascular Image-
guided Intervention, Part One, Section 9, First Edition. Philadelphia: Elsevier-Mosby, 2007
13. Georgiades C, and Geschwind JF. Re: Prognostic accuracy of 12 liver staging
systems in patients with unresectable hepatocellular carcinoma treated with transarterial
chemoembolization. J Vasc Interv Radiol. 2006 Oct;17(10):1619-24. J Vasc Interv Radiol.
2007;18(3):456-7.
14.Buijs M, Vossen J, Geschwind JF and Kamel I. Assessment of Tumor Response Imaging
after Locoregional therapy. In: Jean-Francois H. Geschwind, Michael C. Soulen, Eds.
Interventional Oncology, Principles and Practice. .New York: Cambridge University Press,
2008.
15. Liapi E, Georgiades C, Hong K and Geschwind JF. Transcatheter Arterial
Chemoembolization: Technique and Future Potential. In: Jean-Francois H. Geschwind,
Michael C. Soulen, Eds. Interventional Oncology, Principles and Practice. New York:
Cambridge University Press, 2008.
16. Liapi E, Georgiades C, Hong K and Geschwind JF. New Concepts in Targeting and
Imaging Liver Cancer. In: Jean-Francois H. Geschwind, Michael C. Soulen, Eds.
Interventional Oncology, Principles and Practice. New York: Cambridge University Press,
2008.
17. Georgiades C, Hong K and Geschwind JF. Intrahepatic Cholangiocarcinoma. In: Jean-
Francois H. Geschwind, Michael C. Soulen, Eds. Interventional Oncology, Principles and
Practice. New York: Cambridge University Press, 2008.
18. Georgiades C and Geschwind JF. Microwave Ablation. In: Shahran Vaezy and Vesna
Zderic, Eds. Image-guided Therapy and Systems. Boston/London: Artech House, 2009.
19. Loffroy R, Rao P, Kwak BK, and Geschwind JF. Letter to the Editor re: superselective
arterial embolisation with a liquid polyvinyl alcohol copolymer in patients with acute
gastrointestinal hemorrhage. Eur Radiol. 2011 Jan;21(1):213.
20. Liapi E and Geschwind JF. Radioembolization for Hepatocellular Carcinoma. In: Mauro M,
Murphy K, Thomson K, Venbrux A, and Zollikofer C, Eds. Abdominal Vascular Image-
guided Intervention, Part One, Section 9, Second Edition. Philadelphia: Elsevier-Mosby,
2012

Books

1. Interventional Oncology Principles and Practice, Edited by JF Geschwind and M Soulen,
Cambridge University Press, New York, NY, USA (2008)
2. Abram’s Angiography Interventional Radiology, Edited by JF Geschwind and MD Dake,
Wolters Kluwer/Lippincott/Williams and Wilkins (2013)
3. Interventional Oncology, Principles and Practice of Image-Guided Cancer Therapy. Second Edition. Edited by JF Geschwind and M Soulen, Cambridge University Press, New York, NY, USA (2016)

PATENTS

U.S. Patent No. 9,737,487 B2, issued August 22, 2017
Cyclodextrin compositions encapsulating a selective ATP inhibitor and uses thereof. Inventors: JF Geschwind, MD, Shanmugasundaram Ganapathy-Kanniappan, PhD, Surojit Sur, PhD, Bert Vogelstein, MD, and Kenneth Kinzler, PhD.

2. U.S. Patent 9,492,417, issued November 15, 2016 Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production.
Inventors: Young H. Ko, Ph.D, J.F. Geschwind, M.D., and Peter L. Pedersen, Ph.D.
A method of treating cancer in a subject, wherein the cancer is selected from the group consisting of: liver cancer, pancreatic cancer, lung cancer and breast cancer……wherein the pharmaceutical composition has an acidity of greater than or equal to about pH 2 and less than pH 5; and wherein the pharmaceutical composition further comprises NaHCO3
3. U.S. Patent 8,119,116 B2, issued February 21, 2012
Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production.
Inventors: Young H. Ko, Ph.D, J.F. Geschwind, M.D., and Peter L. Pedersen, Ph.D.
A method of treating a cancerous tumor in a subject comprising administering to the subject an effective amount of 3-bromopyruvate directly to the blood supply of the tumor in the subject via proximal catheterization.
U.S. Patent No. 7,545,673 B2, issued June 16, 2009
Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production. Inventors: Young H. Ko, Ph.D, J.F. Geschwind, M.D., and Peter L. Pedersen, Ph.D.
4. U.S. Patent No. 60/936,460 filed on June 20, 2007. Rapid Fire embolic catheter: A device for creating alginate based microparticles in vivo for intravascular delivery of cellular and molecular therapeutics. Inventors: J.F. Geschwind, MD, and Brad Barnett
5. Julius Chapiro, Ming De Lin, Jean-François Geschwind, “TACE Navigation Guidance Based on Tumor Viability and Vascular Geometry,” 2014P00975/ 62/062241, Patent application filed, October 2014.
6. Julius Chapiro, Ming De Lin, Jean-François Geschwind, Kelvin Hong, “3D Quantitative Evaluation of Uterine Fibroids after Loco-regional Therapy,” 2014PF00073/ 61/930989, Patent application filed, January 2014.
7. JF Geschwind, MD, Shanmugasundaram Ganapathy-Kanniappan, PhD, Surojit Sur, PhD, Bert Vogelstein, MD, and Kenneth Kinzler, PhD. Methods of Treating Liver Fibrosis by Administering 3-Bromopyruvate.

Report of Inventions

Fusion Drug Delivery System – Novel Catheter /Stent Design for Targeted Drug Delivery
Inventors: J.F. Geschwind, MD, and Brad Barnett
Therapeutic effects of pyruvate analogs: Molecular mechanism and biological effect of 3-bromopyruvate. Inventors: J.F. Geschwind, MD, M. Vali, MD, and Ganapathy S, PhD. (2007).